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Flap endonucleases (FENs), in conjunction with proliferating cell nuclear antigen (PCNA), 
catalyse the removal of single stranded 5'-DNA or RNA protrusions known as flaps. These 
bifurcated structures, which are the result of polymerase strand displacement activity 
during lagging strand DNA synthesis and repair, are migrating structures in-vivo due to 
sequence complementarity. In-vitro studies of FEN1 activity frequently use the optimal 
FEN1 substrate known as the static double-flap (DF), which consists of a single nucleotide 
3' and a 5' flap of any length including zero. Moreover, the static DF substrates have 3' or 
5' flaps that are not complementary to the template strand to reduce conformational 
variability. To understand better the mechanism of human FEN1 in a true biological 
context, nine migrating DF substrates were designed to determine the effect of increasing 
substrate-conformational complexity on the rates of FEN1 phosphate diester hydrolysis 
under multiple- and single-turnover conditions. The multiple-turnover analyses reveal that 
human FEN1 produces a single 5' flap product and nicked DNA even on equilibrating 
double flap substrates that have many potential conformers. This shows that hFEN1 action 
always recognises and hydrolyses a single conformer bearing a single 3'-nucleotide flap. 
The kcat/KM and kSTmax conditions showed generally that the rate of reaction was inversely 
proportional to the number of potential conformers. Due to the decrease in hydrolytic 
efficiency with complex migrating flaps, whether PCNA could assist FEN1 in the 
hydrolysis of such substrates was investigated. Surprisingly, we found that PCNA did not 
stimulate the reactions of FEN1 with static or migrating double or single flaps.  
 
During the FEN1 reaction 5’-flaps are threaded through a hole in the protein known as the 
helical arch, which covers the active site. Threading is thought to occur while the arch is 
disordered, but when substrate is present it is believed that the arch forms its helical shape 
to catalyse the reaction. We investigated the role of conserved arch residues by mutation 
of basic amino acids to alanine to remove the positive charge or by using glycine mutations 
to destabilise the helices. Evaluation of the rates of reaction and the ability to stabilise the 
threaded state was undertaken by adapting a streptavidin capture assay. All mutants had 
some impact on the rate of reaction, but relatively small deficiencies in threading were 
revealed in the mutants. The ability of arch mutants to transfer the substrate to the active 
site were assessed using an ECCD assay with tandem 2-aminopurine containing substrates. 
The data show that the arch must be fully ordered to promote the distortion of the DNA 
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required for active site transfer and subsequent hydrolysis. Basic arch residues are required 







𝐾𝑀  Michaelis constant  
𝑘𝑆𝑇  single-turnover rate constant  
𝑘𝑐𝑎𝑡  catalytic rate constant  
2-AP  2-aminopurine  
aa  amino acid  
Ala / A  alanine  
Arg / R  arginine  
Asp / D  aspartic acid  
BER  base excision repair  
bp  base pair  
BSA  bovine serum albumin  
CD  circular dichroism  
Cm  chloramphenicol  
DDR  DNA damage repair  
dHPLC  denaturing high pressure liquid chromatography  
DMSO  dimethyl sulfoxide  
DNAP  DNA polymerase  
dNTP  deoxynucleoside triphosphate  
double flap  double flap  
DR  direct repair  
dRP  deoxyribose phosphate  
ds  double stranded  
DTT  dithiothreitol  
E  enzyme, macromolecule  
ECCD  exciton coupling circular dichroism  
EDTA  ethylenediaminetetraacetic acid  
EMSA  electrophoretic mobility shift assay  
EP  enzyme-product  
ES  enzyme-substrate  
ESI  enzyme-substrate-inhibitor complex  
ETDM  electronic transition dipole moments  
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FA  fluorescence anisotropy  
FAM  fluorescein  
FRET  fluorescence resonance energy transfer  
HEPES  hydroxyethylpiperazineethane sulphonic acid  
His / H  histidine  
HJ  holliday junction  
IDCL Inter-domain connector loop 
IMAC  immobilised metal ion affinity chromatography  
IPTG  isopropyl β D-I-thiogalactopyranoside  
ITC  isothermal titration calorimetry  
Kan  kanamycin  
LB  Luria-Bertani broth  
Leu / L  leucine  
LFER  linear free energy relationship  
lp-BER  long-patch base excision repair  
Lys / K  lysine  
MMR  mismatch repair  
NER  nucleotide excision repair  
nt(s)  nucleotide(s)  
OD  optical density  
P, Q  product  
PARP1  poly (ADP-ribose) polymerase 1  
PCNA  proliferating cell nuclear antigen  
PCR polymerase chain reaction 
Phe / F  phenylalanine  
Pro / P  proline  
pY  pseudo Y  
RRB  reduced reaction buffer  
RT  room temperature  
SA  streptavidin  
SDS-PAGE  sodium dodecyl sulphate- polyacrylamide gel 
electrophoresis  
SOC  super optimal broth with catabolite repression  
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sp-BER  short-patch base excision repair  
ss  single stranded  
ST  single-turnover  
TBE  trisborateEDTA  
TBSE  tris borate saline EDTA  
Tris  tris(Hydroxymethyl)aminomethane  
Tyr  tyrosine  
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Chapter 1: Introduction 
 
1.1 Deoxyribonucleic acid 
 
Most organisms including humans, animals, fungi, protists and bacteria carry genetic 
information in the form of Deoxyribo-Nucleic-Acid (DNA). In the 1950s, Chargaff 
discovered that the four components of DNA cytosine, C, adenine, A, guanine, G or 
thymine, T1 vary in different types of organism but that the amount of dA was always equal 
to the amount of dT with a similar relationship between dG and dC2. Later, investigations 
into the structure of DNA by X-ray diffraction revealed its helical nature. Watson and 
Crick continued the study of DNA structure using modelling methods and proposed that 
DNA structure consisted of two antiparallel strands and twisted around each other. As 





Figure 1.1: The Watson and Crick model for DNA structure. (a) The rungs are form by 
pyrimidines-purine base pairs with the outside of the double helix composed of the sugar-
phosphate backbones. (b) Antiparallel of two DNA strands. (c) The carbon numbering in 




The double helix is formed from two strands or two polynucleotide chains intertwined to 
form the DNA duplex structure. Monomers consist of nucleic acids known as nucleotides 
that are the basis to construct polynucleotides. There are three components of nucleotides; 
a phosphate group, four nitrogenous heterocyclic bases (either A, C, G and T) and a pentose 
sugar. Each DNA strand has either 5’-3’ or 3’-5’ direction because of the structure linked 
by phosphodiester bond between 5’-OH group of one nucleotide and the 3’-OH of the 
neighbouring nucleotide1,4,5. 
 
The backbone of DNA is constructed of alternating phosphate and sugar. The sugar has 
the nitrogenous bases attached at 1’-carbon and is called as 2’-deoxy-D-ribose because of 
the hydroxyl group missing at 2’-carbon. Nitrogenous bases that carry genetic information 
are either monocyclic pyrimidines (T, C and uracil for RNA) or bicyclic purines (A and 
G). A forms two hydrogen bonds with T (in DNA) and U (in RNA), while three hydrogen 
bonds form between C and G. DNA is comprised of two antiparallel strands in which the 
deoxyribonucleotide repeat units are linked by esterification of phosphate to the 5’-
hydroxyl of one sugar and the 3’-hydroxyl of the next sugar to construct the polymeric 
chain. The DNA sugar-phosphate backbone is incredibly stable4,5. 
 
In Ribo-nucleic-Acid (RNA) the sugar is D-ribose since it has the hydroxyl group at 2’ 
position. RNA is a single-stranded molecule, which also carries genetic information by 
copying and transferring the data from DNA to the synthesis of protein and convey the 
genetic in into another chemical form. The difference between RNA and DNA is that 
whereas RNA contains uracil, DNA uses thymine as one of the two pyrimidines. Uracil 
and thymine have similar structure but thymine has a 5-methyl group on its ring. Multiple 
non-covalent hydrogen bonds form to complementary nitrogenous bases with specific 
preferences. Figure 1.2 shows the differences between DNA and RNA4,5. 
 
These different features between DNA and RNA contribute to their functions. Generally 
both (DNA and RNA) are responsible for carrying the genetic information, however the 
DNA molecule is more stable because of the 2’-deoxyribose sugar. Whereas the hydroxyl 
group on the second carbon in RNA can attack the phosphodiester linkage and reduces the 







Figure 1.2: The three differences between DNA and RNA. a) The second carbon; the DNA 
has hydrogen group and the RNA has hydroxyl group at the sugar. b) The DNA has thymine 
(methyl group), the RNA has uracil at the nitrogen bases. c) The DNA has double-stranded, 
the RNA has single stranded. 
 
 
1.2 Phosphodiester hydrolysis 
 
Phosphodiester hydrolysis of nucleic acids in cells is catalysed by enzymes called 
nucleases. The nucleases found in eukaryotic organisms are some of the most important 
enzymes in the cell. They catalyse the hydrolysis of the inter-nucleotide phosphodiester 
bonds of DNA or RNA and are essential for DNA replication, gene expression, and DNA 
repair. There are two groups of nucleases; endonucleases cleaving within the DNA or RNA 
strand and exonucleases cleaving at end of the nucleic acid strand. Enzymes have their 
specific structure and pathway to cleave including the active site, the structure of protein 




The phosphodiester linkage is the backbone of DNA and is extremely stable under aqueous 
conditions10. However, this bond needs to be hydrolysed due to important roles in 
biological processes, for example the removal of an RNA primer during DNA 
replication11. The intermolecular nucleophilic attack of water molecules or hydroxide on 
phosphorus can cleave either at 3’ to produce a 3’-phosphate and 5’-OH products or at 5’ 
and generate product terminating 3’-OH and 5’-phosphate. However, the preferred 
nucleophile attack generates a at 5’-monophosphate where the 3’-OH can be used for other 
DNA reactions while the 5’-phosphate can be further used as a substrate in DNA 








1.3 Flap endonuclease-1 
 
Flap endonuclease-1 (FEN1) enzymes are present in all living things and catalyse 
phosphodiester hydrolysis during DNA replication and repair13. FEN1s are structure-
specific endonucleases that also have a 5’-3’ exonuclease activity on double-stranded 
DNA14. They were first discovered and called DNAse IV as an enzyme15 that demonstrated 
specific binding and activity at 5’-flap structures16. It is a member of the Rad2 structure-
specific nuclease family17 and also originally known as maturation factor (MF1) and 
responsible to complete lagging strand replication18. Observing in-vitro studies of simian 
virus 40 DNA, it was proposed that the FEN1 is capable of removing the RNA moiety of 
the Okazaki fragment yielding nicked DNA that can be ligated by Lig119. 
 
In eukaryotes, FEN1 acts as both an endonuclease and exonuclease and is reported to play 
important roles in biological processes such as Okazaki fragment maturation20, apoptotic 
DNA fragmentation, telomere maintenance, stalled replication fork rescue, and long-patch 
base excision repair. Studies on FEN1 expanded rapidly because of the complex structures 
and properties of FEN1. Genetic and biochemical studies suggested that an interaction 
between FEN1 and other proteins involved in metabolic pathways such as proliferating 
cell nuclear antigen (PCNA)21, will authorize miscellaneous activities of FEN1. 
 
There are many crystal structures of FEN1 from wide range of organisms including yeast22, 
humans9,17,23, thermophilic bacteria24,25, bacteriophage26–28 and archaea24,29,30. The first 
FEN X-ray crystal structure was published without the DNA substrate in 1995 using the 
FEN domain from Thermus aquaticus (Taq) DNA polymerase. Following this structures 
from bacteriophage T5FEN, T4RNaseH and the flap endonucleases from Pyrococcus 
furiosus (Pf), Methanococcus jannaschii (Mj), Pyrococcus horikoschii (Ph) and Homo 
sapiens (H) were reported. Later in 2004, the first structure to be co-crystallised with DNA 
bound was Archaeoglobus fulgidus (Af), although the DNA was only part but not the whole 
of a substrate. Later the structure of T4RNaseH, the T4 FEN, bound to DNA substrate but 






1.4 The biological role of FEN1 
 
FEN1 plays an important role in intracellular processes including the maintenance of cells 
such as telomere maintenance and suppression of trinucleotide repeats31. Flap 
endonucleases are nucleases which have the capability to catalyse the structure-specific 
endonucleolytic and exonucleolytic32 hydrolysis of nucleic acids to give 5’-
monophosphate and a 3’-hydroxyl products. They are essential for genomic stability and 
DNA processing at the key steps of metabolism including DNA replication and repair33.  
 
 
1.4.1 DNA replication 
 
DNA replication occurs rapidly and effectively in eukaryotic and prokaryotic cells. Before 
the division happens, cells have to make exact copies of their DNA through replication and 
reproduction processes. The accuracy of this process is vital for the next generation to have 
the same genetic instructions as the parents. The DNA structure assists the efficiency of 
the replication processes. Various enzymes are involved during the replication process 
including pol-δ/Ɛ, helicase, pol-α, FEN1, DNA lig-1, and PCNA. In the beginning, the 
double strands of DNA unwind forming two parent strands to act as a template34,35. 
Complementary base pairing of nucleotides to this parent template guides formation of the 
new double strands. To form the new strand, nucleotides will be adding to the 3’ since the 
direction of DNA replication occurs in 5’-3’ direction35.  
 
E.coli have been used as a model organism (in the beginning) to understand the DNA 
replication processes, then followed with more complex eukaryotic organisms. Once the 
replication fork is created, various enzymes are required for replication to begin. The 
double helix is unwound by helicases by breaking the hydrogen bonds between two 
polynucleotides to form two new single stranded regions. The presence of topoisomerases 
are important to prevent the double strand (outside of the replication fork) forming 
supercoils. DNA polymerase will take part once replication fork is stable by adding new 






The model of DNA replication can be seen at Figure 1.4. After the DNA double helix is 
unzipped, both strands will act as a template for the synthesis of a new strand. Primase is 
responsible for the synthesis of the short RNA primer by polymerising complementary 
ribonucleotides. The DNA polymerase pol-α extends the synthesis and forms the RNA-
DNA primer (~20 – 25 base pairs)36. Polymerisation process moves continuously by pol 
Ɛ, whereas pol-δ syntheses the new strand as fragments. Polymerisation of both strands 
occurs concurrently with a unidirectional nature of DNA synthesis since new nucleotides 
are added to the 3’ end. The consequence of this is that, one of the daughter strand will 
grow continuously in the 5’-3’ direction; this is called the leading strand. The other strand, 
called the lagging strand, undergoes discontinuous DNA synthesis growing in the 3’-5’ 




Figure 1.4: The model of DNA replication fork. The helicase unzipped the DNA and split 
into a leading and lagging strand. The leading strand will polymerase continuously, 
whereas the lagging strand has discontinuous DNA synthesis. 
 
On the lagging strand, the addition of new nucleotides actually occur in the 5’-3’ direction 
in short fragments; these are called Okazaki fragments. Short sequences of nucleotides will 
be added to the primer by DNA polymerase-α and then these are extended by polymerase-
δ to form Okazaki fragments. These steps continue until the complete strand is replicated. 
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In eukaryotes polymerase-δ catalyses strand displacement synthesis; that is the extension 
of one Okazaki fragment displaces the 5’-end (primer) of the next Okazaki fragment form 
the template DNA as a single-stranded flap38. The flap or primers must be removed 
precisely to leave a nicked structure that is easily ligated by DNA ligase. Precision is 
required to prevent gaps or overlaps in the structure, where a DNA repair mechanism will 
be required. FEN1 and RNaseH are responsible for removing the flap or primers. New 
identical copies of the DNA appear, once the replication of leading and lagging strands 
have been completed39. 
 
This unique process demands a complicated mechanism to prevent accidental genomic 
lesions. Previous studies revealed many mechanisms to synthesise a new daughter strand 
at the lagging strand. One study proposed that when the pol-δ meets the 5’-end from 
previous Okazaki fragment, it may continue the synthesis by replacing the mature primer 
with new DNA. Then Dna2 protein and the RPA continue cleaving the flap, follow with 
FEN1 cleaves the flap and forms nicked DNA duplex and finally, DNA Lig-1 seals the 
nick40 to produce a new DNA daughter strand35,37. 
 
 
1.4.2 Okazaki fragment 
 
Replication of double stranded DNA is a critical process to produce efficient and precise 
genome duplication. Two antiparallel strands will form; lagging and leading strands which 
have discontinuous and continuous replication respectively because of the direction of 
polymerization occurs in a 5’-3’ direction. Therefore, to continue the synthesis at the 
lagging strand, RNA primers are essential which will be extended initially by DNA 
polymerase alpha. Circular plasmid and Simian virus 40 (SV40) studies, proved that FEN1 
acted as an enzyme to degrade the RNA primers in Okazaki fragments41. In one model it 
was suggested the RNaseH will remove the RNA primers and leave a residual 
ribonucleotide upstream at the RNA-DNA junction. The PCNA, encircles the DNA duplex 
at the 3’-terminus and the polymerization continues with pol-δ producing un-annealed 5’-
flap. FEN1 eliminates the 5’flap formed by strand displacement synthesis leaving a nick 




Studies have proven that, FEN1 plays an important role during Okazaki fragment 
maturation by removing the flapped DNA. Double flap DNA molecules are the most 
common substrate structure; these two-way junction DNAs have a one nucleotide 3’-flap 
on the upstream duplex and a 5’-flap of various length of nucleotides protruding from the 
downstream duplex. The upstream and downstream can be seen in Figure 1.5. In double-
stranded DNA, with the anti-parallel nature of DNA, the upstream is one nucleotide 3’ flap 





Figure 1.5: Double flap DNA. The green is downstream, red is upstream and blue is the 
template of the DNA. 
 
 
1.4.3 Base excision repair 
 
Studies have revealed that lesions in DNA occur from alkylation, oxidation, deamination 
and depurinatiation or depyrimidination damage. Base excision repair (BER) is a common 
and pivotal biological processes in DNA repair capable of removing modified bases that 
occur. The DNA glycosylases, an AP endonuclease, DNA polymerase and DNA ligase are 
four proteins that essential for BER processes. The whole host of auxiliary proteins are 
important for the correctness and effectiveness of the cells’ repair processes33,42.  
 
Figure 1.6 shows the diagram for BER process. Firstly, the DNA glycosylase will 
acknowledge the damaged bases by hydrolysing the glycosidic bond between sugar and 
the base removing it and as a result creating an abasic (AP) site. A number of glycosylases 
are able to function at specific types of DNA damage and generate the same AP site that 
will be used by the handful of downstream enzymes. Then an AP lyase or AP endonuclease 
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will hydrolyse the DNA backbone and a new nucleotide can be inserted by polymerase-β. 
The AP lyase (an activity present in glycosylase) will cleave the phosphodiester bond 3’ 
of the AP site and generate the 3’-unsaturated aldehydic sugar and a 5’-phosphate end. 
Then, AP endonuclease incises on the 5’-side at the 3’-unsaturated aldehydic sugar to 
generate a 3’-OH and 5’-deoxyribose phosphate (dRP)43. DNA pol-β will replace the dRP 




Figure 1.6: The function of FEN1 in BER during the DNA repair processes43. 
 
Diverse factors that influence whether the long or short patch BER pathways are used 
include the level of cell dividing, the stage of cell cycle and the type of lesion. Once the 
electrophilic centre of the aldehyde is off-track, the switch of sp-BER and lp-BER will 
occur. In sp-BER, pol-β has a lyase activity in addition to its polymerase activity. While 
in lp-BER many proteins are recruited at the AP site including pol-β, pol-δ, PCNA, DNA 
11 
  
ligase and FEN1. In lp-BER, FEN1 will cooperate with pol-β through the ‘hit-and-run’ 
mechanism or capturing the 5’-flap associated with a modified sugar created by pol-β or 
pol-δ/Ɛ to remove a modified sugar. This process will continue in multi-nucleotide 
replacement where the FEN1 cleavage results in a ligatable nick and DNA ligase 1 joining 
the DNA strand44,45.  
 
 
1.4.4 The miscellaneous activities of FEN1 
 
For optimal activity during DNA replication, DNA repair, the cell cycle and apoptosis 
processes, studies have shown that FEN1 interacts or acts in concert with other proteins 
including the proliferating cell nuclear antigen (PCNA)46, Dna247, Apurinic/apyrimidinic 
(AP) endonuclease 148, Replication Protein A (RPA)49, Werner syndrome ATP-dependent 
helicase (WRN)48,50,51 and p30052. By interacting with the C-terminal portion of FEN1 it 
is claimed that the WRN protein can stimulate the FEN1 cleavage of branch-migrating 
double-flap structures and increase the FEN1 activity during Okazaki fragment maturation. 
In contrast, it is suggested that p300 inhibits FEN1 endonuclease activity52, impairing flap 
cleavage by catalysing the acetylation of FEN1 in-vivo and in-vitro. The role of RPA is to 
block the single-stranded DNA from forming secondary structures and it is claimed to be 
able to stimulate FEN1 cleavage on short lengths and inhibit FEN1 action at longer flaps49. 
AP endonuclease is suggested to interact with FEN1 when it acts with FEN1 in the DNA 
BER pathway to repair the damage and create a nick at the phosphodiester backbone.  
 
The biological importance of FEN1 is underscored by several lines of evidence. FEN1 is 
mandatory to upregulated proliferation in cancer cells and could be a possible target for 
therapeutic drugs. In cancer cells, FEN1 is responsible for DNA repair. If there ae errors 
in FEN1 mediated DNA repair, cell proliferation increase. Therefore, inhibition of FEN1 
will kill off the cancer cells faster than normal cells in a similar way to chemotherapy. 
Using FEN1 as a target for treatment has advantages and disadvantages, including dose –






Knockouts of FEN1 homologues in animals demonstrated that FEN1 is required for the 
organism to survive. In mice studies, a heterozygous knockout exhibited some 
considerable tumour growth, while a homozygous knockout of FEN1 was embryonically 
lethal; this indicates that FEN1 has an essential role in genomic stability54. Moreover, 
FEN1 deletions resulted in defects in DNA processing pathways, increased susceptibility 
to mutagens, trinucleotide expansion and telomeric destabilisation. In DT40 chicken cells, 
viability in maintained despite homozygous knockout, but cells are more sensitive to DNA 
damaging agents55.  
 
In other research using Saccharomyces cerevisiae, null mutants of FEN (∆rad27) exhibit a 
complex mutator phenotype and temperature sensitive growth defects. Additionally, FEN1 
is obligatory in DNA repair processes based on the experiments with the homologue of 
FEN1 (Rad27). This research showed the mutants of Rad27 were sensitive to the DNA 
alkylation agent, methyl methane sulphonate. Furthermore, studies in yeast demonstrated 
FEN1 mutation caused a rise in the rate of spontaneous mutation, showed a high frequency 
of chromosome recombination and also increased inter/intra-chromosomal recombination. 
The mutations became worse when merged with a nuclease deficiency mutation in the 3’-
5’ exonuclease domain of pol-δ56–58. 
 
Recently, there has been interest in the investigation of the specific association between 
two important proteins involved in DNA repair and replication11 processes; FEN1 and 
PCNA, the processivity factor for DNA polymerases δ and ε59. Previous studies proposed 
that in-vivo PCNA recruits FEN1 to branched DNA substrates near the replication fork30 
because FEN1 interacts with a hydrophobic cleft on the front face of the PCNA30,60.  
 
 
1.5 FEN1 superfamily 
 
The FEN1 superfamily have been found in bacteriophage viruses T4 and T5. By nature, 
these viruses have minimalist self-contained biological units. Consequently it is believed 
that the FEN1 superfamily are some of the most important proteins for DNA replication, 
repair and recombination processes. Studies of other enzymes from mouse and human cells 
revealed that other members of the 5’-nuclease superfamily have specific nucleolytic 
activity such as; human FEN1, exonuclease-1 (EXO1)17, gap endonuclease-1 (GEN1)61 
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and xeroderma pigmentosum complementation group G (XPG)32. Although the FEN1 
superfamily have similar structural features and use divalent metal ions for DNA 
hydrolysis, each of the superfamily members have high specificity with substrate structure 
and tight regulation of function. The differences in structural characteristics of the FEN1 
superfamily are important to explain the substrate recognition. However, generally the 
FEN1 superfamily have ability to recognise the 5’-duplex end and hydrolyse the 
phosphodiester bond6. 
 
Several key features of FEN1 superfamily members have been preserved throughout 
evolutionary time. These include the acidic active site metal coordinating residues which 
are supported by the conserved positively charged sidechains to catalyse the reaction. Most 
FEN1 proteins (bacteria, yeast, archaea and mammals, but not bacteriophage) preserve a 
3’flap recognising loop and all have a helical arch (I domain) over the active site. In 
addition, some of the FEN1 superfamily have extremely different I domain to FEN1, while 
other regions (N and C-domain) are conserved features. By sequence homology and X-ray 
structures, each of these enzymes are able to recognise DNAs junction and have three 
separate binding sites for DNA9. All of these FEN1 superfamily members incise DNA one 
base pair into the duplex region of substrate9.  
 
Crystal studies have shown that the nuclease core domain of human FEN1 (hFEN1) folds 
into seven-stranded β-sheets, surrounded by 15 α-helices that form a long positive charged 
groove. hFEN1 consists of three main regions, intermediate (I), N and C terminal domains. 
The intermediate domain is responsible for connecting the terminal N and C to produce 
the saddle structure. Full length hFEN1 is comprised of 380 amino acids including the 
helical arch or cap, the helix-two-turn-helix, the hydrophobic wedge and the 3’flap binding 
pocket62 and others. A crystallographic study between hFEN1 and other organisms, shows 
that the archaeal FENs have sequence and structural similarities (Figure 1.7)6,37. 
 
The similarities and differences between human FEN1 and human EXO1 are useful in 
understanding the function of the enzyme and the product release. Physically, EXO1 is 
much larger than FEN1 but has smaller nuclease domain. EXO1 was found in many 
organisms including humans and it was first purified from S. pombe. EXO1 is vital for 
genome maintenance during the mismatch repair (MM) and double-strand break repair 
(DSB) and carries out processive 5’-exonucleolyic reactions on DNA nicks, gaps and blunt 
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ends7,17,61. During DNA replication, there are many processes which can give errors such 
as insertion, transition, deletion and also double strand DNA breaks. Orans et. al., 
published the structure of human EXO1 demonstrating similarities with the human FEN1 
structures for binding and substrate placement over the active site. Furthermore, EXO1 
binds at ss/ds DNA junctions and it was proposed that the ends of the DNA are frayed 




Figure 1.7: FEN superfamily architecture. (a) Six of FEN superfamily showed each of 
them have a conserved architecture by sequence alignment to interact with DNA. (b) The 
juxtaposition of FEN superfamily structures6. 
 
Another FEN1 superfamily member is GEN1 that was isolated from humans, yeast and 
Drosophila melagonaster (DmGEN)63. GEN1 is proposed to play a role in homologous 
recombination acting at four-way Holiday junctions (HJ) that form during replication by 
acting in a dimeric form to generate the bilateral cleavage. GEN1 also has a capability to 
endonucleolytically cleave 5’-flaps at lower efficiency. GEN1 is a monomer in free 
solution. Moreover, GEN1 has the ability to fit with the general mechanism of action of 
15 
  
other holiday junction resolvases, to produce symmetric nicks in the structure and to 
oligomerise in a substrate-induced fashion7,61,64.  
 
XPG is a part of a multi-protein complex require to cleave a bubble at the 3’-end 
subsequent to a 5’ cut during nucleotide excision repair (NER)65 and transcription-coupled 
DNA excision repair66,67. In-vitro studies revealed, XPG can cleave various DNA 
structures including single-strand 5’-overhangs. However, in-vivo the unique features of 
XPG allow it to recognize DNA bubble structures (Figure 1.8). Bubble structures are a 
cellular reaction to photo-damaged nucleotides and to bulky chemical mutagenic adducts57. 
The intermediate domain XPG plays an important role allowing reaction of the bubble 
structure37. Since the FEN1 arch is a narrow space and requires DNA with free 5’-termini 
to pass through this is adapted in XPG to have more than 600 amino acids while other FEN 
superfamily at this region only have approximately 70 amino acids68. This spacer region 
allows accommodation of the bigger substrate. The activity of a FEN1-XPG hybrid with a 
FEN1 arch has been tested and revealed that the catalytic efficiency is reduced for the 
bubble structure69.  
 
The conservation of the core elements of FEN structure between different types and 
between different members of the superfamily is an obvious indicator of the importance of 
the reaction for DNA maintenance (protection). Members of this superfamily act on a 
variety of DNA structures found in cells. Therefore, the basic structural components are 
conserved throughout evolution in a multitude of organisms, but the structure has been 
modified for specific tasks, proving the versatility of the core structure. FEN1 is studied as 
a paradigm of this superfamily as it contains all the relevant structural elements. A 
summary of the FEN1 superfamily functions and biological pathways were shown in 











Table 1.1: FEN1 superfamily, functions and their biological pathway. 
Structure Functions Biological Pathway 
hFEN1 5’-endo/exo-nucleoytic cleavage of 
DNA double flap. 
DNA replication and lp-BER. 
EXO1 5’-exonucleoytic cleavage of 
DNA nicks, gaps, blunt ends. 
Double strand break repair 
and mismatch. 
GEN1 5’-endonucleoytic cleavage of 
DNA Holliday junction resolvase. 
Double strand break repair. 
XPG 5’-endonucleoytic cleavage of DNA 
bubble. 




Figure 1.8: DNA structures within normal cellular activity. The FEN1 superfamily have 
their specific preferred substrate which occur in different biological pathways. Red arrow 
indicates the position of FEN1 superfamily incise the DNA. 
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1.6 Structural studies and the mechanism of FEN1superfamily 
 
Generally, FEN1 superfamily members have a similar protein structure. Crystal structures 
reveal some interesting features in FEN1 and the superfamily including the flexible loop 
containing a helical motif9,29,70 sometimes called the arch or cap (Figure 1.9). The arch 
interacts with the 5’-flap prior to reaction. At the base of helical arch, also referred to as 
the gateway, the FEN1 active site binds divalent metal ions that can execute endo-
nucleolytic and exo-nucleolytic cleavage. A long adaptable arch and a seven or eight 
carboxylate active site with specific metal ion organization are the two unique features of 
the FEN1 superfamily. These characteristics contribute to the different roles of each 
enzyme during DNA metabolism on top of their substrate specificity. The N-terminal 
domain, intermediate (I) linker domain and C-terminal domain are the three domains that 
construct the structure of eukaryotic FEN1 proteins9,71. Other homologues of FEN1 can be 
defined as proteins that share high homology of N and C domains with FEN141 but 
sometimes differ in the I domain and the nature of C-terminal extensions that allow family 
members to play different roles in DNA metabolism. The full length hFEN1 structure 
comprises 380 (42 kDa) amino acids with 1-332 amino acid residues for nuclease core 









Figure 1.9: The structures of human FEN1 with DNA substrate (PDB:3Q8K). The cartoon 
shows the ss-5’-flap, the 1nt-3’-flap and template from DNA. hFEN1 consists of 380 amino 
acid residues which comprise of 15-alpha and 7-beta sheet; helical arch (α4 and α5), 
hydrophobic wedge (α2 and α3), active site, H2TH. 
 
 
1.6.1 Helical arch 
 
The helical arch is the intermediate domain of FEN1 structure and T5FEN was the first 
organism in which the helical arch structure was visualised26. The arch of T5FEN is made 
up by two alpha-helices; one has positively charged residues and another consists of 
hydrophobic residues26. When the arch is in ordered form, only single stranded DNA, but 
not double-stranded DNA can fit through. FEN1 crystal structures have revealed that 
diverse factors influence the degree of helicity of the arch including crystal contacts and 
substrate or product binding to the protein. Three ranges of structural rigidity have been 
found; either the helical arch is completely disordered, partially structured or completely 
structured72. Thus it is proposed that the helical arch has an inherent flexibility and ability 
to stretch. As an example, the conformation of the helical arch in substrate-free structures 
of the bacteriophage T5FEN and AfFEN are in helical ordered conformations, while in 
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T4RNaseH the arch is partially disordered and in MjFEN and hFEN1 without substrate 
they were completely disordered13,73,74. 
 
The delineation of these regions is based on alignments of 5’-nucleases, with the gateway 
residues being well conserved in all superfamily members. In the crystal structure of FEN1, 
the helical cap consists of all α5 (Q121 – L130) and the C-terminal half of α4 (R105 – 
A116), whereas the gateway comprises by a part of α4 (P90-R104) and α2 (A35 – V46), 
and it is thought that the helical cap in hFEN1 enforces its specificity to discontinuous 
substrates. Alignments of FEN1s and EXO1s show that the helical cap is also present in 
hEXO1, which is consistent with hEXO1 also preferring discontinuous substrates. In 
GEN1, the helical cap is missing, whereas XPG has a large ~600 amino acid insert. The 
absence of helical cap in GEN1 is thought to allow it to cleave continuous DNA Holliday 
junctions by acting as a dimeric interface7,61,63,64. The large insert in XPG, which is 
predicted to be disordered, is important for protein-protein interactions with other 
nucleotide excision repair proteins and is a site for many post-translational modifications. 
The role of this large disordered region in XPG remains to be elucidated, but its interactions 
with other NER pathway members may be important for triggering scissile phosphate 
diester hydrolysis by XPG57,66–69.  
 
In substrate-free structures of human FEN1, the arch is disordered. However, upon the 
binding of substrate or product the arch adopts a helical conformation. hFEN1 has two 
helices with a short linker, whereas T5FEN only has α5 at the same region to run behind 
the main N-terminal domain of the protein. K93 and R100 in human FEN1, K83 and R86 
in T5FEN are the two basic residues that are positionally conserved in all FEN1 proteins. 
Mutating the helical arch residues K93, R100 (hFEN1) and K83 (T5FEN) residues to 










1.6.2 The divalent metal ion active site  
 
The active site is the cleft where catalysis happens and where the substrate is productively 
bound. The FEN1 superfamily are metalloenzymes. In FEN1 reaction, metal ions play a 
catalytic role (key role) in hydrolysis76. The studies on different mechanisms including 
human, archaea, and bacteriophage, revealed that two divalent metal ions bound to the 
active sites with varying spaces6,26,28,37,77.  
 
Nucleases with two metal ions (Mg2+, Mn2+ or Zn2+) are more common and Mg2+ is the 
most frequently associated with nucleic acid enzymes. For example in FEN1 divalent metal 
ions, are coordinated by 7-8 conserved carboxylates, located within the active site9. Three 
or four acidic amino acids are usually used to create a negatively charged pocket to 
coordinate the metal ions either through direct interaction (inner-sphere binding) or outer 
sphere binding through indirect interaction (via hydrogen bonding links) with metal bound 
waters. The inner and outer sphere binding can be as a bridge for activation of nucleophile 
and stabilisation of the DNA substrate. For example , in human FEN1 studies, the two 
metal ions are less than 4 Å apart allowing them both to contact the same scissile phosphate 
in the transition state19. 
 
In theory for the ‘two metal ion mechanism’ the inter-metal ion gap should be 
approximately 4 Å. However, diverse metal ion-metal ion distances have been published 
for FEN1 homologues of between 5-8 Å with most exceeding the 4 Å separation78. It was 
suggested that for a ‘two metal ion mechanism’ a conformational change in the protein 
would have to occur upon substrate binding to bring the two metal ions near each other to 
interact with the same scissile phosphate diester76. Small-Angle X-ray Scattering (SAXS)79 
and Fourier Transform Infra-Red (FTIR) spectroscopy80 were used to detect the 
conformational changes. Furthermore, the presence of third ion binding during the 
formation of T5FEN-substrate complex was detected kinetically and ultimately 
crystallographically allowing a ‘the two metal ion mechanism’26.  
 
To start the hydrolysis of the phosphodiester bond, the presence of Y40 (from α2), K93 
and R100 (from α4), help to stabilise the substrate during and after the reactions and are 
important for DNA positioning. These two metal ions are held in place with four residues 
(Asp34, Asp86, Glu158, Glu160) to make the inner sphere and three residues (Asp179, 
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Asp181, Asp233) interact with H2O to make outer sphere carboxylic groups that are vital 




Figure 1.10: The seven main residues (D179, D181, D233, D34, D86, E160 and E158) of 





Another of the conserved structural elements in FEN1 and family proteins is the classical 
DNA binding site, helix-two turn helix (H2TH) motif, also known as helix-three turn helix 
(H3TH) motif14 in archaeal enzymes. The H2TH or H3TH is the downstream duplex 
binding site, for non-specific binding of DNA27,28,81,82. Crystallographic images of a 
truncated hFEN1 and DNA revealed the presence of potassium ions (K+) in crystal 
structures. The K+ ion coordinates the DNA phosphate backbone, protein carboxyl 
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oxygens (from Leu238 and Leu241) and hydroxyl (from Ser237) group within the H2TH 
motif of α10 and α11. Four residues; Arg239, Lys244, Arg245 and Lys267 and the 
H2TH:K+ ion provide the surface interaction with the duplex mostly with the DNA 
template strand6,9,83. Mutation studies on T5FEN (K125A and R216A) of the extended 
basic residues showed a deficiency in binding cleavage and studies on double mutations 
hFEN1 (K244AK245A and K252AK254A) impaired the cleavage significantly81. 
 
 
1.6.4 Hydrophobic wedge 
 
The hydrophobic wedge was first discovered in AfFEN and consists of α2, the connecting 
loop and α322. The position of this protruding binding feature is adjacent to the upstream 
binding site and below the helical arch. The hydrophobic wedge is responsible for forcing 
open the dsDNA-ssDNA or dsDNA-dsDNA bifurcated junction. In wild type human 
FEN1, when the upstream duplex bent at 1000 angle, the top of helices α2-α3 and the 
connecting loop interact with the terminal base pair22. There is an extra interaction between 
some of the hydrophobic wedge residues and the last base pair face help to stabilise the 
bent configuration9. Hydrophobic wedges undergo a disorder to order conformational 
changes upon substrate binding6,9. 
 
 
1.6.5 3’-flap binding pocket 
 
Studies reported that FEN1 cleaves double flap substrates which have unpaired single 
nucleotide 3’-flap endonucleolyticaly or exonucleolyticaly with greater efficiency than a 
single 5’-flap substrate84. A specific binding pocket for this single nucleotide flap is 
observed. Structural studies of FEN1 proteins from different organism showed, only the 
higher organisms possess a 3’-extrahelical nucleotide binding pocket13 to attach with their 
preferred double flap substrates (a 5’ displaced single-stranded DNA flap and 1 nt at 3’-
flap)22. This binding pocket stimulates catalysis of substrate hydrolysis including at lower 
concentration by stabilising the enzyme-substrate complex – it orientates the positions of 
the scissile phosphate near to the active site to facilitate the cleavage specificity. In 
bacteriophage enzymes, no stimulation occurs on introduction of a 3’-flap because of the 
absence of the binding pocket. Theoretically, in human FEN1 an acidic block of residues 
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will select a one nucleotide 3’-flap by creating a ‘road-block’. The binding pocket is 
proposed to sterically block the 3’-flap from being longer than one nucleotide9,73. The 
single nucleotide of 3’-flap is directed by a specific contact to the 3’-hydroxyl group on 
the nucleic acid, and DNA backbone contacts in the minor groove together with a Leu 
residues that stacks between the unpaired nucleobase and the next nucleobase - help to 
anchor this construct in place. In human FEN1, 10 amino acid residues (M65, L53, T61, 
Q54, N55, Q315, K314, F316, R320 and S317) surround the 3’ flap binding pocket to 
thread the one nucleotide into the pocket.6,13,37.  
 
 
1.7 FEN1 and substrate binding specificity 
 
FEN1 is a so-called multifunctional and structure specific enzyme because of the capability 
to recognise different DNA structure with various “activities”7. The substrate specificities 
including with or without 5’-flap or 3’-flap on FENs superfamily have been discussed in 
detail. In vitro studies indicate that, FEN1 substrates possess multiple potential reaction 
sites either endonuclease or exonuclease7. Few aspects can decrease the effectiveness of 
FEN1 superfamily to cleave 5’-flap; there are; 1) more than 20 nucleotides length of 5’-
flap - the presence of secondary structure, 2) the presence of non-nucleotide molecules 
attached to the flap and 3) the modification of the 5’-phosphate group of the reacting 5’-
duplex. The mechanism for FEN1-substrate binding involves firstly the protein interacting 
with the ds-region downstream of the cleavage site at the ss-ds DNA junction. Another site 
interacts with the upstream ds-region (3’-flap binding pocket) and the last part is involved 
in the binding of the ss-flap region of the DNA substrates6,9,13,37.  
 
Studies of FEN1 from yeast S.cerevisiae, proposed that when the upstream primer consists 
of 1 nt 3’-flap, the reaction is more efficient compared with a fully annealed upstream 
primer85. A study of the 5’-nuclease of Taq DNA polymerase I9, has shown that a substrate 
with 1 nt overlap between the 3’-end of the primer strand and the 5’-end of the downstream 






Generally, all FENs cleave double flap substrates endo-nucleolytically. The reactions 
occur at the bifurcated site, but the main hydrolysis is a single nucleotide into the 5’ 
downstream region. The one nucleotide 3’-flap substrate produces a specific reaction one 
nucleotide into the double-strand to give rise to a nicked DNA product. In-vivo 5’-flaps 
and 3’-flaps are mobile because both displaced DNAs are complementary to the template 
and can therefore potentially equilibrate into different lengths of double 5’-3’ flaps86–88.  
 
Besides that, FEN1 superfamily can also cleave other flap substrate structures including a 
pseudo Y DNA structure (lower organisms) and 5’ overhangs which do not have the 
upstream duplex. FENs also can cleave exo-nucleolytic substrates which does not have a 
single-stranded 5’-flap including, 5’ blunt ended duplexes with a 3’-flap, nicked DNA and 
duplex DNA. For the FEN1s of higher organisms reactions of substrates that lack a single 
nucleotide 3’-flap or the ability to generate one are generally very slow81.  
 
A substrate that has a portion of secondary structure in the 5’-flap is has been termed a gap 
substrate. The gap endonuclease activity of FEN1 is also important. In-vivo, secondary 
structure such as hairpins in the 5’ single stranded flap can appear when flapped DNA is 
self-complementary. Genetic disorders such as Huntington’s diseases are related to the 
presence of tri-nucleotide repeat (TNR) sequences within the genome. These can form 
higher order secondary structures within the strands. FEN1 gap endonuclease activity 
suppresses TNR expansion. On double flap substrates that have a region of duplex within 
the 5’-flap, the reaction efficiency depends on the gap length89.  
 
To prevent any error during the processes, the right substrate must participate. Therefore, 
hFEN1 as a structure-specific nuclease, displays strand specificity and is totally 
independent of sequence for recognising the substrate. Studies revealed that hFEN1 is 









1.8 FEN1 catalysed mechanism 
 
The mechanism of FEN1 catalysis has been debated. Most of the studies proposed that the 
mechanism of the substrate positioning, the helical arch and divalent metal ions play 
crucial roles. Older studies suggested that FEN1 recognizes single-stranded flaps and could 
bind to 5’ flaps regardless the length and nucleotide sequence72. An important recognition 
feature is the ability to bend the DNA junction (100o bend), which allows the 3’ flap bind 
at the binding pocket and the threading of 5’-flap. Additionally, FEN1 could hydrolyse 
DNA with and without a 5’-flap as long as the 5’-end is phosphorylated13,37,72.  
 
There has been much discussion about the role of the helical arch in the FEN1 reaction and 
how it interacts with the substrate. Three mechanisms have been suggested: tracking90–92, 
threading86 and clamping17 (Figure 1.11). Bambara et al. postulated, that FEN1 captured 
the end of 5’-flap and tracked down in a threading fashion or with a ratcheted movement 
from a clamped enzyme until it reached the junction with dsDNA when reaction would 
occur36. However, this mechanism is not efficient for 3’-single flap (3’-SF) and gapped 
substrates that lack 5’ flaps. Another hypothesis proposed that FEN1 binds with the double 
strand regions of its substrate first and then continues by accommodating the 5’ portion of 
the substrate by threading it through the arch to form cleavage competent complex9,71. 
However, the problem of how single-strand DNA passed through the small hole of the arch 
remained a question.  
 
 
Figure 1.11: The threading and clamping mechanism. Route 1 shows the 5’ flap threaded 
through the helical arch (between α4 and α5), allowing cleavage when dsDNA is 
encountered. Route 2 and 3 show the clamping scheme; 5’ flap is passed to one side of the 




Alternatively studies suggested the arch of FEN1 worked as a ‘clamp’ and not by threading 
the flap through. The clamping model proposed FEN1 recognises the dsDNA junction first, 
then the DNA passes to either side of the helical arch rather than threading through it. Next 
biochemical evidence in 2012 by Patel et al., proposed a disorder to order mechanism72 of 
the helical arch and this model solved some of problems with the previous threading 
theory. A disorder-thread-order model has been developed in which FEN1 initially 
recognises the dsDNA junction while the helical arch is disordered. Once the DNA 




1.9 Human FEN1 in threading mechanism 
 
To date, the most relevant mechanism for FEN1 accommodation of DNA substrates with 
a 5’ ssDNA flap is a threading mechanism. The theory is the arch is in disordered position, 
but once ss-5’-flap thread through, it changes to an ordered form and known as ‘disordered-
thread-ordered’ mechanism72 (Figure 1.12). As we know, the ordered helical arch width 
allows only single-stranded DNA through, therefore this mechanism is the best technique 
to organise specific DNA structure. Various methods have been used to investigate the 
threading processes including the use of 5’-biotinylated flap substrates. Streptavidin is a 
53 kDa tetrameric moiety that binds with very high affinity to biotin72,90. The size of 
conjugated streptavidin prevents the passage of a 5’-flap through even a completely 
disordered helical arch. The binding of streptavidin to a 5’-biotinylated substrate has a 








Figure 1.12: A model for threading mechanism (model based on PDB: 1UL1). a) with free 
DNA, the arch are in disordered position, b) the single-strand 5’-flap threaded through 
the disordered helical arch and c) ordered helical arch with presence of DNA6. 
 
The threading of the ss-5’-flap into the disordered helical arch, forces the scissile phosphate 
to move near the active site and undergo hydrolysis providing that the 3’-flap has been 
recognised6. The interaction with the active site can occur through direct contact with 
active site metals or contact with amino acid residues of the active site. Studies suggested 
the ordered position is stabilised by two residues of α2 (M37 and Y40), four residues of α4 
(K93, R100, R103 and R104) and also three residues of α5 (K125, K128 and R129)6,9,37.  
 
The streptavidin-binding assay had two possible outcomes depending on the order of 
addition of components; if streptavidin is added first followed by hFEN1 later, the 
irreversible binding of streptavidin to the DNA takes place and ‘blocked’ (Figure 1.13) 
the DNA from threading through the helical arch. When Mg2+ is added to initiate reaction 
the substrate only reacts very slowly. On the other hand, if the streptavidin was added after 
incubation of the 5’-biotinylated substrate with hFEN1, the substrates becomes ‘trapped’ 
(Figure 1.13) within the helical arch and unable to unthread. In this case when Mg2+ is 
added to initiate reaction the substrate is hydrolysed rapidly. It was found that double flap 
substrates contain a region of duplex in the flap could be trapped on the protein. These 
substrates could not thread through a structured arch. It was therefore proposed, that the 
dsDNA binds to the protein when the helical arch is partially or completely disordered. 






Figure 1.13: The two schemes for the threading analysis performed by Patel et al., either 
trapped or blocked. S is a 5’-biotinyated substrate, E is an enzyme, SA is a streptavidin72. 
 
 
1.10 FEN1 protein partners  
 
During the replication and repair processes, various proteins work together. One of these 
interactions is between PCNA a sliding clamp protein and human FEN1. In vitro studies 
suggest that the activity of hFEN1 can be stimulated by PCNA46. DNA polymerases and 
DNA ligase also interact with PCNA11. In DNA replication, PCNA is proposed to 
coordinate DNA polymerase, FEN1 and DNA ligase to maximise the throughput of DNA 
and maintain fidelity11. The C-terminus of FEN1 has been shown to be disordered until it 
encounters other proteins such as PCNA. Figure 1.14 shows the cartoon of hFEN1-PCNA 
interaction. hFEN1-PCNA binding orders the C-terminus into a β-strand that packs against 





Figure 1.14: The cartoon representation of the hFEN1-PCNA interaction visualised by 
PyMOL Viewer (PDB ID: IUL1), where the PCNA homotimer consists of three domains 
(blue, green and turquoise) each bound to hFEN1 (red). 
 
 
1.11 Proliferating cell nuclear antigen  
 
A similar structure of DNA sliding clamp proteins have been found in archaea, bacteria 
and eukaryotes. In eukaryotes, the sliding clamp protein is called the proliferating cell 
nuclear antigen (PCNA), also known as cyclin or the DNA polymerase δ auxiliary 
protein95. Based on discovering PCNA in the nucleus of animal, plant, and yeast cells 
during cell separation it was proposed that PCNA plays a key role during the synthesis 
phase (S) of the cell cycle and it is highly conserved protein96. PCNA is a dynamic protein 
that was originally distinguished as the processivity factor for DNA polymerase delta and 
as necessary protein for eukaryotic chromosomal DNA replication94.  
 
In-vitro studies with Simian virus 40 (SV40) DNA replication aided understanding of the 
function of the proteins at the replication fork including the PCNA and pol-δ97. A later 
investigation reported numerous X-ray crystal structures of PCNA bound to peptides 
derived from PCNA-binding proteins98. More recent studies have discovered that the 
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sliding clamp of PCNA allows it to work and cooperate with many different proteins 
involved in several different metabolic pathways. PCNA is a multifunctional protein with 
responsibility in various processes including DNA replication and DNA damage repair94. 
 
 
1.12 Structures of PCNA 
 
PCNA is a sliding clamp in eukaryotes, which is responsible for providing replicative 
polymerases with the high processivity needed to duplicate the cells. PCNA has a ring 
structure that binds the DNA topologically and can slide freely along the DNA. 
Crystallographic studies demonstrated that PCNA has a ring shaped structure in solution 
and the central hole is adequate to accommodate the double helix of DNA. The structure 
of the PCNA trimer consists of three monomers, each of them containing a domain A (N-
terminal) and a domain B (C-terminal). These two domains are held together by an 
extended β-sheet across the inter-domain boundary on each subunit99. The inter-domain 
connector loop (IDCL), residues 119 to 134, is a flexible linker and a region of PCNA 
where a large number of proteins bind. The six-fold symmetry and six repeating domains 
generate a hexagonal shape and are bound in a head-to-tail96 order to form ring-shape 
homo-trimer37,94,100 (Figure 1.15). 
 
 
Figure1.15: The cartoon representation of the structure of PCNA visualised by PyMOL 
Viewer (PDB ID: IUL1); where the purple colour represent IDCL (119 - 134 residues), 
the blue colour show N- terminal (1 - 118 residues) and green colour show C-terminal 
(135 – 258).  
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The approximate diameter of PCNA ring was found to be 80 Å and the central hole was 
approximately 35 Å large enough for dsDNA to pass through. PCNA has non-equal 
surfaces between the inner side and outer side. Generally, the electrostatic potential for 
PCNA is negative due to the β-sheets at the outside surface of PCNA. The inside surface 
of PCNA ring is strongly positively charged, due to the presence of lysine and arginine99. 
Besides that, the layer of α-helices at the inner side allow PCNA to encircle the double 
helix DNA by interaction with the phosphate backbone of DNA. The unique topological 
nature of PCNA surfaces, allow it to slide along a duplex DNA stably and freely in either 
direction. Most of the protein-protein interactions occur at the front face of PCNA ring 
because it presents the IDCL. The role of the back face of PCNA is not fully investigated 
to date. Previous studies have revealed that PCNA can interact with a diverse set of proteins 
to play many cellular processes including binding with PIPs (PCNA interacting peptides) 
and full-length proteins23,94.  
 
 
1.13 The FEN1 and PCNA interaction 
 
The human FEN1-PCNA complex visualised by X-ray crystallography is composed of 
three FEN1 molecules, bound to one PCNA trimer in the absence of DNA101. The three 
PCNA subunits tightly associate to form a closed ring, with each subunit exhibiting 
symmetry23. The main interface of FEN1-PCNA complex involves the C-terminal tail of 
FEN1, which forms two beta-strands connected by a short helix, the βA-αA-βB motif, 
participating in beta-beta and hydrophobic interactions with PCNA23 and keeping the 
enzyme in an inactive locked-down orientation. These interactions are furnished by the 
residues forming the consensus PIP-box102 or binding motif “Qxxhxxaa”, where ‘h’ is an 
aliphatic hydrophobe (leucine, isoleucine or methionine) and ‘a’ an aromatic hydrophobe 
(phenylalanine or tyrosine), which serves to anchor the client protein to the clamp23,94,102.  
 
Three-dimensional crystal structures of the hFEN1-PCNA complex have revealed that 
PCNA also interacts with other regions of FEN1103, including the short linker of FEN1 
hinge region; 333QGST336 connecting with FEN1 via the strand βA of the C-terminal tail 
and α13 of the core domain FEN1. It has been suggested that this may be responsible for 
the stimulation of FEN1 nuclease activity. Further backed up by mutations in the hinge 
region affecting the nuclease activity. Biochemical studies suggested that the FEN1-PCNA 
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complex has three possible functions. These are (1) recruitment of FEN1 to the site of 
DNA replication, (2) stimulation of the cleavage of RNA primer flaps and (3) coordination 
of highly ordered RNA primer processing and DNA ligation103.  
 
 
1.14 The role of PCNA 
 
PCNA is required for replicative polymerases to duplicate an entire genome. Various 
studies have revealed that PCNA plays a key role in cell systems, especially eukaryotic 
cells. Proteins binding to PCNA have specific function in cells. The proteins interact with 
PCNA via PCNA-interacting peptides (PIPs). PIPs that have function in enzymatic activity 
including DNA replication, DNA repair and translesion synthesis94. 
 
 
1.14.1 PCNA in DNA replication 
 
DNA replication involves many processes such as initiation, elongation, replication fork 
progression, DNA replication proteins, replication machinery and termination. In 
eukaryotic cells, DNA replication occurs at the Synthesis phase (S) of the cell cycle. PCNA 
has no enzymatic activity, but PCNA is a central and essential factor for DNA replication 
acting as a moving platform to strengthen the process. According to these particular 
features, the presence of the Replication Factor C (RFC) is important to localise the PCNA 
trimer to the 3’-OH of a DNA primer by binding to the C-terminus of PCNA94,100. 
 
At the leading strand in DNA replication, the PCNA trimer will encircle DNA, secure 
polymerases firmly, then displaces pol-α/primase and allows the recruitment of pol-δ or 
pol-Ɛ to replicate the leading strand continuously in an error free manner. The four subunits 
of DNA pol-δ are p125, (contains the catalytic activity), p66 (contacts with PCNA), p16 
and p5094,104. However, on the lagging strand, FEN1 and DNA ligase-1 interact with PCNA 
at the IDCL to seal the nicks between Okazaki fragments. Studies proposed, during the 
Okazaki fragment maturation, pol-δ and FEN1 readily can associate with PCNA and 
dissociate from PCNA then replace one another on a single PCNA monomer. The 
switching processes in the correct sequence between pol-δ and FEN1 on a single PCNA 
monomer will need to be adequate for effective replication94.  
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The PCNA trimer ring like structure allows itself to encircle around DNA and slide along 
the DNA double-helical structure freely in both directions99. PCNA plays important roles 
in coordinating the process of switching the pol-α and pol-δ (or pol-Ɛ) at the discontinuous 
lagging strand and the synthesis initiation of leading strand and in the completion of the 
Okazaki fragment maturation process94.  
 
 
1.14.2 PCNA in DNA repair  
 
DNA damage can occur to the DNA molecules in cells at a rate of approximately one 
million individual molecular lesions per cell per day during metabolic activities and from 
environmental factors. The lesions will produce a big impact to the code of the genome 
such as structural damage and harmful mutations. Two types of DNA damages have been 
identified either endogenous damage or exogenous damage, which occur from an external 
agent (e.g. ultraviolet radiation from the sun). DNA repair is a process where many proteins 
work concurrently often with PCNA involvement. Some of the DNAs can be repaired with 
metabolic pathways such as mismatch repair (MMR), base excision repair (BER), and 
nucleotide excision repair (NER) which all involve a DNA synthesis step requiring 
polymerase, which further indicates a function for PCNA.  
 
Previous studies have shown that in DNA, the PCNA can recruit and coordinate repair 
proteins in MMR process by interaction with mispair-binding proteins forming a ternary 
complex and the complex will be transferred from PCNA to ATP105–108. While, under lp-
BER in-vitro, PCNA is involved in the re-synthesis and incision steps for repairing specific 
sites during the DNA synthesis109–115. In addition, the NER pathway is the process where 
mammalian cells eliminate carcinogenic lesions. Normally the DNA damage occurs from 
sunlight or other common mutagens. Two stages are involved in NER pathway; a) incision 
at sites of DNA damage and b) synthesis of new DNA to restore the damaged 
nucleotides116. PCNA plays a role at the early step of the NER pathway. PCNA will recruit 
the endonuclease XP-A and XP-G proteins to the specific site of lesion and binding with 






1.14.3 PCNA in translesion synthesis 
 
Another pathway for repair of damaged DNA is known as translesion synthesis (TLS). 
TLS authorize the DNA substrate replication machinery to duplicate over DNA lesions by 
changing out the normal DNA polymerase119. TLS polymerases have the unique potential 
to duplicate using damaged DNA as a template. In most cases, the TLS can incorporate the 
correct nucleotide. PCNA is in charge of coordinating the interchange between replicative 




1.15 Aims of project 
 
Flap endonucleases (FENs) catalyse the essential removal of single-stranded 5’-DNA or 
RNA protrusions known as flaps that occur during DNA replication and repair. When flaps 
occur in vivo they are migrating structures that can adopt a number of conformations, but 
it is believed that FEN1 will only act on one conformer. In addition, when FEN1 acts in-
vivo, it is typically in complex with the protein PCNA (Proliferating Cell Nuclear Antigen). 
This project will investigate the effects on FEN1 reaction specificity and rate of reaction 
of flapped structures of increasing complexity. The project will also investigate how PCNA 
alters the reactions of static or migrating double or single flaps and how the interaction 
between FEN1 and PCNA is mediated. The project will use the techniques of molecular 
biology, enzyme kinetics and biophysical chemistry. Various methods have been used to 
investigate the mechanism of how the hFEN1 select and accommodate the DNA substrate 
with a single-stranded 5’-flap. However, the accurate and precise mechanism is still 
unclear. This project aims to further investigate the role of hFEN1 during Okazaki 
fragments using threading analysis on the helical arch. Site directed mutagenesis of the 
human FEN1 are presented in order to understand the importance of conserved residues 
on helical arch. Finally, investigation on how the conformational changes of substrate on 
mutated human FEN1 compared with wilt type human FEN1. Exciton-Coupled Circular 
Dichroism (ECCD) will be used to monitor any distortion of DNA at reaction site by 




Chapter 2: Materials and Methods 
 




Figure 2.1: The diagram of standard operating procedures for human FEN1 and K125 
mutant expression and purification. 
 
Equipment 
Instrument AktaPURE (GE Lifesciences) 
Column OLIGOSep® Prep HC Cartridge 
Temperature 4 °C 





Media and buffers 
LB agar (1 L) 10 g tryptone, 10 g NaCl, 5 g yeast extract, 10 g agarose, H2O, 
(antibiotics; 25 mg/mL kanamycin + 34 mg/mL chloramphenicol) 
SOC media (1 L) 20 g tryptone, 0.6 g NaCl, 5 g yeast extract, 0.19 g KCl, 1.2 g 
MgSO4, 3.6 g D-Glucose, H2O 
2XYT (1 L) 16 g tryptone, 5 g NaCl, 10 g yeast extract, H2O (pH to 7.5) 
TY media (1 L) 12 g Tryptone, 24 g Yeast Extract, H2O 
20XP (1 L) 1 M Na2HPO4 (142 g), 1 M KH2PO4 (136 g), 0.5 M (NH4)2SO4 (66 
g), 900 mL H2O 
50X 5052 (100 mL) 2.5 g glucose, 25 g glycerol, 10 g α-lactose, 73 g H2O 
All media 25 mL 20XP, 10 mL 50X 5052, 1 mL 1M MgSO4, 100 μL trace 
metals, 500 μL (34 μg/mL) chloramphenicol, 4 mL 50 μg/mL 
kanamycin  
PBS 10 mM Na2HPO4, 2 mM KH2PO4 pH 7.4, 137 mM NaCl, 2.7 mM 
KCl 
Cell lysis buffer SIGMAFAST Protease Inhibitor Cocktail was dissolved in 100 mL 
IMAC A buffer  
50X TAE buffer (1 L) 100 mL 500 mM EDTA pH 8.0, 242 g tris base, 57.1 mL glacial 
acetic acid 
Resolving gel buffer 1.5 M tris pH 8.8, 0.4% SDS (w/v) 
Stacking gel buffer 0.5 M tris pH 6.8, 0.4% SDS (w/v) 
Agarose gel (100 mL) 100 mL 1X TAE, 10 μL SYBR safe DNA gel stain (10,000X) 1 g 
agarose  
Imac A1 20 mM tris, pH 7.0, 1 M NaCl, 5 mM imidazole, 0.02% NaN3 
Imac A2 20 mM tris, pH 7.0, 0.5 M NaCl, 40 mM imidazole, 0.02% NaN3, 
0.1% Tween-20 
Imac B1 0.5 M NaCl, 250 mM imidazole, pH 7.2, 0.02% NaN3 
Anion exchange A1 20 mM tris, pH 8.0, 1 mM EDTA, 0.02% NaN3, 20 mM βME 
Anion exchange B1 20 mM tris, pH 8.0, 1 mM EDTA, 1 M NaCl, 0.02% NaN3, 20 mM 
βME 
Heparin A1 25 mM tris pH 7.5, 1 mM CaCl2, 0.02% NaN3, 20 mM βME 




Storage buffer 100 mM HEPES (pH 7.5), 200 mM KCL, 2 mM CaCl2, 0.04% 
NaN3, 20% glycerol, 10 mM DTT 
 
 
2.1.1 Site-directed mutagenesis 
 
Primers for site directed mutagenesis were designed using 
http://www.genomics.agilent.com/primerDesignProgram.jsp and standard site directed 
mutagenesis protocols were used to create single point mutations. Briefly, the wild type 
plasmid (pET-28b) was sequenced by GATC Biotech. Once the sequence had been 
verified, a PCR reaction was set up. The mismatched primers (primer pair) were re-
suspended with water to make the concentration to 100 μM. PCR samples were prepared 
on ice by PFU ultra reaction buffer with 10 mM dNTPs, template DNA (pET28b hFEN1-
WT vector), 0.3 μM of each primer and PFU ultra HF Hot start polymerase. Samples were 
placed in PCR machine and run with following programme as shown in Figure 2.2, 




Figure 2.2: Thermocycling protocol for PCR mutagenesis reaction. First step was initial 
denaturation for 5 minute at 95 0C. Then 16x cycles for DNA polymerization at 95 0C (60 
sec), 55 0C (60 sec) and 68 0C (14 minutes). Continue the polymerization with extra 10 
minutes at 72 0C for final extension and lastly, hold the DNA at 4 0C. 
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On completion of the PCR programme, 1 μL of DPN1 was added, and the mixture was 
incubated for 1-2 hours at 37 0C. Agarose gel electrophoresis was used to analyse the 
products of PCR. Agarose (0.4 g) was dissolved in 50 mL 1x TA in the microwave for 50-
60 seconds and then cooled to 50 0C in a water bath for 10 minutes with addition of 5 μL 
SyBr safe DNA gel stain. After loading the PCR mixture (10 μL), 100 bp marker and 1 kb 
marker the agarose gel was run in 1X TAE at 120 volt for one hour and imaged using the 
ChemiDoc MP system (BioRad). 
 
 
2.1.2 Transformation of cells 
 
The plasmid was transformed into E. Coli XL10 and incubated for 45 minutes in ice and 
then heat shocked at 42 0C for 45-60 and subsequently recovered by cooling the cells on 
ice for 5 minutes. 1000 μL of SOC media was added and incubated at 37 0C for one hour 
at 180 rpm. The cells were spun for 60 seconds and the pellet was re-suspended the with 
250 μL SOC media. Finally, the cells were plated on the LB agar plates with 50 mg/mL 
kanamycin and incubated overnight at 37 0C. 
 
 
2.1.3 Plasmid preparation 
 
When the colonies had grown on the LB agar, one colony was added to 5 mL LB media 
containing 50 μg/mL kanamycin and incubated at 37 0C at 180 rpm overnight. The next 
day OD at 600 nm was used to confirm the starter cultures had grown. 
 
 
2.1.4 Plasmid extraction and purification 
 
A Monarch plasmid mini prep kit was used for the plasmid extraction and purification. The 
starter culture was divided into 1.5 mL Eppendorf tubes and pelleted at 13.3 rpm for 10 
minutes at 4 0C. The pellet was re-suspended in 200 μL of buffer B1 (pink) and mixed by 
vortexing. 200 μL of buffer B2 (green) was added and gently inverted and incubated at 
room temperature for 1 minute. 400 μL of buffer B3 (yellow) was added and mixed slowly 
by inverting until the colour was uniformly yellow and a precipitate formed. After 
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incubation at room temperature for 2 minutes the tube was and spun down at 13000 rpm 
for 5 minutes. The supernatant was transferred to a spin column and centrifuged for 1 
minute and the flow-through was discarded. The spin column was washed by adding 200 
μL of wash buffer and spun discarding the flow through. This step was repeated by washing 
the spin column with a further 2X 400 μL of wash buffer and centrifuged for one minute 
to remove all remaining wash buffers. The spin column was placed in a 1.5 mL clean tube 
and 40 μL of elution buffer was added. After 1 minute the plasmid was collected. The 
concentration of the plasmid was measured by absorbance at 260 nm using a Nanodrop 
UV spectrophotometer. The plasmid were prepared for sequencing by adding 5 μM of T7F 




2.1.5 Protein expression 
 
The chosen expression vector was transformed into Escherichia coli BL21(DE3)-RILP 
cells using the same procedure described above. When the colonies had grown on the LB 
agar, a single colony was added to 25 mL 2XYT media supplemented with 15 μL of 50 
mg/mL kanamycin and 25 μL of 34 mg/mL chloramphenicol. Shaking overnight at 37 0C, 
180 rpm the culture was grown until an OD reading at 600 nm around 0.6 was achieved. 
50 mL of the starter culture was used to inoculate a flask with 500 mL 2XYT media 
containing 500 μL 34 mg/mL chloramphenicol, 4 mL 50 mg/mL kanamycin, 10 mL 50X 
5052 media, 100 μL trace metals, 1 mL 1 M MgSO4 and 25 mL 20XP buffer. The cultures 
were grown for 4 hours at 37 0C, 225 rpm, then shaken (225 rpm) at 18 0C overnight. The 
cells were harvested by centrifugation at 6000 x g for 15 minutes at 4 0C. The supernatant 
was discarded and re-suspended in ice-cold phosphate buffered saline. The cells were 
transferred to 50 mL tubes and pelleted again by centrifugation at 4700 x g for 1 hour at 4 
0C. The supernatant was removed and the cells were suspended with 30 mL of lysis buffer 
and 5 mL of lysis buffer containing 2% of lysozyme. The cells were incubated and mixed 
gently in the cold room for 1 hour. A small portion of the cell lysate was analysed by SDS 






2.1.6 AKTA and columns 
 
AKTA 
To ensure that are no carry over from previous analysis, the AKTA system was washed 
with 0.1 M NaOH, H2O, 20% ethanol and H2O. The same procedure (wash or rinse the 
AKTA) was performed after each chromatographic step in the PCNA purification 
procedure. All super loops were also cleaned with sodium hydroxide and ethanol. 
 
Columns 
To prevent any contamination from previous protein purifications, all columns were 
washed manually via syringe according to manufacturer’s protocols before beginning the 
purification. Table 2.1 showed the type of columns and the buffers that have been used to 
wash the column. 
 
Table 2.1: Columns and buffers to clean up. 
Column Buffers 
HiTrapTM 5 mL TALON crude Co(NO3)2, stripping buffer, IMAC B1, H2O 
HiTrapTM QFF 5 mL 0.2 M NaOH, H2O, 20% EtOH,  
HiTrapTM Heparin FF 16/10 (20mL) 0.2 M NaOH, H2O, 20% EtOH,  
HiPrepTM 26/10 Desalting 0.2 M NaOH, H2O, 20% EtOH,  
0.2 M NaOH, H2O, 20% EtOH, 
0.2 M NaOH, H2O, 20% EtOH 
0.2 M NaOH, H2O, 20% EtOH,  





2.1.7 Protein purification 
 
The cell lysate was defrosted in cold water around for ~1 hour until completely thawed. 
The suspension was sonicated on ice at 75 % intensity for 10 minutes of pulsation for 5 
seconds with 25 second cooling intervals. 5 mL of buffer IMAC A1 containing 1% Tween-
20 was added to each lysate. The insoluble cell debris was removed by ultracentrifugation 
(30 000 × g at 4 0C for 30 min) leaving the clear lysate for purification. Protein purification 
was conducted on a AKTA pure chromatography system (GE Healthcare Life Sciences) in 
the cold room. All buffers were filtered and degassed prior to use for purification.  
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First, the supernatant was applied using a 50 mL superloop to the three tandem HiTrapTM 
5 mL TALON crude column. The column was washed with 5 column volumes of IMAC 
buffer A1 and 5 column volumes of IMAC buffer A2. The bound protein was eluted as 
single fraction with 8 column volumes of IMAC buffer B1. Fractions containing the protein 
of interest were identified by SDS-PAGE. The eluted fraction was diluted 1:1 ratio with 
anion exchange A1 buffer.  
 
Second, using the hFEN1_HiTrap_5mL method, the diluted eluate was applied to 
HiTrapTM QFF 5 mL column pre-equilibrated with the anion exchange A1 buffer. The 
column washed with anion exchange buffer A1, and then a linear NaCl gradient of 0 to 1 
M NaCl was applied over 10 column volumes. The fractions containing target protein (the 
protein is found in the flow through) were pooled and 10 μL of the fraction were retained 
for SDS-PAGE analysis. The eluted fraction was diluted further with an equal volume of 
cold heparin A1 buffer.  
 
Using the hFEN1_336_Heparin method, the protein solution was then applied to a 20 mL 
HiTrapTM Heparin FF 16/10 column, pre-equilibrated with 2 column volumes of heparin 
A1 buffer. The protein was applied to the column, washed with heparin buffer A1 and 
eluted using 15 column volumes of heparin B1 buffer containing a linear gradient of 0 to 
1 M NaCl. Fractions containing target protein were pooled and concentrated to less than 
10 mL using a 250 mL Amicon Ultra-filtration cell. The membrane used has a molecular 
weight cut off with a 10 kDa (Millipore) pressurised with 40 psi nitrogen gas.  
 
The protein was exchanged into the appropriate storage buffer using 
hFEN1_Desalt_HiPrep method. The protein was applied to 53 mL HiPrepTM 26/10 
Desalting column and the fractions were collected in 1.5 mL tubes. Samples were 




2.1.8 Determination of protein concentration 
 
Protein concentration was determined by the absorbance at 280 nm using a Nanodrop 
spectrophotometer and the calculated extinction coefficient for human FEN1, 22,920 M-1 
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cm-1. Once the protein was at a concentration of 200 μM in storage buffer (100 mM HEPES 
(pH 7.5), 200 mM KCL, 2 mM CaCl2, 0.04% NaN3, 20% glycerol, 10 mM DTT) an equal 
volume of glycerol was added to create a glycerol stock. The final protein concentration 
was 100 μM. The proteins were stored at −20 °C and purity of protein was assessed by 
SDS-PAGE with various concentrations (0.1 μg/μL until 1.6 μg/μL). 
 
 
2.2 PCNA purification 
 
Human PCNA was expressed previously by Dr L. David Finger using auto induction media 
and Bl21(DE3)-RILP cells. These were transformed with a pET41a vector harbouring the 
human PCNA gene cloned into the NdeI/XhoI sites in frame with the C-terminal (His)6-
tag. Cells were pelleted by centrifugation at 6000 × g, and the supernatant was discarded. 
The cells were re-suspended in 1X PBS and re-pelleted at 4700 × g. The supernatant was 
discarded, and the cell pellet was re-suspended in IMAC Buffer A1 (20 mM Tris pH 7.0, 
1 M NaCl, 5 mM imidazole, 0.02% NaN3) containing 1 mM ME. Once re-suspended, a 
solution of IMAC Buffer A1 containing 1 mM ME and 10 mg/mL lysozyme was added. 








IMAC A1 20 mM Tris pH 7.0, 1 M NaCl, 5 mM imidazole, 0.02% NaN3 
PCNA IMAC A2  
(1 L) 
25 mM Tris pH 7.5, 100 mM NaCl, 0.17% Brij-35, 0.02% NaN3, 
10% glycerol, 5 mM imidazole 
PCNA IMAC B1  500 mM NaCl, 0.02% NaN3, 250 mM imidazole pH 7.4 
PCNA IMAC B2  
(1 L) 
100 mM NaCl, 0.05% Brij-35, 0.02% NaN3, 10% glycerol, 250 
mM imidazole pH 7.4 
PCNA Anion  
Exchange A1 (1 L) 
25 mM Tris pH 7.5, 100 mM NaCl, 0.17% Brij-35, 0.02% NaN3, 
10% glycerol, 1 mM EDTA 
PCNA Anion  
Exchange B1 (1 L) 
25 mM Tris pH 7.5, 1000 mM NaCl, 0.17% Brij-35, 0.02% NaN3, 
10% glycerol, 1 mM EDTA 
PCNA Heparin A1 
(5 L) 
25 mM NaH2PO4 pH 7.0, 0.17% Brij-35, 0.02% NaN3, 10% 
glycerol 
PCNA Heparin B1  
(1 L) 
500 mM NaH2PO4 pH 7.0, 0.01% Brij-35, 0.02% NaN3, 10% 
glycerol 
PCNA PS/A1 (1 L) 25 mM Tris pH 7.5, 0.17% Brij-35, 0.02% NaN3, 10% glycerol, 
1 mM imidazole 
PCNA PS/B1 (5 L) 25 mM Tris pH 7.5, 0.02% NaN3, 1 mM EDTA, 1.5 M (NH4)2SO4 
Stripping buffer 20 mM Na phosphate pH 7.4, 50 mM EDTA, 0.5 M NaCl, 0.02% 
NaN3 
PCNA SEC buffer  
(3 L) 
100 mM HEPES pH 7.5, 200 mM KCl, 2 mM EDTA, 10 mM 
Na2S2O5, 10 mM DTT, 0.01% Brij-35, 0.04% NaN3 
 
 
2.2.1 PCNA purification 
 
The frozen cell suspension was thawed in a beaker of cold water until little lysate-ice was 
left whereby it was placed on ice. The viscous lysate was transferred into a beaker and 
sonicated on ice with 5 sec burst at 75% amplitude with 25 sec rest periods for a total of 1 
min and 30 secs of burst phase. The sonication was repeated until the lysate was no longer 
viscous. Then, 5 mL of 1% Tween-20 solution in IMAC Buffer A1 was added and mixed. 
The lysate was clarified by centrifugation at 30,000 × g for one hour. The supernatant was 
poured into a beaker and kept on ice. The pellet was washed once with 1X PBS, and then, 
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re-suspended in 10 mM tris pH 7.5, 2% SDS. The re-suspended pellet was then set aside 
for further analysis later. 
 
All protein purification steps were conducted in the cold room (4 °C) using an AktaPURE 
(GE Lifesciences). Two tandem 5 mL cobalt columns were charged with 0.1 M CoCl2 
according to the manufacturer’s protocol. The column was equilibrated with 5 column 
volumes (CV) of IMAC Buffer A1. The PCNA clarified lysate (~100 mL) was then applied 
to column using a 150 mL superloop (GE Lifesciences). The column was subsequently 
washed with 5 CV of IMAC Buffer A1 and then 10 CV of PCNA IMAC Buffer A2. The 
target protein was eluted as a single fraction with 10 CV of PCNA IMAC Buffer B1. A 10 
µL aliquot of the washes and the eluted fraction was retained for SDS PAGE. 
 
The eluate from the Co2+-IMAC column was diluted two-fold with water and then applied 
to two tandem 5 mL HiTrapTM Q FF column (2 x 5 mL in tandem) previously equilibrated 
with 5 CV of PCNA Anion Exchange A1. The protein was eluted using a 20 CV linear 
NaCl gradient (100 mM to 730 mM NaCl). Fractions containing hPCNA were confirmed 
by SDS-PAGE and then pooled. The pooled PCNA fraction was then dialysed against three 
× 1 L of Heparin A1 buffer at 4 °C. 
 
The dialysate was then applied to two tandem 5 mL HiTrapTM SP HP (2 x 5 mL) columns 
equilibrated with 5 CV of PCNA Heparin A1. Note, this is a subtractive column whereby 
the protein of interest flows through the column, whereas the impurity that needs to be 
removed is retained on the column. The column was eluted using a 10 CV gradient with 
buffer PCNA Heparin A1 and B1. Confirmation of PCNA in the flow through was 
achieved by SDS-PAGE.  
 
The flow through from the heparin column was then dialysed 3 × 1 L against PCNA 
Heparin A1. The dialysate was applied to a 26 × 100 mm hydroxyapatite-ultragel (Sigma) 
column that was equilibrated in PCNA Heparin A1. The column was then washed with 2 
CV of PCNA Heparin A1. The protein was eluted from the column by linear salt gradient 
to 500 NaH2PO4 pH 7.0 (PCNA Heparin B1) and collected in 50 mL tubes. The presence 
of the protein was confirmed by SDS-PAGE analysis and protein-containing fractions were 
concentrated using Vivaspin-20 (10,000 MWCO). Concentrated protein was dialyzed 
against 3 × 1 L of PCNA PS/B1 buffer in the cold room. 
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The dialysate was then applied to a HiTrap Phenyl Sepharose (16 x 100 mm) previously 
equilibrated with PCNA PS/B1 Buffer. The column was washed with 2 CV of PCNA 
PS/B1 buffer and then the protein was eluted from the column by an inverse linear salt 
gradient generated using buffers PCNA PS/A1 and B1. PCNA containing fractions were 
detected by SDS PAGE then pooled and concentrated by ultrafiltration using a 50 mL 
Amicon Ultrafiltration cell with 10,000 MWCO PES membrane (Millipore) pressurized 
with N2 (40 psi). The protein concentration was determined by absorbance at 280 nm using 
calculated extinction coefficients.  
 
 
2.2.2 Determination of PCNA concentration 
 
The concentrated protein sample was dialysed 3 × 1 L in SEC buffer at 4 °C. The protein 
concentration was re-measured as above and was concentrated to greater than 600 μM 
using a vivaspin-20 (4500 xpg at 4 °C for 10 min). The concentration of PCNA was 
measured again, and if above 600 μM was adjusted by the addition of SEC buffer. The 
volume of glycerol equal to the volume of protein solution was added to make a 300 μM 
PCNA stock solution in 50% glycerol. The aliquots were stored at -20 °C. The final 
concentration will be 300 μM of hPCNA, but as hPCNA is a trimeric protein, the 
concentration of (hPCNA)3 is 100 μM. 
 
 
2.2.3 Checking the nuclease activity of PCNA 
 
To ensure that the PCNA preparation lacked nuclease activity, the procedures for the 
multiple turnover analysis of FEN1 on double flap substrate was used except only 
proliferating cell nuclear antigen (PCNA) was added at 0 µM (blank), 0.025 µM, 0.05 µM 
1 µM and 10 µM using the UP31-9ST substrate. Table 2.2 summarized the concentration 




















50 20 160 18 0 50 60 
50 20 160 18 0.025 50 60 
50 20 160 18 0.05 50 60 
50 20 160 18 1 50 60 






Instrument denaturing High Performance Liquid Chromatography 
(dHPLC)  
Detector Fluorescence 
Column OLIGOSepTM Cartridge 
Temperature 75 °C 
Retention time 11 minutes 




10X RB (50 mL) 0.5 M HEPES (pH 7.5), 1 M KCl, 0.08 M MgCl2, 1 mg/mL 
BSA 
5X RRB (1 mL) 500 μL 10X RB, 5 µL DTT (1 M), 495 μL H2O 
1X RRB (2 mL) 400 μL 5X RRB, 1600 μL H2O 
MM (2.8 mL) 0.63 mL 5X RRB, 2.17 mL H2O 
10X FB (50 mL) 0.5 M HEPES (pH 7.5), 1 M KCl 
1X FB (10 mL) 1 mL 10X FB, 9 mL H2O 
ST quench (1 L) 50 mM EDTA, 1.5 M NaOH 
10X RB quench  
(1 L) 
0.5 M HEPES (pH 7.5), 1 M KCl, 0.08 M MgCl2, 1 mg/mL 
BSA, 0.02% NaN3 
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1X RRB quench (1 L) 100 mL 10X RB quench, 900 mL H2O 
1X RB quench (1 L) 55 mM HEPES (pH 7.5), 110 mM KCl, 8 mM MgCl2, 15% 
glycerol, 0.02% NaN3 
Wave buffer A (5 L) 0.1% MeCN, 1 mM EDTA, 2.5 mM TBAB, H2O 
Wave buffer B (5 L) 70% MeCN, 1 mM EDTA, 2.5 mM TBAB, H2O 
Wave buffer C (5 L) 8% MeCN, H2O 
Wave buffer D (5 L) 80% MeCN, H2O 
 
 
2.3.1 Multiple turnover analysis 
 
The DNA oligonucleotides listed in Table 2.3 were purchased from DNA Technology 
A/S. The DNA substrates were prepared using the indicated oligonucleotide as 5 μM stocks 
by heating (95 0C) and annealing the appropriate oligos in a 1:1.5:1.5 ratio; downstream: 
upstream: template (Table 2.4) in 1X folding buffer (55 mM HEPES (pH 7.5), 110 mM 
KCl). Reactions were prepared with varying concentrations of substrate below KM (2.5, 
5.0, 7.5 and 10.0 nM) and pre-incubated at 37 °C in 1X RB (55 mM HEPES pH 7.5, 110 
mM KCl, 8 mM MgCl2, 0.1 mg/mL BSA, 1 mM DTT). Reactions were initiated with wild 
type human FEN1 concentrations empirically determined to give ~10% hydrolysis of 
substrate in 10 minutes. Once initiated, 20 μL aliquots of the reaction were removed at 2, 
4, 6, 8, 10, 12 and 20 minutes and quenched in 50 μL of 250 mM EDTA. The analyses 
were carried out in triplicate. Quenched reactions were subsequently analysed by rp-ip-
dHPLC on a WAVE system equipped with fluorescence detector (ADS Biotech – formerly 
Transgenomics) using a 4.5 X 50 mm OLIGOSep™ column (ADS Biotech) at 75 °C. 
Substrate and product peak separation were achieved using a gradient as shown in Figure 
2.4 of Buffer A (2.5 mM tetrabutylammonium bromide (TBAB), 1 mM EDTA, 0.1% 
acetonitrile) and Buffer B (2.5 mM TBAB, 1M EDTA and 70% acetonitrile). The ratio of 
product formed was determined by integration of the chromatograms and calculating the 
ratio of product using Equation 2.1; 
 





Where Z is the area under the peak and S0 is the initial substrate concentration. Linear 
regression of a plot of concentration of product versus time of reaction produced slopes 
that are initial rates of reaction. Plots of normalized initial rates of reaction (v0/[E]0) versus 
substrate concentration produced a slope is the second order rate constant of the reaction 
(kcat/KM). Curve fitting was carried out using GraphPad Prism 7 software. 
 
Table 2.3: List of oligonucleotides. 








/5Bio/GGT CCT ACT ACG ATT CAA GAG 





/56-FAM/TTT TTT TTT TGA ATC GTA GTA 
GGA CC 3’ 
266460 8509.8 
UP31-9ST /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT CTC C3’ 
275300 9748.5 
F26-9EQ /56-FAM/TCT CTC TCT TGA ATC GTA 
GTA GGA CC 3’ 
262860 8449.7 
UP31-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT CTC T 3’ 
275900 9763.5 
UP30-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT CTC 3’ 
268100 9459.3 
UP29-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT CT 3’ 
260600 9170.1 
UP28-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT C 3’ 
252800 8865.9 
UP27-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TCT 3’ 
245300 8576.7 
UP26-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC TC 3’ 
237500 8272.5 
UP25-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 




UP24-9EQ /5Bio/CCA GAT CCA GTT CAG CTC AGC 
GTC 3’ 
222200 7679.2 





Table 2.4: Oligonucleotide combination used to make the substrate constructs the 
experiments. 
Downstream; 1 Upstream; 1.5 Template; 1.5 
F26-9ST UP31-9ST Temp-48 
 
F26-9EQ 
UP31-9EQ, UP30-9EQ, UP29-9EQ, 
UP28-9EQ, UP27-9EQ, UP26-9EQ, 







Figure 2.4: Gradient for kinetics analysis at 75 0C by Denaturing HPLC used to separate 
the reaction products from substrate. The specific gradient switch points are as follows: 0 
min 5% B 95% A, 1 min 35% B 65% A, 6.5 min 55% B 45% A, 7.1 min 100% B, 8.5 min 







2.3.2 Single turnover analysis 
 
Single turnover analysis was carried out using a RQF-63 quench flow device (Hi-Tech Sci 
Ltd, Sailsbury, UK) at 37 °C. The reactions between enzyme and substrate were carried 
out between 4.5 ms to 51241 ms (21 points) in 8 mM MgCl2, 110 mM KCl, 55 mM HEPES 
(pH 7.5), 0.1 mg/mL BSA and 1 mM DTT. 80 µL of enzyme solution and substrate 
solution were injected and quenched with 80 µL of 1.5 M NaOH, 80 mM EDTA. The final 
concentrations of enzyme and substrate were 1 µM and 2.5 nM, respectively. The 
quenched reaction mixtures were removed from the sample loop and analysed using rp-ip-
dHPLC equipped with a fluorescence detector as described above. The analyses were done 
in triplicate. The concentration of product was determined using Equation 2.1. The 
concentration of product with time was then non-linear regression fitted (GraphPad Prism 
7 software) using Equation 2.2; 
 
{P% = A1 (1-e-kfast*t) + A2 (1-e-kslow*t)} 
Equation 2.2 
 
Where A1 and A2 represent the amplitude @ span of the exponential phase for fast and 
slow phases respectively and kfast and kslow are the observed rate constant associated with 
the process and at t time kfast was used to obtain first order rates of reaction.  
 
 
2.4 Oligonucleotide purification 
 
Equipment 
Instrument High Performance Liquid Chromatography (HPLC)  
Detector Tunable Absorbance Detector 
Column OLIGOSep® Prep HC Cartridge 
Temperature 60 °C 
Retention time 25 minutes 
Flow rate 1.5 mL/min 






Stock 1 M TEAAc pH: 7 
Buffer A 0.1 M TEAAc pH: 7 
Buffer B 0.1 M TEAAc pH 7, 25% acetonitrile 
High salt buffer 10 mM Tris pH 8, 1 M NaCl, 1 mM EDTA, 0.02% NaN3, 
Low salt buffer 10 mM Tris pH 8, 100 mM NaCl, 1 mM EDTA, 0.02% 
NaN3, 
 
Oligonucleotide purification was achieved by HPLC using an OLIGOPrep™ (9.2 × 50 
mm) eluting using a gradient as shown in Figure 2.5 with a linear gradient Buffer A (100 
mM triethylammonium acetate, 0.1% acetonitrile) and Buffer B (100 mM 
triethylammonium acetate, 25% acetonitrile). The peak corresponding to the 
oligonucleotide was collected and then applied manually to a 5 mL HiTrapQ column 
equilibrated with Low Salt Buffer. The column was then washed manually with 10 CV of 
Low Salt Buffer. The oligonucleotide was eluted manually with 10 CV of High Salt Buffer 
with fractionation into 1.5 mL tubes. The fractions containing oligonucleotide were 
determined using A260 and pooled. The oligonucleotide was then desalted using NAP-25 
desalting columns according to the manufacturer’s protocol. Oligonucleotides were dried 
in a speed vac, and then, re-suspended in water. The concentration of the oligonucleotide 
stocks were determined by UV spectrophotometry (A260) and calculated extinction 








Figure 2.5: Gradient for oligonucleotide purification analysis by HPLC used to collect the 
pure oligonucleotide. The specific gradient switch points are as follows: 0 min 5% B 95% 
A, 0.5 min 5% B 95% A, 18.0 min 50% B 50% A, 19.0 min 100% B, 21.0 min 100% B, 21.5 
min 5% B 95% A, 25.0 min 5% B 95% A. 
 
 
2.5 Threading analysis 
 
Buffers 
10X CaRB (50 mL) 250 mM HEPES (pH 7.5), 0.5 M KCl, 20 mM CaCl2, 1 
mg/mL BSA 
5X CaRB (2 mL) 1000 μL 10X CaRB, 5 μL 1 M DTT, 995 μL H2O 
1X CaRB (2 mL) 400 μL 5X CaRB, 1600 μL H2O 
10X MgRB (50 mL) 250 mM HEPES (pH 7.5), 0.5 M KCl, 160 mM MgCl2, 1 
mg/mL BSA 
1X MgRB (2 mL) 200 μL 10X MgRB, 1800 μL H2O 
MM (2 mL) 572 μL 5X CaRB, 1430 μL H2O 
10X FB (50 mL) 
1X FB (10 mL) 
0.5 M HEPES (pH 7.5), 1 M KCl 
1 mL 10X FB, 9 mL H2O 
Bench quench (1 L) 8 M urea, 80 mM EDTA 






Figure 2.6: SB5-1 structures were prepared by KF-2DL as a flap strand, which have biotin 
for streptavidin attach on the DNA and FAM for detection by fluorescence detector and 
TEM-2E as a template strand for threading analysis. 
 
All substrate (Figure 2.6) binding reactions were prepared with 100 nM of the biotinylated 
substrate SB5-1 in 50 mM HEPES pH 7.5, 100 mM KCl, 4 mM CaCl2, 0.2 mg/ml BSA, 
and 2 mM DTT. The DNA substrates were prepared using the indicated oligonucleotide as 
5 μM stocks by heating (95 0C) and annealing the appropriate oligonucleotides in a 1:1.1 
ratio between flap and template strand in 1X folding buffer.  
 
As can see in Figure 2.7, premixed complexes were prepared by incubating the 5 nM 
substrate with indicated 500 nM hFEN1 protein for 2 minutes at room temperature in 
master mixed (MM) and continued by adding 18 μL 1X Ca buffer and equilibrated for 5 
minutes in room temperature. Trapped complexes refer to binding reactions that were 
prepared by incubating the 5 nM substrate with the indicated 500 nM hFEN1 protein for 2 
minutes at room temperature in MM. Then streptavidin was added to 5 times excess of 
substrate (dissolved in 1X CaRRB) and equilibrated for 5 minutes at room temperature. 
Blocked complexes refer to binding reactions that were prepared by incubating the 
substrate with a 5 molar excess streptavidin for 5 minutes in room temperature in MM. 
Then continued by adding the indicated 500 nM hFEN1 protein and equilibrated for 2 






Figure 2.7: Threading analysis procedures for premixed, trapped and blocked. (S: 
substrate, E: enzyme, SA: streptavidin). 
 
After the addition of the second component in both blocked and trapped binding reactions, 
the reactions were incubated for a further 1 minute at 37 0C. Then, 20 μL of aliquots were 
took out before the reaction was started as a control for the experiment. Then, magnesium 
reaction buffer (25 mM HEPES (pH 7.5), 0.05 M KCl, 16 mM MgCl2, 0.1 mg/mL BSA) 
was added to the samples to initiate the reaction at 37 0C. The reaction was quenched in a 
quench solution of 8 M urea and 80 mM EDTA at varying time points on the bench 
(Premix: 10 s, 20, 30, 40, 1 minute, 2, 4, 8, 16, 30, 60, 120; Trapped: 10 s, 20, 30, 40, 1 
minute, 2, 4, 8, 16, 30, 60, 120, 240, 360 and Blocked: 30 s, 1 minutes, 2, 4, 8, 16, 30, 60, 
120, 180, 240, 360). Further analyses were done (especially for premixed and trapped) at 
lower delay times using a RQF-63 quench flow device at 37 °C. The reaction was quenched 
in a quench solution of 8 M urea and 300 mM EDTA at varying time (between 30.6 ms to 
14041 ms). Final substrate and enzyme concentrations were 5 nM and 500 nM 
respectively. Quenched reactions were subsequently analysed by rp-ip-dHPLC on a 
WAVE system equipped with fluorescence detector at 50 0C. The specific gradient switch 
points are as follows: 0 min 5% B 95% A, 1 min 30% B 70% A, 5.5 min 55% B 45% A, 






Figure 2.8: Gradient for kinetics analysis at 50 0Cby Denaturing HPLC used to separate 
the reaction products from substrate. The specific gradient switch points are as follows: 0 
min 5% B 95% A, 1 min 30% B 70% A, 5.5 min 55% B 45% A, 7.1 min 100% B, 10.0 min 
100% B, 10.1 min 5% B 95% A, 12.5 min 5% B 95% A. 
 
 
2.6 2-aminopurine Exciton-Coupled Circular Dichroism (ECCD) Spectroscopy  
 
Buffers 
10X buffer (Ca2+) 0.5 M HEPES (pH 7.5), 100 mM CaCl2, 1 M KCl,  
10X FB 0.5 M HEPES (pH 7.5), 1 M KCl,  
Storage buffer (SB) 100 mM KCl, 1 mM CaCl2, 5 mM DTT, 50 mM HEPES (pH 
7.5), 0.02% NaN3, 50% glycerol  
 
The concentration of the final stocks was measured by UV Nanodrop at 260 nm and using 
extinction coefficients generated by IDT oligo analyser 3.1 tool 
(http://www.idtdna.com/calc/analyzer). Solution of substrate oligonucleotides (100 μΜ) 
were prepared in 0.5 m HEPES (pH 7.5) and 1 M KCl from appropriate constituent 
oligonucleotides. The substrates with 2-aminopurine were bought from DNA Technology 






A mixture of 1X FB and storage buffer (SB) was used as a blank and 10 µM substrates 
with none template (ssFEC1) incubated in 100 mM KCl, 1 mM CaCl2, 5 mM DTT, 50 mM 
HEPES (pH 7.5), 0.02% NaN3, 50% glycerol was used as a control. Samples containing 10 
µM of the indicated DNA construct, 55 mM HEPES pH 7.5, 110 mM KCl, 1 mM DTT, 
and either 10 mM CaCl2 or 10 mM CaCl2 + 25 mM EDTA and appropriate 12.5 µM 
indicated protein (hFEN1, R103A, R125A and R129A) where incubated at 20 °C for 10 
minutes. 
 
ECCD spectra were collected using a quartz cuvette with a 5 mm path length and with 
subsequent acquisition at 20 0C of ECCD spectra (300–480 nm) using an Applied 
Photophysics Chirascan CD spectrophotometer. ECCD spectra are an average of two 
repeats in set recorded in 0.8 nm step size (time per point: 0.5 s) that were baseline 
corrected using spectra recorded on samples containing the same components, but lacking 
DNA. The baseline-subtracted spectra were smoothed using Chirascan Pro-Data software 
(version : Chirascan v.4.4.2.0). The signal was normalized to account for baseline shift 
observed for day to day variation. To normalize for baseline shifts, the signal was averaged 
between 400-480 nm, a region in which 2-APs has no absorbance and was subtracted from 
the associated spectrum. The ECCD spectra data were analysed and plotted as Δε per mol 
2-AP residue versus wavelength using GraphPad Prisam 7 Software. Each measurement 




Chapter 3: Migrating Flap Substrates 
 
To date most in-vitro studies of human FEN1 reactions have used static (non-equilibrating) 
flap substrates bearing non-complementary 5’ and 3’ flaps, where the single stranded 
regions are not complementary to the template (continuous) DNA. However, when flaps 
occur in-vivo, they are migrating or equilibrating structures as the flaps can base pair with 
template DNA. This study will focus on how the full length wild type human flap 
endonuclease-1 (WT-hFEN1) acts on migrating flap substrates. The behaviour of 
migrating flap substrates will be compared to those of static flaps.  
 
During Okazaki fragment maturation, there are two regions to a double-flap substrate. The 
downstream duplex that has a 5’-flap generated by a polymerase on the previous Okazaki 
fragment, whereas the upstream duplex is generated by a polymerase from the latest 
Okazaki fragment synthesised. In-vivo, the double-flap of substrates are equilibrating 
because the Okazaki fragments are synthesised from the same parental template during the 
replication of new strand41. As a consequence of this, the length of 3’ flap and 5’ flap can 
vary giving rise to a number of different conformations. However, FEN1 is thought to act 
upon the substrate in one particular conformer that is a conformer with single nucleotide 




Figure 3.1: General structures of double flap for this study. 
 
To investigate how the migrating flap substrates affect the ability of hFEN1 to catalyse the 
reaction, nine different migrating flap substrates were designed by Dr. L David Finger. For 
this research, the migrating flap substrate were designed to have between 1 to 9 
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overlapping base pairs as shown in Table 3.1. The continuous template strand, Temp-48 
is 48 nucleotides bases long in all cases and forms a downstream double-stranded DNA 
(dsDNA) of variable length. As a comparison for each result in the analysis, a static 
substrate, that has an 8 nucleotides 5’-flap was be used as a control. As shown in Figure 
3.2, each flap substrate was constructed by annealing three oligonucleotides; a 26 
nucleotide 5’-FAM labelled strand that formed the downstream duplex, a 48 nucleotide 5’-
biotinylated DNA as complementary template strand and a variable upstream 3’-flap strand 
with 5’ biotin. Biotin was attached to allow detection of the oligonucleotides using a 
streptavidin antibody system. In addition, the relatively small biotin (244.3 Da) was 
unlikely to perturb the function of the substrate. The 5’-FAM allows flap removal to be 
monitored. The oligonucleotides can be used to create a static double flap control and 
migrating flaps. hFEN1 is predicted to cleave at a specific site location when the substrate 
adopts a conformer with a single nucleotide 3’-flap.  
 
Table 3.1: A variable 10 upstream 3’-flap strand with 5’ biotin. The length of 5’ flap 
between zero to eight nucleotides to form different length single-strand 5’ flap products. 
Each substrate were annealed at 95 0C for 5 minutes with the ratio 1 (downstream), 1.5 
















product 5’ 3’ 
UP31-9ST 8 1 1 0 9 
UP23-9EQ 0 1 1 of 2 1 1 
UP24-9EQ 1 1 1 of 3 2 2 
UP25-9EQ 2 1 1 of 4 3 3 
UP26-9EQ 3 1 1 of 5 4 4 
UP27-9EQ 4 1 1 of 6 5 5 
UP28-9EQ 5 1 1 of 7 6 6 
UP29-9EQ 6 1 1 of 8 7 7 
UP30-9EQ 7 1 1 of 9 8 8 






Figure 3.2: A schematic of the designed DNAs with 5’-FAM for reaction monitoring and 
5’-biotin on the template and upstream strands. This illustration of the migrating flaps 
shows one of the potential conformers with a single nucleotides 3’ flap and corresponding 
length 5’ flap. The static flap, 8 nts 5’ flap and 1 nt 3’ flap (UP31-9ST) used as a control 
for the analysis. The template strand is common to each structure whereas the flap and 
upstream strands are different.  
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3.1 Full length human FEN1 purification 
 
To carry out this study, full length wild type hFEN1 bearing an C-terminal (His)6-tag was 
purified following expression in Escherichia coli BL21(DE3)-RILP using auto-induction 
methods as described in section 2.1. Proteins were purified using four different 
chromatographic media including IMAC, anion-exchange, heparin and desalting column. 
Initially, the target protein was captured by an IMAC column and was then further purified 
by anion exchange chromatography to remove nucleic acid contamination that coelutes 
with the protein. To remove further contaminants, the protein purification was further 
polished by heparin affinity chromatography. The protein was concentrated and exchanged 
into storage buffer. The protein purity was assessed by SDS PAGE as shown in Figure 
3.3. The single band from each of concentrations; 0.1, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.6 μg/μL 
proved that the human FEN1 was totally pure and not contaminated by other proteins.  
 
 
Figure 3.3: SDS PAGE gel showing the purity of full length human wild type FEN1 after 
purification and concentration steps. Lane 1 and lane 9: Protein ladder (representing 10, 
15, 20, 25, 37, 50, 75, 100, 150 and 250 kDa), lane 2: 0.1 μg/μL, lane 3: 0.2 μg/μL, lane 
4: 0.4 μg/μL, lane 5: 0.6 μg/μL, lane 6: 0.8 μg/μL, lane 7: 1 μg/μL and lane 8: 1.6 μg/μL. 
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3.2 Kinetics studies 
 
Measuring the kinetics of hFEN1 reactions allows for a comprehensive comparison of 
altered conditions and reagents that can ultimately lead to a mechanistic understanding and 
the elucidation of structure-function relationships. Comparing measured rates of reaction 
with static and migrating substrates will allow us to understand the influence migrating 
flaps on hFEN1 activity. hFEN1 prefers to bind at a double flap DNA structure with 1 nt 
3’-flap, because occupation of the 3’-flap binding site by a single 3’-flap nucleotide is 
crucial to reaction. However, detailed kinetic information with migrating flap substrates is 
lacking. 
 
Both multiple and single turnover kinetic analyses are routinely employed to determine the 
rate of reaction of human FEN1-catalyzed hydrolysis. Under second order or steady-state 
multiple turnover (MT) conditions where substrate concentration is in a large excess to the 
enzyme and lower than KM, the catalytic efficiency (kcat/KM) of hFEN1 acting on a static 
double flap is close to the bimolecular diffusion association rates in solution (kon) of 
roughly 107-1010 M-1 s-1. Typically under MT conditions, enzyme must catalyse multiple 
hydrolyses of substrate to create detectable amounts of product. Because substrate 
hydrolysis decreases the substrate concentration only the first 10% of the reaction is 
monitored37. 
 
The proposed enzyme kinetics reaction pathway with static double flap substrates is shown 
in Figure 3.4. The scheme shows that enzyme and substrate form an encounter complex 
that must change conformation to become catalytically competent. Once hydrolysis has 
occurred, the 5’-flap product (P) is thought to be released and an enzyme product complex 
(EN) is former with the dsDNA product. This must them dissociate for turnover to occur. 
If we allow the substrate to have many conformations and all can bind to the enzyme, albeit 
with different affinities, then there are also at least ES1, ES2, ES3 until ESn states (where n 
is the number of potential conformers) possible. It is also likely that the ESn states must 
reach the ES state to then proceed through these conformational changes as well to become 
cleavage competent. An alternative model, which could also be represented by Figure 3.4 
assumes only one conformer (that with a single nt 3’-flap) can bind to the enzyme, but that 






Figure 3.4: The proposed reaction pathway of FEN1 catalysed reaction of double flaps 
substrates37. Where E; enzyme, S; substrate, ES; P; the flap or single-stranded product 
and N; nicked or double-stranded product. 
 
Downstream, upstream and template strands were mixed with specific ratios and heated at 
95 0C for 5 minutes and then annealed in 100 mM KCl, 50 mM HEPES-KOH pH 7.5 and 
0.02 % NaN3 to pre-form a static or migrating double flap substrate. Reverse-phase ion-
pairing denaturing high performance liquid chromatography (dHPLC), using 
tetrabutylammonium bromide (TBAB) as the interface with solid phase was utilized along 
with a fluorescence detector to monitor and quantify the cleavage reaction catalysed by 
human FEN1. In the analysis, only the fluorescein-labelled product and substrate were 
observed, and these were quantified by integration using the WAVETM system software to 
calculate the percentage product at each time point. The concentrations of product 








Under the substrate-limiting multiple turnover analysis, the specific substrates 
concentrations were prepared and initiated with an appropriate enzyme concentration and 
measured by discontinuous assay at 37 0C. A linear relationship between product 
concentration (nM) versus time (minutes) demonstrate that initial rates (v0 min
-1) under 
steady state conditions were being calculated. The initial rates (v0) were determined by 
linear regression and normalised by dividing by enzyme concentration [E]0. The 
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normalised rates of reaction (v0/[E]0) versus substrate concentration [S] were measured 
three times and plotted. Linear regression using GraphPad Prism 7 software was used to 
acquire kcat/KM rate constants (gradient).  
 
Under maximal single turnover (ST) conditions, where the enzyme is in excess of the 
substrate and adding more enzyme does not increase the rate of reaction, the rate of reaction 
is the decay of the ES complex. The maximal MT rate (kcat) is slower than the respective 
ST maximal rate when enzyme is saturating, suggesting that product release (krelease) is the 
rate-limiting step under saturating substrate conditions. During the human FEN1 catalytic 
activity, there are additional steps to substrate binding and catalysis. The enzyme and 
substrate undergo a series of distinct conformational changes before it is ready for 
hydrolysis including the threading of the DNA flap, helical arch ordering, un-twisting of 
DNA nucleotides and finally phosphodiester hydrolysis. Thus, using ST conditions at time 
points faster than enzyme-product release allows us to assess the effects of these additional 
steps in our reaction scheme.  
 
 
3.2.1 Kinetic characterisation of full length WThFEN1  
 
The kinetic parameters of full length WThFEN1 were determined using a static double flap 
substrate with a 5 nts 5'-flap and a 1 nt 3'-flap (DF5,1) (Figure 3.5) and 5’-fluorescein 
(FAM) similar to the substrates that have been used previously by Dr. Jack Exel121. The 
full Michaelis-Menten curve was analysed, under conditions where the [𝐸]≪[𝑆] at pH 7.5 
and at 8 mM MgCl2. The final concentration of the substrates were 5, 10, 25, 50, 75, 100, 
250, 500, 750, 1000, 2500 and 5000 nM with the final enzyme concentration less than 
0.01% of that of the substrate concentration. Only the initial phase (10% or less) of product 
formation was used to determine the rate of reaction. The formation of single strand and 
nicked products were assessed by dHPLC and calculated via Equation 3.1. Each substrate 
was analysed in triplicate at different concentrations. A plot of the normalized initial rates 
of reaction v0/[E]0, min
-1 versus substrate concentration was curve fitted to the Michaelis-
Menten equation as shown in Figure 3.6. The variation of the concentration of substrates 









Equation 3.2  
Where, 




          Equation 3.3 
 
Where V0; initial reaction velocity, S; substrate concentration, KM; the Michaelis constant 
and Vmax; the maximum reaction velocity (all the active sites are saturated). While KM is 




Figure 3.5: The structure of static double flaps, 5 nucleotides 5’-flap and 1 nucleotide 3’-





Figure 3.6: Michaelis-Menten plots for endonucleoytic cleavage of DF5,1 by new batch 
of full length human WTFEN1. Result of fitting data using non-linear regression of the 
Michaelis-Menten equation. 
 
The results show that initially the enzyme activity increases linearly with substrate 
concentration. Then, v0/[E]0, follows saturation reactions with respect to [S]. By plotting 
the curve using non-linear regression and the Michaelis-Menten model in GraphPad Prism 
7 software, the value of kcat and KM can be measured. In this analysis, the value of KM is 
43 ± 6 nM, which is double the previous result of 20 ± 3 nM121. The value of kcat is 218 ± 
14 min-1, slightly higher than measured by Dr. Jack Exell at 165 ± 9 min-1.  
 
The single turnover rates of substrate hydrolysis were measured to complement the 
multiple turnover measurements of human FEN1. The final enzyme concentration was 10-
fold higher than KM value and the substrate concentration was 2.5 nM. Data were fitted to 
Equation 2.2 in section 2.3.2, and each single turnover data point is representative of at 
least three replicates (Figure 3.7). The rate was significantly faster than maximal multiple 
turnover rates of reaction with a value of 723 ± 59 min-1 as shown in Table 3.2. The 
multiple turnover parameters are the rate limited by product release as discovered by earlier 
FEN studies37. The measurement is slightly slower when compared with previous values 






Figure 3.7: The kst rate for DF5,1 cleavage by human FEN1 protein. The [S] was 2.5 nM 
and the final enzyme concentrations was 450 nM. Reactions were performed in 55 mM 
HEPES-NaOH pH = 7.5, 8 mM MgCl2, 1 mM DTT, 110 mM KCl and 0.1 μg/μL BSA and 
at 37 ˚C.  
 
Table 3.2: Comparison of catalytic of DF5,1 with full length WThFEN1 new and old 
batch121. 
Protein kcat, min-1 KM, nM kst, min-1 
Full length WThFEN1 
new batch 
218 ± 14 43 ± 6 723 ± 59 
Full length WThFEN1 
old batch 
165 ± 9 20 ± 3 918 ± 50 
 
 
3.2.2 Oligonucleotide purification 
 
When oligonucleotides were purchased initial purification was requested. Three 
oligonucleotides have been further purified; 48 nucleotides template (Temp-48), 31 
nucleotides static upstream (UP31-9ST) and 26 nucleotides static downstream (F26-9ST) 
to see if there are any differences in the substrate properties of initially-purified versus 
extra-purified oligonucleotides. The second order rate of reaction analyses were 
determined by heating and annealing downstream, upstream and template strands in 
1:1.5:1.5 ratio, respectively in buffer to form a static double flap substrate; 8 nts 5'-flap 
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and a 1 nt 3'-flap and 5’-fluorescein (FAM) labelled. Multiple turnover analysis were 
conducted, final [S] were 2.5, 5.0, 7.5 and 10.0 nM and final [E] were 0.5 pM and 1 pM 
for 10% of products in 8 mM MgCl2, pH 7.5 at 37 °C.  
 
Results showed that there were no significant differences between initial purified and 
extra-purified oligonucleotides. The slope of plots of v0/[E]0 versus [S] were determined, 
as shown in Figure 3.8 for initial purified and extra-purified substrates which yielded 
kcat/KM of 6.29 ± 0.59 nM
-1min-1 and 4.58 ± 0.53 nM-1min-1, respectively. The 95% 
confidence intervals slope were between 3.40 to 5.77 for extra-purified and 4.98 to 7.59 
for the initial. In this useful analysis, it is believed that the initial-purified and extra-purified 




Figure 3.8: The means of oligonucleotide purification analysis for second order rate 
analysis on static double flap substrate; 8 nts 5'-flap and a 1 nt 3'-flap (UP31-9ST) and 
5’-fluorescein (FAM) labelled. Purple and red represent the initial purified and extra-
purified substrates respectively. Errors represent standard errors of experiments 









3.2.3 Determination the ability of human FEN1 to process substrates that can adopt 
multiple conformers 
 
For steady state analysis, reaction mixtures were prepared at lower concentrations of the 
substrates of 2.5, 5.0, 7.5 and 10 nM to determine kcat/KM for the ten different double flap 
substrates. The range of enzyme concentrations were between 0.5 to 12 pM. To examine 
the rate of the human FEN1 in-vitro, we carried out the MT analyses on the different 
substrates with variable numbers of potential conformers. Each measurement was the 
average of at least three independent experiments at 37 0C. The reaction mixture were 
removed and quenched at seven time points; 2, 4, 6, 8, 10, 12 and 20 minutes after initiation 
of reaction. The reaction was stopped by addition of EDTA to chelate the essential divalent 
metal ions. It was hypothesised that as the number of potential conformers increase the 
second order rate constants would get lower. 
 
Sample dHPLC chromatograms of the fluorescence intensity (mV) of product and 
substrate versus retention time (min) are shown in Figure 3.9. From the analysis with 4 
different concentrations of each double flap substrate, there is only one product peak 
appearing in the reactions of the migrating substrates, despite their ability to adopt multiple 
conformers to different degrees. This demonstrates the ability of hFEN1 to hydrolyse in 
only one place despite the various length of nucleotides and the ability of substrates to 






Figure 3.9: Multiple turnover analyses of the hFEN1 catalysed reactions with 10 different 
double flap migrating and static substrates. Each of the figure represents; a) for UP23-
9EQ, b) for UP24-9EQ, c) for UP25-9EQ, d) for UP26-9EQ, e) for UP27-9EQ, f) for 
UP28-9EQ, g) for UP29-9EQ, h) for UP30-9EQ, i) for UP31-9EQ and j) for UP31-9ST. 
The separation by dHPLC at 75 0C produced two peaks; single-strand products (small 




Furthermore, the retention time for each single peak of product is proportional with the 
predicted length 5’ single stranded DNA product assuming reaction one nucleotide into 
the downstream duplex and that the only conformers undergoing reaction all have a single 
nucleotide 3’flap. Figure 3.10 illustrates that the retention time (min) for the peak of 
single-stranded product appeared between 3 to 5 minutes for 10 different sets of double 
flap substrates. The UP23-9EQ substrate has a one nucleotide 5’ flap ssDNA product 
having the shortest retention times at 3.2 minutes whereas the products from UP31-9EQ 
and UP31-9ST substrates appeared at 4.8 and 5 minutes respectively. Both substrates have 
9 nucleotides 5’ flap ssDNA products. The retention times for the products of UP24-9EQ, 
UP25-9EQ, UP26-9EQ, UP27-9EQ, UP28-9EQ, UP29-9EQ and UP30-9EQ were 3.3, 3.5, 
3.7, 3.9, 4.0, 4.2 and 4.4 minutes respectively. Thus the shorter the 5’ flap single stranded 
DNA products detected by the fluorescence detector, the faster the peak will appear in 
chromatogram. The results show that the number of nucleotides in the 5’-flap is 





Figure 3.10: The retention times of the 5’-flap products of the different equilibrating 
substrates. Analysis by dHPLC show the retention time increases when the length of 







3.2.4 Studies of the second order rate constant, kcat/KM for the hFEN1-catalysed reaction 
of static and equilibrating double flap substrates  
 
These experiments were carried out and initiated as described in section 3.2.3. The v0/[E]0 
min-1 versus substrate concentration [S] nM for 10 substrates which have zero to 8 
nucleotide 5’ flaps in cleaved conformation and increasing numbers of potential 
conformers were plotted in Figure 3.11. The derived second order rate constants were 
summarized in Table 3.3. The graph in Figure 3.12 plotted kcat/KM versus the number of 
potential conformers. Figure 3.12 shows that, the cleavage by human FEN1 on the 
migrating flaps occurs at a different rate depending on the amount of potential conformers. 
Generally, the average kcat/KM for the 10 substrates were decreased when amount of 
potential conformers increased reflecting our initial hypothesis. 
 
Table 3.3: The kcat/KM for the 10 DNA substrates in these studies. The various length of 
the 5’ flap formed with a 1 nucleotide 3’ flap is noted for all DNA substrates. All analysis 










UP31-9ST 1 8 1 6.28 ± 0.59 
UP23-9EQ 2 0 1 6.22 ± 0.61 
UP24-9EQ 3 1 1 3.70 ± 0.44 
UP25-9EQ 4 2 1 0.45 ± 0.19 
UP26-9EQ 5 3 1 4.79 ± 0.77 
UP27-9EQ 6 4 1 0.58 ± 0.15 
UP28-9EQ 7 5 1 2.85 ± 0.47 
UP29-9EQ 8 6 1 1.45 ± 0.31 
UP30-9EQ 9 7 1 2.25 ± 0.27 






Figure 3.11: Second-order, kcat/KM rates of the hFEN1 reaction were determined by 
plotting by v0/[E]0 (min
-)1 versus substrate concentration (nM) with the 10 different 
substrates with differing number of conformers. Each of the figure represents, UP23-9EQ, 
UP24-9EQ, UP25-9EQ, UP26-9EQ, UP27-9EQ, UP28-9EQ, UP29-9EQ, UP30-9EQ, 





Figure 3.12: The second order constant; kcat/KM, nM
-1 min-1 versus the number of potential 
conformers were plotted. Potential conformers 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 represent of 
UP31-9ST (static control), UP23-9EQ, UP24-9EQ, UP25-9EQ, UP26-9EQ, UP27-9EQ, 
UP28-9EQ, UP29-9EQ, UP30-9EQ and UP31-9EQ respectively. The data points (open 
blue circle) are the average of three replicates and standard errors are shown. 
 
A linear regression (straight line) and no constrain (‘y’ not constant equal to zero) was has 
been used to fit all the data by GraphPad Prism 7. Based on the results, three factors 
probably contribute to the outcome. First, theoretically, assuming the enzyme acts on 
substrate in one conformational state, the more potential conformers of the migrating flaps 
substrates the slower the expected kcat/KM rate constants to form the product. This is 
because the equilibrating double flap substrates has to undergo a conformational change to 
form enzyme-substrate complex via interchangeable lengths of 3’ and 5’ flaps in solution 
or on enzyme to achieve a 1 nt 3’ flap for hydrolysis. For example, Figure 3.13 
demonstrates the 10 potential conformers of UP31-9EQ and since only one conformer 
reacts its reaction should be the slowest rate when compared to the other equilibrating 
substrates. However, UP25-9EQ, where only 1 of 4 potential conformers reacts, and UP27-
9EQ where only 1 of 6 potential conformers reacts have the slowest rates for second order 
analysis of 0.45 ± 0.19 nM-1 min-1 and 0.58 ± 0.15 nM-1 min-1 respectively. Figure 3.14 
display the static double flaps (UP31-9ST) which has the same length of single stranded 
5’-flap as the migrating flap UP31-9EQ but presumably is not undergoing conformational 
change to make the 3’-flap form. Based on the data, the conformational changes for 
migrating flaps substrates before the incision of hFEN contribute to the rate of reaction. 
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Figure 3.13: Scheme illustrating 10 potential conformers of UP31-9EQ. The diagram 
shows 10 potential conformers for the equilibrating flap. FEN1 catalysed incision occurs 
only when there is a 1 nucleotide at 3’ flap. Other potential conformers indirectly 
contribute to the rate of reaction by reducing the amount of “reactive” substrate. As well 
as the lengths of the 5’- and 3’-flaps the length of downstream and upstream duplex are 







Figure 3.14: The model of static double flap substrate in-vitro. The direct incision 
contribute to the fast reaction by human FEN1. 
 
The second conclusion form this study is that the rate of reaction varies with the length of 
the ssDNA product produced, which is in turn related to the number of conformers that 
can be accessed by these substrates. The longer the length of nucleotides on 5’ flaps, the 
slower the kcat/KM rate constant. Table 3.3 shows the kcat/KM, for UP31-9EQ (where one of 
1 of 10 potential conformers reacts) which has a 9 nucleotide single stranded 5’ flap 
product is 0.90 ±0.11 nM-1 min-1 compared with UP23-9EQ (where 1 of 2 potential 
conformers reacts) which was 6 fold higher (6.22 ± 0.61 nM-1 min-1) and only has a 1 
nucleotide single stranded 5’ flap product. This pattern applies generally for all the 
migrating substrates in this study.  
 
Moreover, there are also additional more subtle effects. Because of the substrate design, 
which economises on the number of DNAs required, the identity of the base pairs 
surrounding the scissile phosphodiester bond differ as the number of potential conformers 
are adjusted. Notably, the nucleotides surrounding the position of the incision (TA or GC), 
may also have an effect on the rate of reaction. The pattern of second order constants 
(kcat/KM,)
 (Figure 3.12) vary where those with odd numbers of potential conformers have 
higher rates of reaction compared with those with even numbers of potential conformers. 
This is probably because of the sequence of the DNA substrates, whereas for 3, 5, 7 and 9 
potential conformers the position of the hydrolysis of human FEN1 were on G-C base 
pairs, while for 2, 4, 6, 8 and 10 potential conformers the phosphate bond were cut off on 




Alternatively, all the data could be plot with a nonlinear regression Michaelis-Menten (‘y’ 
constant equal to zero) by GraphPad Prism 7.  Figure 3.15 shows the results of 10 
potential conformers via Michaelis-Menten. However, using this method, there are some 




Figure 3.15: Second-order, kcat/KM rates of the hFEN1 reaction were determined by 
plotting by v0/[E]0 (min
-)1 versus substrate concentration (nM) with the 10 different 
substrates with differing number of conformers via Michaelis-Menten. 
 
 
Figure 3.16: The second order constant; kcat/KM, nM
-1 min-1 versus the number of potential 
conformers were plotted by Michaelis-Menten. Potential conformers 1, 2, 3, 4, 5, 6, 7, 8, 
9 and 10 represent of UP31-9ST (static control), UP23-9EQ, UP24-9EQ, UP25-9EQ, 
UP26-9EQ, UP27-9EQ, UP28-9EQ, UP29-9EQ, UP30-9EQ and UP31-9EQ respectively. 






3.2.5  The effect of lengths of 5’ flaps and the number of potential conformers on static 
and migrating DNA flap substrates 
 
As our substrate design altered the length of the 5’ flap in the substrates, we decided to 
investigate the impact of this on the rate of reaction in the range of flap length studies. To 
investigate this static flaps substrates were used as a control. The equilibrating and static 
flaps substrates were studied; UP23-9EQ and F18-1ST (F18 = flap strand of 18 nucleotides 
, 1ST = 1 nt of ssDNA 3’ flap, ST = static) which both have a zero nucleotide 5’ flap in 
their cleaved conformation, UP27-9EQ and F22-5ST (F = flap strand of 22 nucleotides, 
5ST = 5 nts of ssDNA (4 nts 5’flap and 1 nt 3’ flap), ST = static) which both have 4 
nucleotide 5’ flaps and UP31-9EQ and UP31-9ST which both have 8 nucleotides 5’ flaps 
(Figure 3.17). 5’-FAM labelled downstream (F26-9ST), and a 5-biotinylated DNA as 
complementary template (Temp-48) were heating and annealed as mentioned before with 
a variable upstream 3’-flap strand with 5’ biotin (either F18-1ST or F22-5ST or UP31-9ST 
individually) to preform a static double flap substrate which has zero nt for F18-1ST or 4 
nts for F22-5ST and 8 nucleotides for UP31-9ST 5'-flap length. 
 
Comparison of the catalytic parameters for endonucleoytic cleavage of the three static 
double flaps, F18-1ST, F22-5ST and UP31-9ST by human FEN1 show that at low[S] here 
is no statistical difference in the turnover rate (Table 3.4), 6.02 ± 0.45 nM-1 min-1, 6.40 ± 
0.32 nM-1 min-1 and 6.28 ± 0.59 nM-1 min-1 respectively, although each of the substrates 
has different length of nucleotides in its 5’ flap. The kcat/KM rate constant for UP23-9EQ 
where 1 of 2 potential conformers reacts is 6.22 ± 0.61 nM-1, close to that of the static flap. 
However, for UP27-9EQ (1 of 6 potential conformers reacts) and UP31-9EQ (1 of 10 
potential conformers reacts), the values of kcat/KM are 0.58 ± 0.15 nM
-1 min-1 and 0.90 ± 
0.11 nM-1 min-1 respectively, are slower than the kcat/KM rate constant of their static 
counterparts (control) with the same length of 5’ flap. This almost certainly arises because 
both these substrates can adopt conformations that do not present the 1 nucleotide 3’ flap 
that is preferred by human FEN1. These results signify that the amount of potential 






Figure 3.17: The sequence of equilibrating (EQ) and static (ST) substrates comprised of 
48 nts of template and 26 nts of upstream DNA. Each of the static substrates has 1 
conformer, while for the migrating flaps; a) UP23-9EQ has 2 potential conformers with 
zero nucleotide at 5’-flap in reactive conformation, b) UP27-9EQ has 6 potential 
conformers with 4 nucleotides of 5’-flap in reactive conformation and c) UP31-9EQ has 
10 potential conformers with 8 nucleotides of 5’-flap in reactive conformation. 
 
Table 3.4: The kcat/KM comparison data between equilibrating and static flaps. Each of the 
static double flap substrates has one conformer and various length of nucleotides at 5’ 








UP23-9EQ 2 0 1 6.22 ± 0.61 
F18-1ST 1 0 1 6.02 ± 0.45 
UP27-9EQ 6 4 1 0.58 ± 0.15 
F22-5ST 1 4 1 6.40 ± 0.32 
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UP31-9EQ 10 8 1 0.90 ± 0.11 
UP31-9ST 1 8 1 6.28 ± 0.59 
 
 
3.2.6 Estimation of kcat for ten different DNA substrates 
 
The steady-state catalytic parameter (kcat) is the measurement of the rate by which an 
enzyme-substrate complexes [ES] produces the nicked (N) product and free enzyme [E] 
and is also known as the turnover of the enzyme. The kcat represents the rate of the chemical 
reaction and the rate of product release and may also include the rate of on-enzyme 
conformational change steps. Therefore kcat was determined under substrate-saturating 
multiple turnover conditions to determine what is rate limiting. The analyses have been 
done for all 10 of the static and migrating double flap substrates at the final concentration 
of the substrates of 1000 and 3000 nM. For each of the substrate, at least three independent 
analyses were conducted.  
 
Table 3.5 display that the slope of a plot of v0/[E]0 against [S] for all the double flap 
substrates. These are close to zero at high substrate concentration regardless of the numbers 
of potential conformers and the length of nucleotides at 5’ flap. These results indicate that 
the multiple turnover reaction is saturated with substrate, therefore the rate constants are 
similar at both concentrations of substrate and are an estimate of kcat. When the average of 
kcat estimate is plotted against number of conformers (Figure 3.18) UP31-9ST is 208 min
-
1 and UP23-9EQ is 228 min-1 whereas the other substrates are slower. Generally the data 
show the substrates with odd numbers of potential conformers have slightly higher average 
kcat estimates compared with even numbers. Based on these kcat results, 1000 nM substrate 









Table 3.5: The kcat average estimate for 10 DNA substrates in this studies. 1 of 2 until 1 of 













kcat estimate) 5’ 3’ 
UP31-9ST 1 8 1 0.042 ± 0.006 208.49 
UP23-9EQ 2 0 1 0.030 ± 0.005 227.84 
UP24-9EQ 3 1 1 2.5 x 10-4 ± 0.001 65.05 
UP25-9EQ 4 2 1 2.5 x 10-5 ± 0.001 27.22 
UP26-9EQ 5 3 1 -0.004 ± 0.001  63.11 
UP27-9EQ 6 4 1 -0.001 ± 0.000 25.37 
UP28-9EQ 7 5 1 0.005 ± 0.002 91.74 
UP29-9EQ 8 6 1 -0.002 ± 0.001 61.85 
UP30-9EQ 9 7 1 -0.006 ± 0.002 46.20 





Figure 3.18: The multiple turnover analysis the average of kcat estimate min
-1 versus the 
number of potential conformers were plotted by GraphPad Prism 6 software. Potential 
conformers 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 represent of UP31-9ST (static control), UP23-
9EQ, UP24-9EQ, UP25-9EQ, UP26-9EQ, UP27-9EQ, UP28-9EQ, UP29-9EQ, UP30-
9EQ and UP31-9EQ respectively. The data points (open red circle) are the average of 




3.2.7 The investigation of single turnover rate, kst on static and migrating flaps DNA 
substrates 
 
Single turnover rates were measured to complement the study of steady state parameters 
of the 10 substrates and also to explore whether product release affected the rate of reaction 
or not. The single turnover rate was determined at higher concentration of enzyme where 
[E] >> [S]. With these conditions, it is workable to measure the rate of decay of enzyme-
substrate complex [ES] before nicked product (N) release. Previous FEN studies observed 
that the rates of hFEN1-catalysed reactions performed under maximal single turnover (kst) 
analysis were higher compared with maximal multiple turnover (kcat) conditions. During 
replication, the diffusion between enzyme and substrate to form enzyme-substrate complex 
is probably a small factor. As a consequences, it has been proposed that the single turnover 
analysis in-vitro is more relevant to the in-vivo situation.  
 
All 10 double flap DNA substrates were studied at 37 0C using rapid handling apparatus 
(quenched flow). Under single turnover conditions, it was assumed the reaction started 
with enzyme-substrate complex when enzyme and substrate were instantaneously mixed. 
Previous studies have measured identical single turnover rates of reaction under maximal 
rate conditions for a pre-mixed ES complex to those reactions initiated by mixing E and 
S13. In all experiments for the 10 DNA substrates, the final concentration of hFEN1 and 
each substrate were 1000 nM and 2.5 nM respectively. Reactions were repeated with at 
least three replicates to ensure reliability and data was collected in the range of 4.5 ms to 
51241 ms in 55 mM HEPES (pH 7.5), 8 mM MgCl2, 1 mM DTT, 110 mM KCl and 0.1 
μg/μl BSA. The percent of product versus time were plotted as shown in Figure 3.19. The 
data were fitted with Equation 2.2 in section 2.3.2 by non-linear regression fitting 
(GraphPad Prism 7 software). The plotted data in Figure 3.19 show each of the DNA 
substrates display a two phase exponential relationship. The preferable fit to all the data 






Figure 3.19: First-order rate data were plot by percentage of the product (%) versus time 
(minute) with 10 different DNA substrates. Each of the figures represents; a for UP23-
9EQ, b for UP24-9EQ, c for UP25-9EQ, d for UP26-9EQ, e for UP27-9EQ, f for UP28-
9EQ, g for UP29-9EQ, h for UP30-9EQ, i for UP31-9EQ and j for UP31-9ST. The aliquots 
were quenched by RQF-63 quench flow device in 1.5 M NaOH and 80 mM EDTA and 




In each case data was fit to a double exponential with the rate of the fast phase of the 
reaction quoted. As shown in Figure 3.20 and Table 3.6 the kfast rate for static double flaps 
(UP31-9ST), 3758 ± 252 min-1 is the fastest rate to produce a 9 nucleotide 5’ flap product 
compare with other migrating flaps substrates. However, UP23-9EQ and UP27-9EQ have 
similar rates of single turnover to the static substrate of 3650 ± 214 min-1 and 3719 ± 197 
min-1 respectively and UP25-9EQ shows a slightly slower kst rate 3236 ± 179 min
-1. For 
UP28-9EQ , UP26-9EQ, UP24-9EQ DNA substrates the single turnover rate are 1.7-fold 
(2208 ± 174 min-1), 2.6-fold (1421 ± 96 min-1) and 2.9-fold (1291 ± 95 min-1) respectively 
slower than the UP31-9ST substrate. Another three migrating flaps have the slowest kfast, 
of 467 ± 15 min-1 for UP29-9EQ, 598 ± 24 min-1 for UP30-9EQ and 395 ± 17 min-1 for 
UP31-9EQ. Generally, the average of single turnover rate, kst from each DNA static and 
migrating substrates were faster than that measured under multiple turnover conditions. 
Moreover, the general trend is that as the number of conformers increases the single 




Figure 3.20: The first order constant; kst min
-1 versus the number of conformers were 
plotted. Potential conformers 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 represent of UP31-9ST (static 
control), UP23-9EQ, UP24-9EQ, UP25-9EQ, UP26-9EQ, UP27-9EQ, UP28-9EQ, 
UP29-9EQ, UP30-9EQ and UP31-9EQ respectively. The data points (open purple square) 






It is important to note that in all cases the amount of species decaying with a fast rate 
constant is relatively high (> 74%) and there is no relationship between the percentage fast 
and the number of conformers with stochastic variation observed between 74-92%. 
Decreasing proportions of fast decaying species would be expected if increasing number 
of conformers creates increasing proportions of “inactive” substrate that took significant 
time periods to rearrange, but this does not seem to be the case. Instead the formation of 
non-productive [ES] complex at high enzyme concentration, which seems to occur in all 
cases, could contribute to why the reaction failed to all react in the fast phase. It is likely 
that non-productive complexes need to dissociate and reassemble in before completing 
reaction. 
 
The increasing the number of potential conformers in each substrate appears to slow the 
single turnover rate of reaction. UP29-9EQ, UP30-9EQ and UP31-9EQ are three migrating 
substrates where 1 of 8, 1 of 9 and 1 of 10 potential conformers respectively, and produce 
the slowest reactions with 1000 nM enzyme. In one model, where the enzyme can only 
bind substrate in “reactive” (1 nt 3’ flap) conformation, increasing the number of 
conformers would raise the enzyme-substrate dissociation constant. Therefore a control 
was carried out with UP30-9EQ (1 of 9 potential conformers reacts) at a higher 
concentration of enzyme (3000 nM). The kst was 497 ± 42 min
-1 which is similar to the rate 
where [E] = 1000 nM (598 ± 24 min-1). This result demonstrated that the rate constants all 
seem likely to represent the maximal kst value. Thus the maximal single turnover rate is 
decreased with increasing number of conformers. This is likely to be because the enzyme 
and substrate (ES) complex needs more time (multiple conformations as discussed before) 













Table 3.6: The kst for 10 DNA substrates in this studies. Various length of nucleotides 5’ 
flap and 1 nucleotide 3’ flaps in all DNA substrates. All analysis were made triplicates and 
measurements by dHPLC at 75 0C and plotted by GraphPad Prism 7 software. Errors 












UP31-9ST 1 3758 ± 252 78.33 ± 1.87 23.11 ± 7.60 77.90 ± 1.36 
UP23-9EQ 2 3650 ± 214 88.18 ± 2.13 19.56 ± 12.43 93.01 ± 1.84 
UP24-9EQ 3 1291 ± 95 74.87 ± 3.37 76.07 ± 23.04 92.33 ± 1.06 
UP25-9EQ 4 3236 ± 179 91.75 ± 2.07 58.74 ± 48.24 96.15 ± 1.28 
UP26-9EQ 5 1421 ± 96 78.48 ± 2.43 21.22 ± 7.92 94.06 ± 1.73 
UP27-9EQ 6 3719 ± 197 86.72 ± 1.83 88.38 ± 38.64 90.22 ± 0.96 
UP28-9EQ 7 2208 ± 174 80.04 ± 4.02 165.30 ± 67.83 91.72 ± 0.97 
UP29-9EQ 8 467 ± 15 88.73 ± 1.61 5.66 ± 2.62 87.98 ± 1.41 
UP30-9EQ 9 598 ± 24 75.50 ± 1.52 8.50 ± 1.78 73.23 ± 1.01 
UP31-9EQ 10 395 ± 17 83.86 ± 2.00 6.40 ± 17.38 84.11 ± 1.57 
 
The results show a very fast reactions (kst above 3000 min
-1) for the double flap substrates; 
UP31-9ST, UP23-9EQ, UP25-9EQ and UP27-9EQ. This suggests, there are small 
differences in the stability of enzyme-substrates complexes. Most of the even numbers of 
potential conformers, UP23-9EQ, UP25-9EQ, UP27-9EQ, UP29-9EQ and UP31-9EQ 
have percent fast 88 ± 2, 92 ± 2, 87 ± 2, 89 ± 2 and 84 ± 2 respectively which are higher 
than the odd numbers of potential conformers and also share similar results for the rate of 
the single turnover kst. Curiously, this situation is the opposite of that with multiple 












3.3 Discussion and summary 
 
During replication the bifurcated structures that are the result of discontinuous DNA 
synthesis on the lagging strand are likely to be able to adopt multiple structures due to 
sequence complementarity. In contrast, in-vitro studies of FEN1 frequently use the 3’ and 
5’ static flap substrates, wherein the flaps are not complementary to the template strand, to 
remove substrate conformational variability that would complicate interpretation of rates 
of reaction. However, a complete understanding of the human FEN1 mechanism requires 
the study of the effect of flap migration on rates of hFEN1 reaction. Hence, 9 double flap 
migrating substrates were designed to address the effects of substrate conformational 
diversity on hFEN1 rates of reaction using multiple and single turnover kinetics.  
 
Multiple turnover analysis showed that human FEN1 produces a single peak 5’ flap 
product even on migrating double flap substrates that have at least 10 potential conformers. 
This showed that hFEN1 always hydrolyses one nucleotide into the reacting duplex 
presumably by only reacting rapidly on a single conformer bearing a 3'-single nucleotide 
flap and a 5’-flap of varying lengths. The kcat/KM and maximal kst conditions roughly show 
that the rate of reaction was inversely proportional to the number of potential conformers. 
Moreover, controls show that the decrease in the rate is not due to change in 5’- flap length. 
However, the data also showed that the rate is not simply inversely proportional to the 
number of conformers, as the data points do not fit evenly on a line; instead, some 
substrates show lower than expected rates. 
 
Based on the decreases in rate of reaction observed with increasing conformational 
heterogeneity, two models could be proposed. First, the enzyme could only bind the correct 
conformer. This model predicts that the value of kcat/KM would decrease as the KM value 
increases as there would be increasing amounts of substrate not in the correct conformation 
at any given time. This model predicts that the rate of the fast phase of kst max remains the 
same with increasing conformational heterogeneity although its proportion of fast reacting 
species may vary. It is assumed that the DNA substrate is quickly equilibrating among its 
many conformers into its preferred form (i.e., single nt 3’-flap) thus allowing reaction to 
eventually proceed to completion. Alternatively, enzyme could bind with all (or most) 
conformers and then allow the DNA substrate to adopt the correct conformation on the 
enzyme surface. This model predicts kcat/KM would decrease and that the kst max value would 
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decrease with increasing number of conformers and these model is more relevant with all 
the kinetic results. A combination of these two models with various migrating substrates 
could explain why a smooth trend is not observed. In addition, it is possible that there are 
conformational preferences for various migrating flaps that are not well understood.  
 
Although a direct measurement of KM is not available, its value can be derived using 
Equation 3.3 in chapter 1 using the kcat estimate and kcat/KM values. The calculated KM 
values are shown in Table 3.7. The estimates of KM are between 10 and 60 nM for all 
substrates showing that the KM values do not change drastically with increasing substrate 
complexity. Therefore, the conditions for ST are maximal single turnover rates ([E]>10* 
KM) and the model where substrate can re-equilibrate conformation on the enzyme seems 
preferable. 
 











UP31-9ST 1 208.49 6.28 33.20 
UP23-9EQ 2 227.84 6.22 36.63 
UP24-9EQ 3 65.05 3.70 17.58 
UP25-9EQ 4 27.22 0.45 60.49 
UP26-9EQ 5 63.11 4.79 13.18 
UP27-9EQ 6 25.37 0.58 43.74 
UP28-9EQ 7 91.74 2.85 32.19 
UP29-9EQ 8 61.85 1.45 42.66 
UP30-9EQ 9 46.20 2.25 20.53 





Chapter 4: Proliferating cell nuclear antigen 
 
Proliferating cell nuclear antigen (PCNA) is a homotrimeric sliding clamp that encircles 
the DNA substrate and tethers the polymerase to the template DNA to facilitate processive 
DNA synthesis. The presence of an inter-domain connector loop (IDCL) of PCNA, allows 
it to interact with various proteins including FEN1 and DNA Ligase 1. During DNA 
replication and repair, polymerase, FEN1 and ligase interact with PCNA. Previous studies 
proposed that the PCNA-FEN1 interaction stabilized FEN1-substrate complex resulting in 
stimuation of FEN1-catalysed hydrolysis of phosphodiester bonds during the Okazaki 
fragment maturation processes46. For example, previous studies from Hubscher et al., 
suggested that PCNA can load onto a DNA 5’-single flap substrate via the upstream duplex 
using biotin-streptavidin methods123. Other studies by the Bambara lab, have shown that 
PCNA could alter the FEN1 binding by changing the Km value. These studies also 
suggested that PCNA could enhance the FEN1 cleavage activity due to a small increase in 
Vmax. PCNA has been reported to stimulate the FEN1 incision activities from 5 to 50-fold 
on a variety of DNA flap substrates including single flap and gap substrates, suggesting 
that catalytic efficiency is improved46. In addition, structural studies show that the FEN1 
and PCNA form an inter-molecule β-sheet interface between PCNA and the FEN1 
extended C-terminal regions in FEN122. In addition, further studies by FRET have 
suggested that the PCNA assisted the opening of the flap conformation for 5’-flap 
threading processes and indirectly enhanced FEN1 recognition of the DNA substrate124. In 
summary earlier studies suggested that PCNA could stimulate the FEN1 cleavage 
efficiency.  
 
Using double-flap substrates, mild PCNA-mediated stimulation of archaeal FEN1 proteins 
has been demonstrated125. PCNA stimulation of human FEN1 acting on the preferred 
conformer of its double-flap substrates seems unlikely as the reaction of these approach 
the rate associated with diffusion controlled reaction anyhow. However, investigation of 
the interaction between FEN1-PCNA in migrating double flaps are interesting to explore 
because migrating substrates seem to have dropped out of the diffusion control regime. In 
this chapter, we investigate the ability of PCNA to stimulate human FEN1 hydrolysis of a 
static double flap (UP31-9ST), a migrating double flap (UP27-9EQ), and a single flap (SF). 
The aim of study to investigate the role of PCNA with the variety DNA substrates of 
varying conformational complexity and efficiencies.  
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4.1 Proliferating cell nuclear antigen purification 
 
Human PCNA bearing a C-terminal (His)6-tag was purified following expression in 
Escherichia coli BL21(DE3)-RILP cells using auto-induction methods as described in 
section 2.2. Initially, target protein was captured by IMAC, and the purificaion was 
continued with anion exchange step to remove nucleic acid contamination. The other 
chromatograpic steps included heparin affinity, phenyl Sepharose hydroxyapatite and 
desalting columns to obtain pure protein having no contaminating nuclease activity. Using 
a Nanoview spectrophotometer, the protein concentration was measured by absorbance at 
280 nm. The volume of glycerol equal to the volume of protein solution was added to make 
a 300 μM PCNA stock solution in 50% glycerol. The final concentration will be 300 μM 
of hPCNA monomer, but as hPCNA is a trimeric protein, the concentration of (hPCNA)3 
is 100 μM. Multiple turnover kinetic analyses were carried out without human FEN1 to 
confirm that the PCNA was free from nuclease activity. The final concentration of the 
double flap static substrates were 50 nM and various concentrations of PCNA were added; 
0 µM (blank), 0.025 µM, 0.05 µM 1 µM and 10 µM in 8 mM MgCl2, 50 mM HEPES pH 
7.5, 0.02 % NaN3, 100 mM KCl, 0.1 mg/mL BSA at 37 °C. The formation of single peak 
products (Figure 4.1) monitored by reverse-phase ion-pairing denaturing HPLC at 75 0C 




Figure 4.1: The second order rate for PCNA nucleus activity. A plot of the intensity (mV) 
of product and substrate chromatogram versus retention time (min) was plotted. Five 
different concentration of PCNA were analysed with double flaps DNA substrate, UP31-




4.2 PCNA with migrating flaps 
 
The hFEN1-DNA complex structures showed that 12 and 4 base pairs of downstream and 
upstream duplexes is enough for proper binding between FENs and dsDNA substrate, and 
substrates used for reaction with FEN1 reflect this. Based on the model from Finger et. al., 
2012, a substrate capable of being used for PCNA stimulation of FEN1 needed to be 
designed and was done by Dr. Finger. Although 12 base pairs of downstream duplex is 
enough for FEN1 interaction, the stability of the 12 base pairs duplex is too low at 
concentration as low as 1 nM at 37 0C in assay buffer, thus substrates were designed with 
a minimum of 18 base pairs for the downstream region37. Using a model the FENs-dsDNA-
PCNA complex, at least 21 base pairs are needed in the upstream region for FEN1 and 
PCNA to be able to make all necessary contacts. Therefore, the substrates consists of 18 
and 22 base pairs non-migrating downstream and upstream duplex region, respectively, 
and a nine base pairs region in the middle that migrate to form the variable 5’ and 3’ flap.  
 
The second order rate of reaction analyses were carried out by heating and annealed the 
oligonucleotides as mention in chapter 3 to form a migrating double flap substrate, UP27-
9EQ. As described before, UP27-9EQ is a double flaps substrate that has 6 potential 
conformers where the flap structure that undergoes hydrolysis has a 4 nts 5'-flap 
fluorescein (FAM) labelled, a 1 nt 3'-flap with 5’ biotin on the flap and template strand. 
The PCNA and human FEN1 were added and reactions were quenched with 8 M urea and 
80 mM EDTA. The substrate UP27-9EQ (Figure 4.2) was chosen because, the multiple 
turnover analysis from chapter 3 demonstrated that the equilibrating flap UP27-9EQ has 
the slowest kcat/KM rate. The impact of PCNA on the rate of reaction was measured using 
final substrate concentrations of 2.5, 5, 7.5 and 10 nM with 1.5 or 3.5 pM of [WThFEN1] 
and 50 or 100 nM of [PCNA]3. As before fluorescein-labelled oligonucleotide substrates 







Figure 4.2: The diagram represents DNA-PCNA-hFEN1 complexes during the experiment 
with UP27-9EQ substrate.  
 
Figure 4.3 and Table 4.1 show the rate of reactions were 0.58 ± 0.15 nM-1 min-1 for UP27-
9EQ, 0.36 ± 0.07 nM-1 min-1 for UP27-9EQ in the presence of 50 nM [PCNA]3 and 0.32 ± 
0.08 nM-1 min-1 for 100 nM [PCNA]3. It was hypothesised that because UP27-9EQ has 6 
potential conformers and therefore reduced rate of reaction stabilising the DNA protein 
complex with PCNA could assist with formation of productive [ES] complex and therefore 
increase the kcat/KM rate. Instead the kcat/KM rate of FEN1 catalysed reaction of UP27-9EQ 
without PCNA is roughly two-fold higher than with PCNA. These results suggest that 
PCNA does not help to stabilize the human FEN1-DNA complex. This is probably because 
the reaction of the equilibrating double flap substrate approaches diffusion control. 
Furthermore, the high concentration of PCNA in this study, probably modestly inhibited 
human FEN1 activity by competing for binding of DNA with FEN1. Other than that, the 
presence of biotin at two positions; the template and upstream could also contribute to 






Figure 4.3: Determination of the second order rate constant (kcat/KM) from a plot of v0/[E]0 
against [S] for hFEN1 catalysed reaction of UP27-9EQ substrate in the presence of  
PCNA. The open blue circles represent UP27-9EQ substrate without PCNA, the open 
green circles represent UP27-9EQ with 50 nM of [PCNA]3 and the open red circle data 
represent UP27-9EQ with 100 nM of [PCNA]3. The average of three replicates and 
standard errors are shown. 
 
Table 4.1: The second order rate analysis of UP27-9EQ with PCNA. The triplicates data 
were carried out by plotted the normalised rate of reaction v0/[E]0) versus [S] using 
GraphPad Prism 7 software to acquire kcat/KM rate constants.  
 DNA Substrate (UP27-9EQ)  kcat/KM (nM-1 min-1) 
Without PCNA 0.58 ± 0.15 
50 nM PCNA 0.36 ± 0.07 
100 nM PCNA 0.32 ± 0.08 
 
 
4.3 PCNA with single flap substrates  
 
Single flap substrate was created by heating and annealing F26-9ST downstream, UP30-
9EQ upstream and Temp-48 template in 1:1.5:1.5 ratio, respectively in buffer to form a 
static single flap substrate with an 8 nts 5'-flap strand with 5’-fluorescein (FAM) and a zero 





Figure 4.4: The static single flap substrates were constructed from F26-9ST (green), 
UP30-9EQ (red) and Temp-48 (blue). 
 
The stimulation of hFEN1 acting on single flap substrates by PCNA has been reported 
earlier46. We therefore undertook further analyses of the hFEN1 reaction in the presence 
of PCNA and with single flap (SF) substrate. Reactions were analysed under standard 
kcat/KM conditions (2.5, 5, 7.5 and 10 nM SF) with varying ratios of PCNA to substrate 
including 1[SF]:1[PCNA]3, 1[SF]:3[PCNA]3 (Table 4.2 and Figure 4.5 (a)) and enzyme 
1[hFEN]:1[PCNA]3 and 1[hFEN1]:3[PCNA]3 (Table 4.3 and Figure 4.5 (b)). 
 
Table 4.2: The multiple conditions with single flap substrate with the different ratio 
between [SF] and [PCNA]3. The final hFEN1 concentration was 150 pM. The kcat/KM rate 













2.5 2.5  
0.035 ± 0.004 
2.5 7.5  
0.043 ± 0.005 5 5 5 15 
7.5 7.5 7.5 22.5 










Table 4.3: The second order analysis with single flap substrate with the different ratio 
between [hFEN1] and [PCNA]3 whereas the final [hFEN1] both cases were 150 pM. The 














2.5 150  2.5 450  
5 150 0.018 ± 0.002 5 450 0.032 ± 0.002 
7.5 150  7.5 450  





Figure 4.5: The v0/[E]0 conditions for single flap substrate with PCNA. a represent the 
PCNA analysis with different ratio with substrate where, brown for SF without PCNA, 
black for 1[SF]:1[PCNA]3 and purple for 1[SF]:3[PCNA]3. b represent the PCNA 
analysis with different ratio with hFEN1 where, brown for SF without PCNA, pink for 
1[hFEN]:1[PCNA]3 and green for 1[hFEN1]:3[PCNA]3. The average of three replicates 
and standard errors are shown. 
 
The presence of one nucleotide at 3’-flap DNA substrate is required for phosphate diester 
hydrolysis by FEN1 to produce a nicked DNA for ligation and complete the daughter DNA 
strand. Therefore, in the absence of 1 nt 3’-flap, the rate of reaction is slow and produces 
more than one product. In this study, the kcat/KM rate of SF (8,0) without PCNA was 262-
fold slower (0.024 ± 0.002 nM-1 min-1) compared with static double flap substrate UP31-
9ST (8,1). These results are supported by Finger, et. al., 2009 studies where the single flap 
substrate have 34-fold slower kcat/KM rate compared with double flap substrates. The 
different design of substrate between this study and that of Finger et al., probably 
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contributes to the rate of the reaction. The previous study used a substrate consisting of a 
5 nts 5’-flap with the presence of a hairpin turn in the substrate13.  
 
Figure 4.6 demonstrates that the presence of PCNA had a very small impact on the rate 
increasing it to 0.035 ± 0.004 nM-1 min-1 with 1:1 ratio and producing a modest 2-fold 
increase in the rate of reaction with 1[SF]:3[PCNA]3 ratio (0.043 ± 0.005 nM
-1 min-1). 
Similarly, different ratios of hFEN1 and PCNA showed little difference in rate on SF (8,0), 
with a decrease to 0.018 ± 0.002 nM-1 min-1 at 1:1 ratio and a very modest increase with 
1[hFEN1]:3[PCNA]3, 0.032 ± 0.002 nM
-1 min-1. The small differences observed are within 
those associated with reproducibility errors for these experiments and therefore in our 
hands PCNA does not significantly stimulate the FEN1 catalysed reaction of single flap 




Figure 4.6: The kcat/KM rate for SF (8,0) and PCNA. The red triangle data represent the 
conditions with different ratio between substrate and PCNA, while the triangle purple 
represents with different ration between human FEN1 and PCNA. The average of three 









4.4 PCNA on varying DNA substrates with same flap lengths 
 
In the previous studies on PCNA stimulation the substrates all contained a 5’-biotin on the 
downstream template and upstream duplex terminus (Figure 4.2). This is been added to 
allow potentially lock PCNA on DNA after loading using clamp loader protein RFC in 
potential future studies. In the absence of RFC, one possibility that may have lead to a lack 
of stimulation of FEN1 was that this terminal biotin inhibited the ability of PCNA to load 
onto the substrate even in the absence of strptavidin. We therefore decided to examine 
substrates without a 3’-biotin on the upstream region. Therefore the investigation of the 
impact of PCNA on human FEN1 catalysed reaction of three different substrates with 
static, migrating and single flaps were analysed to determine whether PCNA could enhance 
the cleavage efficiency of any of these substrates. All substrates have same lengths at 5’ 
flaps and there are single flaps, SF (8,0), static double flaps, UP31-9ST-NB (8,1) and 
migrating double flaps, UP31-9EQ-NB (8,1). The final [S] was 5 nM and human FEN1 
was 150 pM. The ratio of [S]:[PCNA] were 0, 0.5, 1, 3, 6, 12 and 36 to produce the final 
concentration of PCNA; 0, 2.5, 5, 15, 30, 60 and 180 nM respectively.  
 
Table 4.4 and Figure 4.7 illustrates the variation in v0/[E]0 with the three different DNA 
substrates with PCNA concentration. For single flaps substrates the gradient of this plot is 
close to zero, 0.00006 ± 0.00005, while for UP31-9ST-NB and UP31-9EQ-NB both 
produced a small negative gradient -0.08132 ± 0.01531 and -0.01475 ± 0.00374 
respectively. None of the data show increasing rate of reaction when PCNA is present in 
the reactions. In fact the data show that PCNA does not stimulate the reaction of any of the 
substrates and at the same time can retard the enzyme activities. This can be seen in the 
kcat/KM results, at higher concentration of PCNA (180 pM), where it decreased the rate of 
reaction. The defects start occur when the concentration of PCNA 6 times higher than the 
substrates and this observation obviously can be seen with static double flap (UP31-9ST-
NB). This is probably because PCNA become as inhibitor in the reaction at higher 
concentration by competing with human FEN1 to form enzyme-substrate complexes by 
binding to the downstream DNA duplex. Thus the biotin present on the upstream duplex 






Table 4.4: The kcat/KM rate analysis of single flap, static flap and equilibrating flap 
substrates with PCNA. The triplicates data were carried out by plotted the normalised rate 
of reaction (v0/[E]0) versus [S]. GraphPad Prism 7 software to acquire kcat/KM rate 
constants.  
DNA Substrates Flap Slope of graph of kcat/KM vs 
[PCNA]  (nM-1 min-1) 
 5’ 3’  
SF 8 0 0.00006 ± 0.00005 
UP31-9ST-NB 8 1 -0.08132 ± 0.01531 





Figure 4.7: The v0/[E]0 conditions for single flap, static flap and equilibrating flap 
substrates without PCNA and 6 different concentration of PCNA. a represent analysis with 
single flap (8,0) substrate, b represent analysis with static flap (8,1) and c represent 




4.5 Discussion and summary 
 
The data presented in this study are contradictory to what have been published. Using 3 
different types of DNA substrates, the data consistently show that the rate of reaction is 
reduced at higher concentrations of PCNA. PCNA can load at either duplex end of the 
DNA substrate used in this study. Therefore, when a larger excess of PCNA is present, it 
will compete and prevent hFEN1 binding to the DNA substrate, thereby preventing FEN1 
hydrolysis. This type of inhibition is a consequence of our experimental set up in that the 
substrate possess two duplex ends to which PCNA can add; thus, these results may not 
reflect what occurs in-vivo. Furthermore, this study also revealed that PCNA does not 
stimulate human FEN1 activities on equilibrating flaps. This could be due to the fact that 
PCNA is not oriented on the substrate using our experimental setup. Previous studies 
proposed a few mechanisms that PCNA loaded onto the DNA46. Unfortunately, in these 
studies, none of the experiments follow any of the mechanisms. Furthermore, in cells, 
PCNA is unidirectionally loaded onto the DNA by RFC. Therefore the absence of clamp 
loader RFC in the experiments may be a factor in the absence of stimulation of FEN1 by 
PCNA. However, it should be noted that the majority of earlier studies loaded PCNA in 
the same way attempted here and report a stimulation that we cannot reproduce. In 
summary, this study reveals that a more complicated assay involving the loading and 
trapping of PCNA onto substrates may be necessary to explore more fully how FEN1 and 




Chapter 5: The Effect of human FEN1 Mutants on The Arch 
 
In the human FEN1 crystal structure, a helical arch was discovered consist of two alpha-
helices (α4 and α5) and was large enough for 5’ ssDNA flap to thread via the hole under 
it9. Based on the observation that hFEN1 could accommodate substrates that contained a 
short region of duplex within the 5’-flap that could not have threaded through the structured 
arch, a disordered-to-ordered helical state mechanism was proposed72. In the presence of 
the correct DNA substrate, the arch was believed to adopt an ordered conformation and 
vice versa without the DNA substrates (Figure 5.1). Previous studies showed, the arch 
contained the conserved gateway (base of α4) residues including Lys-93 and Arg-10075 
while the other residues of the arch located in the helical cap (top of α4 and α5) were just 
thought necessary to hold these in place and to confine reaction to substrates with 5’-
termini75. Lys-93 and Arg-100 were believed to facilitate capture of the scissile phosphate 
and also proposed as electrostatic catalysts during the FEN1 cleavage reaction9,73. If the 
arch was disordered it was assumed that the scissile phosphate was located near but not 
within the active site and could not interact with metal ions or amino acid residues for 
hydrolysis. More recent studies have suggested that the helical cap could play a more active 
role in the FEN1 reaction75. In addition to Lys-93 and Arg-100 gateway region (α4), Lys-
125, Lys-128 and Arg-129 in cap region (α5) and also Arg-103 and Arg-104 gateway/cap 
region (α4)6,9 appear to form substrate interactions in the most recent crystal structures. 
 
 
Figure 5.1: The structure of FEN1s with disordered (left) and ordered (right) arch and 
α2-α3 loop. Left (PDB code 1A76121) is the unstructured helical arch in the absence of 
DNA substrate (blue dotted lines). Right (PDB code 5UM9126) is an ordered structure of 
α4 and α5 in the presence of DNA substrate93. 
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Investigation into the role of conserved residues in FEN1 family have involved the 
characterisation of various side-directed mutants, where the helical arch residues (consists 
of α4 and α5) have been mutated either to alanine (A), glycine (G) or glutamic acid (E). 
Side-directed mutations are defined by nomenclature such as K125A, where the lysine (K) 
at position 125 has been mutated to an alanine (A). The 5’ ssDNA has been proposed to 
through the helical arch via threading mechanism. Mutation of the residues in this region 
will help with better understanding as to how the threading mechanism occurs. Each of the 
targeted residues was substituted with alanine to remove charge on the helical arch. Within 
the helical arch of the FEN1 family, there are a number of conserved and semi-conserved 
basic residues, which are proposed to be important in 5’ ssDNA threading93 including, 
Arg-103 (R103), Arg-104 (R104), Arg-129 (R129), Lys-132 (K132) and Lys-125 (K125). 
 
 
5.1 Mutational analyses 
 
To understand more about the importance of helical cap substrate interactions human 
FEN1 Lys-125 on α5 was targeted for mutagenesis. Lys-125 was suggested to be important 
interaction between α5 and the template strand of the DNA together with other residues 
including Lys-128 and Arg-129. Lys-125 is an invariantly conserved residues between 
human and archaeal FEN1 proteins, its sidechain protrudes from the front of the arch and 
makes a salt bridge with a phosphate diester of the DNA template (approximately 6.7 Å) 
(Figure 5.2). The targeted residues were substituted with alanine (K125A) to neutralise 
the charge. Mutagenesis was carried out using the site-directed mutagenesis methodology. 
The resultant protein was expressed in Escherichia coli BL21(DE3)-RILP using auto-
induction methods as describe in section 2.1 and the protein was purified using same 
methods as discussed in section 3.1. The protein purity was assessed by SDS PAGE as 
shown in Figure 5.3. The single band from each of concentrations; 0.1, 0.2, 0.4, 0.6, 0.8, 
1.0 and 1.6 μg/μL proved that the K125A mutant was pure and not contaminated. Apart 
from K125A mutant, mutants of other basic residues have been constructed and purified 
previously including R103A, R104A, R129A, K132A and double mutants R104AK132. 
All of these mutations were believed to interact with the DNA substrates, either with the 






Figure 5.2: The structures K125 residue with DNA substrate (PDB:3Q8L). The cartoon 
shows the view of α4 and α5 from the side. The distance between K125 and DNA template 





Figure 5.3: SDS-PAGE to show the purity of K125A after purification steps. Lane 1 and 
lane 9: Protein ladder (representing 15, 20, 25, 37, 50, 75, 100, 150 and 250 kDa), lane 
2: 0.1 μg/μL, lane 3: 0.2 μg/μL, lane 4: 0.4 μg/μL, lane 5: 0.6 μg/μL, lane 6: 0.8 μg/μL, 
lane 7: 1 μg/μL and lane 8: 1.6 μg/μL. 
 
Kinetic studies of K125A were undertaken using a static double flap substrate (single 
conformer) denoted as DF5,1 (DF = double flap with 5 nucleotides 5'-flap and 1 nucleotide 
3'-flap). The substrate had a 5’-fluorescein (FAM) labelled at 5’-flap similar to the 
substrates that have been used for wild type human FEN1 analysis (Figure 3.5 in chapter 
3). The single turnover analysis (enzyme in excess) were conducted with a final 
concentration of the substrate was 5 nM and the concentration of K125A was 1000 nM. 
Following determination of the concentration of product with respect to time, the data were 
fitted by GraphPad Prism 7 software with a single-phase exponential. The kst rate of 
K125A mutant was 14-fold slower (51 ± 2 min-1) compare with the wild type human FEN1 
rates of 788 ± 39 min-1 as shown in Figure 5.4 and Table 5.1. The slower kst rate is because 
of the absence positive charge and as a consequence the DNA template interacts or binds 







Figure 5.4: The single turnover rate for DF5,1 cleavage by hFEN1 and K125A mutant. 
The data points open blue circle represent the human FEN1 and open blue green 
represents the K125A mutant. The mean of three replicates and standard errors are shown. 
Data has been fit to a single-phase exponential. 
 
Table 5.1: The single turnover rate for WThFEN1 and K125A. All data were plotted with 
single-phase exponential by GraphPad Prism 7 software.  
Parameters Enzyme 
 WThFEN1 K125A 
Plateau  51 ± 2 59 ± 1 
kst, min-1 788 ± 39 51 ± 2 
 
 
5.2 The role of helical arch in threading mechanism 
 
Previous studies have proposed several mechanisms for FEN1 accommodation of DNA 
substrates including the threading, the tracking, the bind and thread and also the clamp 
models. Lyamichev et. al., 1993 first proposed that FEN1 specificity for 5’ flaps could 
originate via a threading mechanism16. It was proposed that the 5’ flap DNA substrate was 
threaded through a hole of appropriate size16 and later the helical arch became a candidate 
for this. For tracking models, the hypothesis was, that FEN1 initially recognised the 5’ 
ssDNA by clamping or threading, followed by sliding down the 5’ termini to the 
bifurcation region where cleavage occurs90–92. In contrast in the bind and thread 
mechanism, FEN1 initially binds with the double strand DNA substrate at the bifurcated 
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region and threads the 5’ flap ssDNA through the helical arch. A further study proposed, 
that the helical arch undergoes a disorder-order transition during the threading of 5’ flaps 
ssDNA9,71,75. The last hypothesis was the bind and then clamp model by Orans et. al., 2011. 
They suggested that FEN1 bound to the double strand DNA substrate initially at bifurcated 
region, and continued by clamping the 5’ flap ssDNA via either side of the helical arch17. 
However, when structures of FENs bound to full substrates were finally solved, in 
agreement with the biochemical data, the single stranded flap was found to be threaded 
through the helical arch26,72.  
 
The helices are amphipathic in character, where positive residues pointing inward and 
outwards (Lys-125) to provide binding surface for DNA substrate. The 5’ ssDNA flap of 
the substrate was seen to interact with the arch region. As discussed before, in the structure 
of human FEN1 without DNA the helical arch region is disordered therefore, the binding 
between helical arch and DNA substrate may promote the ordering of the arch. In this 
study, we aim to investigate each mutation in kinetic experiments to allow effective 
quantitative comparison of catalytic contributions by measuring the kst rate.  
 
Previous studies revealed that addition of a 5’-streptavidin to the 5’ ssDNA flap of a double 
flap substrate is inhibitory to cleavage75. Streptavidin is a large stable protein that creates 
a steric road “block” to the threading of flaps through the helical arch when it is bound the 
5’-biotinylated substrates. As shown in Figure 5.5 b, to create a “blocked” complex the 
streptavidin (SA) and DNA substrate are pre-incubated first to form a SA-conjugated 
substrate, and then human FEN1 is added. In contrast if human FEN1 and 5’-biotinylated 
substrate are pre-incubated to form enzyme-substrate complex (Figure 5.5 a), addition of 
streptavidin would “trap” the threaded 5’flap substrate on the protein. Previous 
experiments have demonstrated that the maximum proportion of trapped complex was 
obtained with human FEN1 in the presence of the inert cofactor calcium ions. The 
properties of these complexes were compared with control experiments where a ‘premix’ 
complex was obtained via the same procedures by adding Ca2+ buffer instead of 
streptavidin. Earlier, it has been shown that when reaction is initiated with Mg2+ the trapped 





The trapping and blocking data were accumulated independently from manual sampling 
(on the bench) and rapid quench-flow experiments and quenched with urea and EDTA. A 
two-phase exponential has been used to fit all the data (trapped and premixed) by 
GraphPad Prism 7 except for blocked experiment where a single-phase exponential was 
preferred. The two-phase exponential was preferred13 because, the ‘fast’ phase was 
considered as the rate of reaction (kst fast), while the second phase (kst slow) has been 
proposed to result from the initial formation of unproductive complex formation93. These 
unproductive complexes would need to dissociate and re-associate to form productive 
complexes to react, thereby giving rise to the slower second phase. The maximal kst rate 
were determined and compared to the wild type human FEN1. Under premixed and trapped 
conditions, the cleavage would be expected occur very fast. Whereas, for blocked 
condition, the hydrolysis occurs very slow because the DNA substrate is blocked sterically 
by streptavidin and therefore cannot thread through the helical arch. If a mutant enzyme 
was deficient in threading the substrate through the helical arch, it would be expected to 
form both trapped (threaded) and blocked (unthreaded) complexes when streptavidin was 




Figure 5.5: Structure of double flap DNA and schematic of threading assay. a illustrating 
the formation of ES-SA under trapped conditions and b showing the formation of ES-SA 
under blocked conditions. Complexes were assembled in Ca2+ buffer with Mg2+ added to 
initiate the reaction. S, E and SA represent substrate, enzyme and streptavidin respectively. 
106 
 
5.2.1 Investigating the effect of mutations of basic residues on the human FEN1 
mechanism using single turnover kinetics 
 
The ability of the 5’ flaps of ssDNA to thread under the helical arch was investigated via 
blocking and trapping experiments. The static double flaps substrate SB5,1 had a 5 nts 5’ 
flap and 1 nt 3’ flap and was FAM labelled and biotinylated. The final concentration of 
SB5,1 and enzyme were 5 nM and 500 nM respectively. Four single mutants of human 
FEN1 were studied: R103A, R104A, K125A, R129A and double mutant R104AK132A. 
5-fold molar excess streptavidin (with respect to substrate) was added in the reaction 
mixtures to produce blocked and trapped complexes. Since Ca2+ is a competitive inhibitor 
with respect to viable cofactor ions, complexes were assembled in the presence of Ca2+ 
ions. Reaction was initiated at 37 0C by the addition of Mg2+ reaction buffer, and aliquots 
were removed at various time points and quenched with 8 M urea and 80 mM EDTA for 
manual analysis and 8 M urea and 300 mM EDTA for experiments performed using RQF-
63 quench flow device. The product formation was measured by dHPLC equipped with a 
fluorescence detector and was plotted to determine the initial rate of reaction.  
 
 
5.2.2 Studying the temperature effect of threading mechanism 
 
Initial experiments were carried out with two conditions for complex formation, either on 
ice or at room temperature. When a complex of enzyme R104AK132A and biotinylated 
substrate was formed and then trapped on ice by adding streptavidin only 16.6% 
(equivalent to 0.83 nM) product formation was observed as the end point of first phase 
when reaction was initiated with Mg2+ ions. In contrast 35% (equivalent to 1.75 nM) 
product formation was observed when the complex was formed and trapped at room 
temperature. In each case and percentage of product formation were calculated via 
Equation 5.1;  
 
% 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛: 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 (𝑛𝑀)
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 (𝑛𝑀)
 𝑥 100 
 
Equation 5.1 
Where, [S] was 5 nM in all cases.  
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Streptavidin trapping is thought to be equally efficient under both temperature conditions 
suggesting that the stability of the enzyme-substrate complex is likely the factor that varies 
with temperature. Table 5.2 and Figure 5.6 show the results of blocked, trapped and 
premixed experiment using enzyme R104AK132A on ice and at room temperature. Under 
trapped experiments, the data displayed two phases. The first phase has a rate which is 
similar to that of the premixed fast enzyme-substrate complexes whereas the second phase 
(kst slow) has a similar rate to that of the blocked condition.  
 
Table 5.2: The results from GraphPad Prism 7 software for double mutants R10AK132A. 
The results were fitted with one-phase association (for blocked) and two-phase association 
(trapped and premixed) to show the plateau, percentage of fast and kst rate for two different 
temperature conditions. 
  R104AK132A 
Parameters Analysis On ice Room temperature 
Plateau (nM) Blocked 3.395 ± 0.1027 3.524 ± 0.06439 
Trapped 3.12 ± 0.05 3.78 ± 0.04 
Premixed 4.40 ± 0.08 4.47 ± 0.06 
Percentage fast 
(%)  
Blocked NA NA 
Trapped 23.69 ± 1.26 43.65 ± 0.85 
Premixed 62.91 ± 1.67 63.80 ± 1.16 
kst, s-1 Blocked 0.0002012 ± 2.102x10-5 0.0002819 ± 0.06439 
 Trapped fast 0.034 ± 0.005 0.049 ± 0.002 
 Trapped slow 0.0003119 ± 2.352x10-5 0.0002342 ± 1.542x10-5 
 Premixed fast 0.261 ± 0.022 0.187 ± 0.011 







Figure 5.6: The threading analysis of double flaps substrate (SB5,1) with double mutants 
R104AK132A. The experiment on the a) ice, b) room temperature whereas the green, red 
and blue colours are represent premixed, trapped and blocked respectively. The dotted 
lines represent the end point of the first phase for threading conditions in each cases.  
 
 
5.2.3 Exploring the function of basic residues of the helical arch of human FEN1 via 
threading analysis at room temperature 
 
The investigation for other mutants via threading analysis were continued with the same 
conditions as described above with complexes formed at room temperature. Arg-103, Arg-
104, Lys-125, Arg-129 and Lys-132 are five basic residues that conserved and semi-
conserved in human and archaea FEN1 proteins. A previous study proposed that Arg-103, 
Arg-104, Arg-129 and Lys-132 could help to stabilize the inverted 5’ ssDNA flap and steer 
the phosphodiester backbone during the threading process126. All the basic amino acids 
were mutated to alanine (R103A, R104A, K125A, R129A, R104AK132A) to remove the 
positive charge and purified in a similar way to wild type hFEN1. For each mutant, except 
K125A, the multiple turnover rates of reaction were analysed by other members of the 
Grasby group. Compared with wild type human FEN1, the rate of reaction of R103A was 
slightly slower, while R104A and R129A both showed 20-fold decreases. The double 






A slower “premixed” rate is expected during trapping/blocking experiments compared 
with the rate of normal single turnover reaction. For direct comparison with trapped and 
blocked experiments, here the premixed complex is formed in the presence of calcium ions 
as these were previously found to be necessary for full threading to occur. Thus a ‘delay 
effect’ is expected when mixing in the excess of Mg2+ to initiate reaction as Ca2+ ions have 
to be displaced from the active site93 (Figure 5.7). This ‘delay effect’ would be expected 
to be greatest when the reaction rates are fastest and can be seen by comparison of results 
for wild type hFEN1. The maximal single turnover rate of reaction of the static double flap 
(SB5,1) form previous study93, the kst rate was 2430 ± 30 min
-1 whereas in the presence of 
Ca2+ in threading experiment the rate is 67 ± 6 min-1. These result showed the ‘delay effect’ 




Figure 5.7: The illustration of Ca2+ as competitive inhibitor of reaction in a “premixed” 
experiment.  
 
The presence of streptavidin-biotin complexes under threading experiments, two 
conditions could happen. First, either ‘blocked’ or ‘trapped’ depending on the sequence of 
addition of the streptavidin. Table 5.3 and Figure 5.8 show the threading analysis for 
WThFEN1 and five mutants. The data can be explained by comparing each mutant with 
end point of premixed (control) condition and end point of trapped conditions. Based on 
Figure 5.8, the wild type human FEN1 showed that the end point of premixed and trapped 
condition were similar. These results demonstrated that the substrate-enzyme complexes 
are fully threaded at equilibrium93, and we observed the same results for R103A. For other 
mutants (R104A, K125A, R129A and R104AK132A), the product formation at the end 
point of first phase are lower compared with the premixed. This results like arose because 





Table 5.3: Trapping and blocking experiments for five mutants. The results are given as the average of at least four replicates and errors. The 
results were fitted with one-phase association (for blocked) and two-phase association (trapped and premixed) to show the plateau, percentage of 
fast and kst rate under Ca
2+ buffer at room temperature. 
  Enzyme 




Blocked 4.18 ± 0.06 4.70 ± 0.03 3.56 ± 0.06 4.70 ± 0.03 4.05 ± 0.05 3.52 ± 0.06 
Trapped 4.47 ± 0.06 4.68 ± 0.08 3.87 ± 0.07 4.74 ± 0.05 4.31 ± 0.08 3.79 ± 0.03 
Premixed 4.71 ± 0.05 4.62 ± 0.05 4.59 ± 0.05 4.74 ± 0.05 4.38 ± 0.05 4.51 ± 0.05 
Percentage  
fast (%) 
Blocked NA NA NA NA NA NA 
Trapped 63.48 ± 1.40 59.96 ± 1.88 49.03 ± 1.15 51.70 ± 1.06 51.02 ± 1.54 43.25 ± 0.69 
Premixed 62.87 ± 1.36 60.24 ± 1.96 63.06 ± 1.14 75.56 ± 1.08 62.41 ± 1.34 63.57 ± 1.01 












 Trapped fast 0.388 ± 0.033 0.429 ± 0.053 0.617 ± 0.047 0.265 ± 0.023 0.243 ± 0.025 0.049 ± 0.002 












 Premixed fast 1.123 ± 0.097 2.340 ± 0.278 0.378 ± 0.023 1.607 ± 0.099 1.300 ± 0.105 0.187 ± 0.011 



















Figure 5.8: Single turnover analysis for threading analysis for R103A, R104A, K125, 
R129A, R104AK132A and WThFEN1. The mean points open green, red and blue circle 
data represent premixed, trapped and blocked experiments respectively. Each analysis 
were done four replicates and standard errors are shown. The dotted lines represent the 
end point of the first phase for threading conditions in each cases. The results were fitted 
with one-phase association (for blocked) and two-phase association (trapped and 
premixed) to show the plateau, percentage of fast and kst rate under Ca





As we can see from Figure 5.8, a second phase that reacts as the ‘blocked’ mechanism, 
and those represent the DNA substrates in the equilibrium that are not threaded or probably 
unproductive products. The blocked reaction in all cases were slow as expected because of 
the presence of streptavidin on the 5’-flap. The rate of reaction for R104A, K125A and 
R129A were decreased roughly 1000-fold above than control complexes after initiation of 
Mg2+. On the other hand, R103A and R104AK132A substrate complexes decay in blocked 
complexes were approximately 600-fold slower than premixed complexes. The WThFEN1 
blocked reaction only is only around 200-fold reduced compared with trapped fast phase.  
 
With the premixed reactions, rapid product formation results (an exponential curve) as 
single-strand 5’-flap threading is uninhibited and substrate-enzyme complexes are fully 
threaded. Without streptavidin, the reaction appears to result in the fastest threading and 
product formation. On the other hand, the slow phase on trapped rate in each case were 
approximately similar or close with blocked rate. This correspondent to the assumption 
that the substrate was not bound and threaded at equilibrium because of the presence 




Figure 5.9: The kst rate of single mutant; R103A, R104A, R129A, K125A and double 
mutant R104AK132A compared with human FEN1. The results were fitted with one-phase 
association (for blocked) and two-phase association (trapped and premixed) by GraphPad 






Figure 5.10: Threading efficiency derived for R103A, R104A, K125A, R129A and 
R104AK132A compared with wild type human FEN1. The data were derived as the ratio 
of fast values from trapped and premixed reactions93. 
 
Figure 5.10 and Table 5.3 represent the threading efficiency (between 0, unthreaded; and 
1 fully threaded93) of WThFEN1 and five mutants residues. These bar graph were 
calculated by Equation 5.2, 
 
𝑇ℎ𝑟𝑒𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑓𝑎𝑠𝑡 𝑡𝑟𝑎𝑝𝑝𝑒𝑑





The residues on the helical arch mutants, R104A, K125A, R129A and R104AK132A all 
revealed threading defects except for R103A. This suggesting that each of these residue 
play a role during the threading processes either to stabilise the ordered helical arch or 
contact with the substrate. While regarding with Tainer et al., 2017, they suggested basic 
residues are required to facilitate threading and protect the flap from reacting by interacting 
with the phosphates in the 5’-flap. Therefore, in our assay, the stability of 5’-flap threaded 





5.2.4 Discussion and summary 
 
Tainer et. al., 2017 proposed Arg-103, Arg-104, Arg-129 and Lys-132 were ‘phosphate 
steering’ residues126. Moreover, these residues helped ‘steer’ the 5’-flap portion of 
substrates away from the active site to prevent inadvertent reaction in the flap. In addition, 
some of these residues were also thought to be important for positioning the scissile 
phosphate through a twisting or rolling type of motion on the active site metal ions126. 
Thus, phosphate steering was define as ‘electrostatic interaction that can dynamically 
position the phosphate diester backbone126.  
 
The similarity of Arg-103 and wild type hFEN1 results proved this residue is not important 
for phosphate steering. It is possible that, the other mutants impair the threading rate by 
destabilizing the ordered threaded state. The results of Lys-125 and Arg-129 indicated an 
important role for contacts made from wild type human FEN1 to the template strand 
phosphate diesters. Even though both residues show strong conservation across eukaryotes 
and archaea, the functional significance of these contacts has not been fully appreciated. 
Arg-104, Lys-125, Arg-129 and Lys-132 results proved that all these residues have specific 
contacts with DNA substrate and play important role in promoting the succession of 
protein and DNA conformational changes leading to catalysis.  
 
An interesting observation under trapped conditions with streptavidin resulted in two 
output: one phase that reacted rapidly known as trapped fast, whereas another phase reacted 
on the timescale of blocked complex known as trapped slow. Generally, the rate of reaction 
of trapped fast enzyme-substrate complexes are approximately similar to the premixed 
rate, showing all substrates are accommodated identically in a threaded state at 
equilibrium. Under trapped substrate conditions, we observed the biphasic correlation. 
This suggest that the reaction is not perfectly trapped, probably due to unproductive 
binding (i.e., incorrect binding between enzyme and substrate). In contrast, 5’-flap blocked 
substrates have drastically decreased the rate of reaction because of the substrate cannot 
be optimal bound to the enzyme and cleavage does not occur on a biologically relevant 
timescale. These results are predicted because of a steric hindrance of streptavidin on the 
5’-flap dsDNA substrate probably affecting the efficient position of helical arch residues. 
In addition, the 5’-flap threading hypothesis was successfully verified by the streptavidin 
binding experiments, with the data regarding the difference order of the adding of 
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streptavidin. The reaction for 5’-blocked is at least 100-fold slower than trapped fast phase 
indicating the importance of the threading. However, in reality, the reaction were 1000-




Chapter 6: Observation Local Conformation Changes of 
Nucleotides in The human FEN1 by Exciton Coupled Circular 
Dichroism  
 
Although the ground state of DNA is a double helix, it is still a dynamic biomolecule that 
is flexible and has the ability to adopt alternative excited states127. Previous studies 
revealed that human FEN1 could discriminate between the structures of potential DNA 
substrates at specific regions by various mechanism. Firstly, a feature of the discontinuous 
bifurcated structures such as flaps is that they have enhanced conformational flexibility at 
the duplex–duplex junction. They can be bent at dsDNA-dsDNA junction removing the 
coaxial stack, or alternatively the two duplex arms can coaxially stack with each 
other9,22,128. Secondly, FEN1 recognizes the one nucleotide 3’-flap of the DNA 
substrate13,85,86. Thirdly, the single-strand 5’-flap of the DNA has to pass through the hole 
under the helical arch (between α4 and α5) for the enzyme-catalysed reaction to occur at a 
significant rate72,129. Finally, the DNA substrate has to untwist to allow the scissile 
phosphodiester bond to enter the active site for hydrolysis126. Understanding the 
requirements for and order of these events will aid understanding of the complex process 
of substrate recognition by FEN1. DNA untwisting is accompanied by substantial helical 
distortion and adjustment to the stacking environments within the duplex. We therefore, 
chose to investigate the ability of FEN1 proteins to bring about this step using the 2-
aminopurine Exciton Coupled Circular Dichroism (ECCD) signal at 326 nm as this signal 
is very sensitive to duplex environment. 
 
ECCD is a sensitive and established technique that can be applied to the study of 
macromolecular structure. ECCD represents an interaction of two chromophores in a chiral 
macromolecule. When the two chromophores are in position to ‘be coupled’, their 
electronic transition dipole moments interact and generate two distinct CD bands, which 
have opposite signs due to Cotton effects. ECCD analysis could help to understanding the 
structural changes at specific site of adjacent bases at the ss/ds junction of human FEN1 
substrates if tandem modified bases with a distinctive ECCD signal are introduced into the 
duplex. Changes in these spectra on addition of protein and/or cofactors demonstrate a 
change in nucleobase orientation has occurred. The circumstances under which the 
changes occurred could lead to information about what the conformation could be and 
what the requirements are.  
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6.1 The role of 2-aminopurine  
 
Nucleobase cross-linking studies by Beddows et al., 2012 first suggested the necessity of 
for DNA conformational change, which at that point was thought to be double nucleotide 
unpairing (DNU), for the FEN1 reaction38. These studies revealed that the nucleotides at 
ss/dsDNA junction must be capable of movement for reaction to occur. To understand the 
nucleotide dynamic, the spectral probe 2-aminopurine (2-AP) was substituted within a 
DNA construct at the base of the 5'-flap in two adjacent sites. 2-AP is an adenine analogue 
that which still pairs to thymine and absorbs and emits light in a region where other 
nucleobases are transparent. The replacement of two neighbouring nucleotides (Figure 
6.1) with 2-AP molecules will affect the energy levels and also excitation coupling of the 
electronic fields130. The substitution of 2-AP for adenine will reposition the exocyclic 
amino group but does not significantly alter the structure of stability of DNA131,132. 
Furthermore, 2-AP in tandem at the end of the flap strand provides a characteristic 
spectrum when contained within duplex DNA and when separated from one another. By 
substituting the nucleotides with 2-AP which has an electric dipole transition moment, the 




Figure 6.1: The hydrogen bond between adenine:thymine (left) and 2-






6.2 Substrate design for ECCD experiment using 2-aminopurine 
 
Previous studies proposed that the eukaryotic FEN1 proteins could recognize specific 
junction known as a 5’-3’ double flap which can have a single nucleotide 3’-flap and any 
5’-flap length including zero. Based on Figure 6.2, the nicked product (P) and single 
stranded product (Q) are formed after substrate hydrolysis resulting in a one nucleotide 3’-
flap and a one nucleotide gap133. In addition, the distortion or untwisting of the double 
strand DNA near the site of cleavage is important for hydrolysis because it places the 
scissile phosphate on the active site metals. 2AP ECCD spectra of substrate alone typically 
show a maxima around 326 nm. ECCD spectra were measured from 300 nm to 480 nm 
with 0.4 seconds per data point and recorded in a 5 mm path length at 20 0C. The analyses 
were performed in a Ca2+ buffer, with and without 25 mM EDTA with final concentrations 
of enzyme and substrate of 12.5 μM and 10 μM respectively. The data were processed by 
Pro-Data Viewer and all spectra had blank subtraction for baseline-correction. Under these 
conditions, we believed that all the DNA was fully bound to the protein during the ECCD 
measurements. The ECCD traces and the ellipticity differences of each complex were 
monitored in the presence and absence of divalent metal ions and calculated from three 




Figure 6.2: The reaction of non-complementary double flap DNA substrate. S is static 
double flap, P is nicked product and Q is single stranded product. The pictures shows the 





Initially, the ECCD experiments were conducted with tandem 2-APs at the -1 and -2 
positions, which are the two terminal nucleotides in the hFEN:product complex. Earlier 
work has shown that the position of the -1 nucleotide is altering relative to the -2 nucleotide 
and unstacked when bound with human FEN1 in the presence of Ca2+ ions9,133. Further 
investigation at +1 and -1 nucleotides positions have been done to understand the relative 
positioning of these two nucleotides. These studies were performed with a static double 
flap comprised of a displaced 5 nts 5’ flap and a 1 nt 3’ flap containing 2-AP dimers 
(downstream of substrate) at +1-1 and -1-2 relative to the scissile phosphate. The 
numbering refers the position of the 2-AP dimer position as shown in Figure 6.3 and 
Figure 6.4. The static substrate was important to restrict the nucleic acid structure to only 
one conformer. The bimolecular DNA substrate were constructed from a 2AP containing 
single stranded flap strand and a template strand that also provided the upstream duplex. 
Due to low sensitivity, the substrate concentration is kept at 10 μM, and at these 
concentrations a shorter downstream duplex is sufficient to maintain stability of the 
construct.  
 
The aim of this chapter to study the specific conformational changes of the substrate at 
ss/dsDNA junction with mutated residues of human FEN1. In this study, we used two types 
of oligonucleotides, FEC1 annealed with Temp-1 and FEC2 annealed with Temp-2 to form 
the static double strand DNA substrate construct dsFEC1+1-1 and dsFEC2-1-2 respectively 
(the subscript numbers denote the place of 2AP substitution). The static substrates were 
used to allow the measurement by ECCD to be precise at the specific position of 2-AP 












Figure 6.4: A schematic representation of the oligonucleotides used to study the 
conformational changes of hFEN1, R103A, K125A and R129A with DNA substrates. Static 
double flaps contain substitutions at -1+1 and -1-2 (numbering relative to cleavage site) 





6.3 ECCD spectra of free static double strand FEC1+1-1 and FEC1-1-2 substrates 
 
The replacement of the nucleotides on 5’ flap strand at +1-1 or -1-2 with a 2-AP dimer in 
dsFEC1+1-1 and dsFEC1-1-2 respectively produced a unique ECCD signal with a maxima 
close to 326 nm. The +1-1 and -1-2 2AP DNAs were analysed as free ssDNAs and dsDNAs 
and also bound with the each of the mutants and wild type human FEN1. Although the 
ECCD signals were recorded from 300 – 480 nm to have a large baseline for spectral 
normalization, only spectra between 300 – 360 nm were presented (no absorbance was 
detected above 360 nm).  
 
To begin, studies were performed with ssDNA and dsDNA in the presence and absence of 
divalent metal ions without enzyme (Figure 6.5). The results show, the intensity of 
dsFEC1+1-1 and dsFEC2-1-2 was approximately 2-fold higher than ssFEC1+1-1 and ssFEC2-
1-2 DNA oligonucleotides. These observations indicated that the 2-AP nucleobase are 
restricted to fewer conformations in dsDNA compared to ssDNA. This spectroscopic 
behaviour also suggests that in the duplex environment, there are greater stacking 
interactions of the two spectral probes. The weaker electronic transitions in the ssDNA are 
the result of reduced the interaction between the two adjacent 2-APs. On the other hand, 
the FEC1+1-1 and FEC2-1-2 DNA substrates showed the same intensity at 326 nm under 
Ca2+ and EDTA conditions. This implies similar interactions occur in the presence and the 












Figure 6.5: ECCD spectra of free single strands (a) and double strands (b) of DNA 
substrates containing 2-AP dimer. FEC1 and FEC2 represent +1-1 and -1-2 positions of 
2-AP at the downstream substrate respectively. The ECCD traces in Ca2+ are represented 
as a solid line, while in EDTA represented as dashed lines. The experiments were done at 
20 0C, n = 2, time per point 0.4 s.  
 
 
6.4 ECCD spectra of static dsFEC1+1-1:hFEN1 and dsFEC1-1-2:hFEN1 
complexes 
 
As shown in Figure 6.6, for both dsFEC1+1-1 and dsFEC2-1-2, a reduction in ECCD intensity 
was related with binding of human FEN1 in the presence of Ca2+ ions. The reduction in 
energy of the exciton-coupling at 326 nm was similar to that obtained in a previous study 
by Finger et. al., 2013, Patel et. al., 2013 and Algasaier et al., 2016. This indicated the 
ability of hFEN1:Ca2+ to distort the DNA substrate. However, the addition of 
hFEN1:EDTA to dsFEC1+1-1 and dsFEC2-1-2 caused the ECCD signal to be higher than that 
with hFEN1:Ca
2+. These results parallel those of a previous study showing that the 2-APs 
remain stacked in the double-stranded DNA substrates when bound to FEN1 in the absence 
of divalent metal ions75,128,133. These results demonstrate that the presence of divalent metal 
ions within the active site is a pre-requisite for the substrate to distort and transfer the 
scissile phosphate to the active site. In addition, this data also proved that DNA 






Figure 6.6: The comparative ECCD spectra between free dsDNA and dsDNA:hFEN1. Two 
different positions of 2-AP, (a) FEC1 (+1-1) and (b) FEC2 (-1-2). 
 
 
6.5 ECCD spectra of static dsFEC1+1-1 and dsFEC2-1-2 substrates and mutated 
FEN1 complexes 
 
To understand the importance and requirements of the ideal local conformational changes, 
the effects of helical arch mutations R103A, R104A, K125A, R129A, A107G, 
R104AK132A and A98GA107G were studied (Figure 6.7). The results were compared to 
wild type human FEN1 to indicate any differences, thereby identifying important residues 
to facilitate DNA conformational changes. All mutants were expressed, purified and 
kinetically characterised by Dr Mark Thompson (member of the Grasby group) except 
K125A. The mutation of basic residues arginine (R) and lysine (K) were designed to study 
the electrostatic interaction between helical arch and phosphate diesters of the threaded 5’-
flap DNA substrate. Arg-103, Arg-104 and Lys-132 were basic residues proposed to be 
responsible to pilot the 5’-flap phosphate diester backbone through the helical arch and to 
play a role in stabilizing the ssDNA orientation126. The α5 residues Lys-125 and Arg-129 
appear positioned to interact with the DNA template strand especially when the DNA is 
active site positioned and the arch has moved forward as discussed in chapter 5. Whereas 
mutations Ala-107 to glycine could inhibit structuring of α4, while double mutant 
A98GA107G was expected to impair structuring of enzyme. Generally, all mutations were 







Figure 6.7: Cartoon represents the position of mutated residues on the helical arch. 
 
The single turnover rates of reaction of R104A, R107G, A98GA107G and R104AK132A 
were measured by Dr Mark Thompson, whereas the result for K125A were described in 
the preceding chapter. These experiments used the static double flap SB5,1. Table 6.1 
represents the maximal single turnover (kst) rates of some of the mutants. The back of arch 
mutation R104A and the corresponding double mutants R104AK132A decreased the rate 
of reaction by approximately 44- and 227-fold. The A107G mutation slowed the rate of 
reaction 16-fold and the double mutant A98GA107G decreased the rate by 105-fold 
compared with WThFEN1 underscoring the importance of the arch to undergo a disorder 
to order transition. As discussed previously K125A decreased the rate by 14-fold. 
Previously, the multiple turnover rates of reaction of  R103A and R129A data were 
determined by Tsutakawa et al., 2017 and the v0/[E]0 (min
-1) rate is reduced 3-fold for 
R103A and 20-fold for R129A relative to WThFEN1.  
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Table 6.1: The single turnover rate and the rate decrease by fold for each mutant relative 
to WT human FEN1. The experiments were done using static double flap DNA 
substrates. 
Enzyme kst, min-1 Rate decrease by fold 
Human FEN1 722.5 ± 58.8 - 
R104A 16.5 ± 0.4 44 
A107G 44.0 ± 2.8 16 
K125A 51 ± 2 14 
A98GA107G 6.9 ± 1.12 105 
R104AK132A 3.2 ± 0.12 227 
 
To monitor the ability of mutant proteins to bring about DNA conformational change 
ECCD measurements of the protein-DNA complexes were performed in the presence of 
divalent metal ions or EDTA using dsFEC1+1-1 and dsFEC2-1-2 substrates. Figure 6.8 
shows the CD spectrum at 326 nm for five mutants comparatively with wild type human 
FEN1. Figure 6.9 displays the ellipticity changes at 326 nm for seven mutants (R104A 
and R104AK132A data were from Dr. Mark Thompson). Because the absolute magnitude 
of the data can vary on a day to day basis, we normalised all data with dfFEC2 measured 
at a similar time in every case. Figure 6.9 a and c represent the original data before 
normalisation, whereas Figure 6.9 b and d show the data after normalisation with dfFEC2 
under +1-1 and -1-2 conditions.  
 
ECCD signals for wild type human FEN1 and all mutant complexes were higher under 
EDTA compared to Ca2+ conditions. As observed previously when the hFEN1:dsFEC1+1-
1 complex was formed in the presence of Ca
2+ ions the ECCD signal was decreased with 
respect to the free substrate and the protein-DNA complex in EDTA128. This indicates that 
the +1 and -1 nucleotides change their relative positions to some extent when the substrate 
is positioned within the active site. Compared with hFEN1:dsFEC1+1-1 complex, the seven 
mutants affected the ECCD traces of their complexes with dsFEC1+1-1 substrate. 
R103A:Ca2+ and R103A:EDTA complexes displayed comparable magnitude to the ECCD 
signal of wild type  human FEN1 with dsFEC1+1-1 and dsFEC2-1-2 substrates (Figure 6.8 
a, b and Figure 6.9 a, b, c, d). The equivalence in exciton-coupling of R103A and wild 
type human FEN1 in all conditions suggests that the positions of the nucleotide are similar 
in both enzyme-substrate complexes. The identical ECCD spectrum for R103A-
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(2AP)2DNAs in comparison with wild type human FEN1 complexes suggested Arg-103 
does not important for orientating of the nucleotides flanking the scissile phosphate of 
DNA. These results are consistent with enzyme activities in multiple turnover experiments, 
where the mutant R103A is only reduce by 3-fold in comparison wild type to human FEN1. 
Although Arg-103 is semi-conserved, it does not show any significance impact on the 
WThFEN1 activity. 
 
The altered protein-DNA complexes R104A:dsFEC1+1-1 (Figure 6.9 a, b). and 
A107G:dsFEC1+1-1 (Figure 6.8 c and Figure 6.9 a, b) complexes produced modestly 
increased ECCD signals relative to the wild type protein in Ca2+ ions. This indicated that 
the relative orientations of +1 nucleotide with the -1 nucleotide was only modestly altered 
regardless being bound to R104A or A107G which have Ca2+ ions bound in the active site. 
Another four mutant complexes, K125A:dsFEC1+1-1 (Figure 6.8 e and Figure 6.9 a, b), 
R129A:dsFEC1+1-1 (Figure 6.8 g and Figure 6.9 a, b), R104AK132A:dsFEC1+1-1 (Figure 
6.9 a, b) and A98GA107G:dsFEC1+1-1 (Figure 6.8 i and Figure 6.9 a, b) produced 
approximately 4-fold increases in the magnitude of the CD spectrum than the comparable 
wild type human FEN1 complex (Figure 6.8 e, g, i and Figure 6.9 a, b) suggesting that 
these mutants cannot induce the same magnitude of conformational change in the substrate 
or alters the partitioning of to change the equilibrium position. Further experiments were 
performed by adding EDTA and overall the calculated ECCD intensity in Ca2+ increased 






Figure 6.8: ECCD spectra of dsFEC1+1-1 and dsFEC2-1-2 containing of (2-AP)2. a, c, e, g 
and i represent the ECCD traces of R103A, A107G, K125A, R129A and A98GA107G for 
dsFEC1+1-1 respectively, whereas b, d, f, h and j represent the ECCD signal of R103A, 
A107G, K125A, R129A and A98GA107G for dsFEC2-1-2 respectively. Solid lines displayed 
the ECCD spectrum in Ca2+, while dashed lines in EDTA. All mutants were plotted with 




Figure 6.9: Ellipticity changes at 326 nm for free substrates, and complexes with human 
FEN1 and all mutant enzymes. Red and blue represent the experiments in Ca2+ and EDTA 
respectively. a and b displayed the bar chart for grouped data and normalised grouped 
data for dsFEC1+1-1 substrates, whereas c and d showed the ECCD results at 326 nm for 
grouped data and normalised grouped data for dsFEC2-1-2. All data sets were collected 
from three replicates and standard errors are shown.  
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Studies have also been carried out with 2-AP at positions -1 and -2 using dsFEC2-1-2 DNA 
substrate. As shown previously, in the presence of Ca2+ ions the ECCD signal associated 
with hFEN1:dsFEC2-1-2 is near zero at 326 nm indicative of considerable change of relative 
positioning of the 2-AP in the active site. Similar to hFEN1:dsFEC1+1-1 complexes, further 
variations were observed with the mutant enzymes:dsFEC2-1-2 complexes compared to the 
corresponding wild type hFEN1:dsFEC2-1-2 complex. The signal at 326 nm associated with 
R104A decreases 3-fold further than human FEN1 in the presence of Ca2+ ions (Figure 
6.9 c, d). This probably reflects a different orientation of the 2-AP nucleobases at -1 and -
2 positions or/and maybe a difference in a partition between active site and non-active site 
positioned forms in the R104A:dsFEC2-1-2 complexes. Interestingly, the 
A98GA107G:Ca2+ complex produced a change in the exciton pair signal (Figure 6.8 j and 
Figure 6.9 c, d), which showed that the dsFEC2-1-2 substrate had undergone a comparable 
conformational change to that when bound to A107G:Ca2+ (Figure 6.8 d and Figure 6.9 
c, d). This implied that when bound to A98GA107G the -1 and -2 nucleotides were in the 
same position as with A107G but they failed to reproduce the positioning observed with 
the wild type enzyme. In Ca2+, more variations of ECCD spectrum for α5 single mutants 
K125A:dsFEC2-1-2 (Figure 6.8 f) and R129A:dsFEC2-1-2 (Figure 6.8 h) complexes were 
observed with 11.3-fold and 15.8-fold higher signals respectively (Figure 6.9 c, d). A more 
modest increase was observed for the double mutant R104AK132A:dsFEC2-1-2, which was 
increased by 3.5-fold relative to hFEN1:dsFEC2-1-2 complex (Figure 6.9 c, d). This 
suggests that the adjacent 2-APs at -1 and -2 do not adopt the same position as in the WT 
protein or the partition between forms is adjusted. All mutants R103A, R104A, A107G, 
K125A, R129A, R104AK132A and A98GA107G complexes produced slightly increased 
between 1.4-fold to 2.5-fold of ECCD signal by adding EDTA to approach the 











6.6 Discussion and summary 
 
The ECCD experiments in this chapter were carried out to understand the active site 
positioning mechanism of seven mutant enzymes compared to human FEN1 using a static 
double flap DNA substrate. By inserting two tandem 2-aminopurines in substrates at 
specific positions, the ability of the mutant enzymes to bring about conformational changes 
of nucleotides within the enzyme-substrate complex could be monitored. The residues 
show differences in the roles played in conformational change of DNA substrate according 
to their positions within the helical arch. For example, Arg-103 at in front of α4 behaved 
similarly to WThFEN1. This indicates that Arg-103 does not play a crucial role in 
positioning the DNA nucleotides for reaction. In contrast Arg-104 and Lys-132, both 
positioned at the back of the arch, displayed a modest effect when tested at both positions 
(+1-1 and -1-2 condition). Based on these data, we can propose that these residues are 
important to rearrange and locate the nucleotides towards the active site.  Similarly, when 
Ala-98 and Ala-107 (top and bottom of α4) were mutated to glycine to decrease helical 
propensity, they displayed similar effects to the back of arch mutations. This suggested 
that for precise positioning of the scissile phosphate on the active site metals depends on 
α4 being able to readily form a α-helix. Additionally, α5 Lys-125 and Arg-129 which are 
believed to interact with the template DNA are important to transfer the DNA substrate to 
the active sites.  
 
Regarding 2-APs position on 5’-flap dsDNA substrates at +1-1 and -1-2 positions, all of 
the seven human FEN1 mutant complexes allows identification of the importance of the 
active site metal ions for the local conformational changes of the DNA reacting duplex. 
The ECCD spectrum intensity at 326 nm were increased to some degree in all cases when 
Ca2+ ions were removed upon adding EDTA. These data proved that the active site metal 
ions are important for the local conformational changes. Without Ca2+ at the active site, 
the nucleotides could not produce the ideal conformational changes to position the scissile 
phosphate for hydrolysis. According to each mutant results with dsDNA substrates, some 
differences of ECCD signal from the corresponding human FEN1 complexes were 





Table 6.2: The summary of electronic interaction for two adjacent 2APs of +1-1 and -1-2 
positions of the seven mutated human FEN1 complexes comparing with WThFEN1. The 
symbols; (=) is similar interaction, (-) is less interaction and (+), (++), (+++) are higher 
interaction with different level of increasing the CD signal. The data were summarised 









dsFEC1 +1-1 = + + ++ ++ +++ +++ 







Flap endonucleases (FENs) catalyse the essential removal of single-stranded 5'-DNA or 
RNA protrusions known as flaps that occur during DNA replication and repair. Thus, 
FEN1 is essential for Okazaki fragment maturation, long-patch base excision repair, 
ribonucleotide excision repair and is purportedly involved a newly discovered DNA repair 
process (α-segment editing). When flaps occur in-vivo they are migrating structures that 
can theoretically adopt a number of conformations, but it is reported that FEN1 will only 
act on one conformer. Using migrating flap structures, this study proved that despite the 
existence of multiple potential conformations of the substrates the specificity of reaction 
one nucleotide into duplex with a one nucleotide 3’-flap was still maintained. Studies of 
FEN1 are generally confined to using static substrates that present DNA in the preferred 
conformation; that is, with a 5’-flap of any length including zero and a single nt 3’-flap. 
The results in this study showed that the rate of reaction (kcat/KM) was inversely 
proportional to the number of potential conformers. Thus, the presence of additional 
conformers slows the hFEN1-catalysed reaction, as might be expected if only one of many 
conformers can undergo reaction. Roughly, the presence of additional conformers slows 
the hFEN1-catalysed multiple-turnover reaction by 10-fold, as might be expected if only 
one of many conformers can undergo reaction. Substrate conformational heterogeneity 
also decreases the single turnover rate of reaction by 10-fold, suggestive of the potential 
for on-enzyme rearrangement to the preferred conformation. Furthermore, under first and 
second order kinetic studies revealed that, the catalytic activity of human FEN1 is not 
affected by the length of 5’-flaps that we have studied, but rather the number of conformers 
influences to the rate of reaction. 
 
In terms of the data and experiments discussed in chapter 3, there are several minor issues 
that need to be addressed for completeness. For a better understanding as to how the human 
FEN1 binds migrating substrate, a measurement with fluorescence resonance energy 
transfer (FRET) would be helpful. This technique involves a non-radiative shift of energy 
from an excited state donor fluorophore to a nearby acceptor134. The insertion of donor-
acceptor pair inside DNA substrate construct could afford dynamic data of any 
conformation changes under equilibrium state135. Besides that, further investigation using 
substrates of similar sequence except for the junction region will be studied, and FRET 
could measure the bending effects for each substrate. This will reveal whether stacking 
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effects alter the proportions of various conformers or whether different sequences around 
the site of reaction alter the rate.  
 
The interaction between wild type human FEN1 and PCNA was tested to determine 
whether PCNA stimulation would be an attractive way of regulating hFEN1 when it acts 
on substrates that can adopt multiple conformers. Flap endonucleases (FENs), along with 
the PCNA catalyse the essential removal of single-stranded 5'-DNA or RNA protrusions 
known as flaps that occur during DNA replication and repair. Interestingly in chapter 4, 
we found that PCNA did not alter or stimulate the reactions of FEN1 with static or 
migrating double or single flaps under the conditions tested. The addition of clamp loader 
RFC could also possibly give better understanding how the PCNA interact with the DNA 
substrate and enzyme proteins. In addition, use of the clamp loader could ensure that PCNA 
is oriented correctly on the substrate. 
 
The capability of FENs to accommodate the single strand 5’-flap DNA substrate has been 
studied for some time from diverse groups with a number of mechanisms9,17,27,72,90. 
Dahlberg and colleagues first came up with the theory of FEN1 specificity for removal of 
ssDNA 5’-flap by passing flaps through a hole in the protein. The work reported in this 
thesis in chapter 5 has sought to understand the mechanism of threading DNA through the 
helical arch (α4 and α5). The 5’-flap of DNA was presumed to be like a needle threading 
via a small hole in wild type human FEN1. We proposed the FENs interact with the double 
strand DNA first and then thread the single stranded 5’-flap through a disordered arch. By 
mutation of the conserved residues at helical arch, we revealed not all the residues are 
important for the threading such as Arg-103. However, α5 Lys-125 and Arg-129 both 
interact directly with template DNA and were observed to play a role in stabilising the 
threaded state.  
 
The objective of chapter 6 was to understand the active site transfer mechanism of the 
FEN1-catalysed reaction. The replacement of nucleotides by 2-aminopurine in a static 
double flap DNA substrate allowed the conformational changes of nucleotides to be 
measured by Exciton Coupled Circular Dichroism (ECCD) when bound with FEN1 and 
mutants. Low-energy CD of (2-AP)2 DNAs is an established technique to understanding 
the dynamics of nucleotides in different nucleic acid structures136. ECCD of 2-AP residues 
inserted into DNA also can be exploited on a large enzyme-substrate complexes to 
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investigate the conformation of specific nucleotides137–139. In this study the comparison 
between single strand and double strand spectra and between wild type human FEN1 and 
mutated human FEN1 were collated. With substitution of 2-AP on two different positions 
(+1-1 and -1-2) in the DNA substrate, this study demonstrated that, the positions of the 
residues either in-front of the arch or at the back will contribute and indicate how important 
each residue is to placing the scissile phosphate near or close to active site. The ECCD 
signals suggested that each residue (except Arg-103) participated in the active site transfer 
mechanism. In addition, the existence of divalent metal ions at the active site are required 
for binding between WThFEN1 and active site positioned nucleotides of the DNA 
substrate.  
 
It has been noted for some time that the helical arch above the active site and the α2- α3 
loop appear unstructured in the absence of DNA substrate, as recently demonstrated by 
NMR studies74. Moreover, a recent publication shows that, at least in part, recognition of 
3’-flaps is a property of the enzyme-substrate complex with the absence of a 3’-flap having 
large impacts on the maximal single turnover rate of reaction93. Thus communication 
between the 3’-flap binding pocket and the active site must occur. The juxtaposition of 
helical arch α5 and the α2- α3 loop, which pack against one another when structured, 
suggests a potential mechanism for this where the substrate induced ordering of one of 
these regions might impact on the other. The work presented here suggests that this would 
occur by controlling the ability of substrate to transfer to the active site, as key residues 
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Enzyme Concs for Experiments (pM) Concentration pM @ nM Stock/Previous Dilution 1X RRB
Total Vol 1200 uL 150 1000000/1000 4 396
10X RB 600 uL 100 10000/10 4 396
H2O 594 uL 50 1500/1.5 15 85
1M DTT 6 uL 30 1000/1 10 90
20 500/0.5 20 380
10 300/0.3 60 40
Total Vol 1400 uL Total Vol 2500 5 200/0.2 40 60
5X RRB 315 uL 5X RRB 500 3 100/0.1 40 160
H2O 1085 uL H2O 2000 2 50/0.05 50 50
(1.125X RRB) 1 30/0.03 30 70
20/0.02 20 80
SUBSTRATE Master Mix 10/0.01 10 90
Stock Conc (nM) --> 500 nM @ 0.5µM
Subsr Concs for Experiments (nM) Actual Conc (10X) 500 nM [S] Stock 1x FB Total Vol
5 50 2 18 20 uL
10 100 4 16 20 uL
25 250 10 10 20 uL [S] + MM Making
50 500 20 0 20 uL MM 160
[S] 20
Stock Conc (nM) --> 5000 nM @ 5µM Total Vol 180
Subsr Concs for Experiments (nM) Actual Conc (10X) 500 nM [S] Stock 1x FB Total Vol
75 750 3 17 20 uL X[S] Stock In tube Before adding [E] After adding [E]
100 1000 4 16 20 uL 1.111111111 1
250 2500 2.5 2.5 5 uL 1.111111111 1
1.111111111 1
Stock Conc (nM) --> 50000 nM @ 50µM Take out control:
Subsr Concs for Experiments (nM) Actual Conc (10X) 500 nM [S] Stock 1x FB Total Vol 18µL
500 5000 0.5 4.5 5 uL
750 7500 0.75 4.25 5 uL
1000 10000 1 4 5 uL
2500 25000 2.5 2.5 5 uL
5000 50000 5 0 5 uL
Final Substrate (nM) MM (uL) Vol. [E] Injection (uL) Final [E] (pM) EDTA Quench in each well  (uL) Vol. to inject onto the WAVE
5 160 18 1 50 65
10 160 18 2 50 65
25 160 18 2 50 65
50 160 18 3 100 77.78
75 160 18 3 100 51.85
100 160 18 5 100 38.89
250 40 4.5 10 100 62.22
500 40 4.5 20 150 46.67
750 40 4.5 30 150 31.11
1000 40 4.5 50 200 31.11
2500 40 4.5 100 200 12.44
5000 40 4.5 150 250 7.78
Dilution 500nM to 250nM EDTA:
10mL EDTA + 10mL H2O
1x RRBMaster Mix
Make 5X RRB Enzyme Dilutions Stock of 100 Um
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Enzyme Concs for Experiments (pM) Concentration pM @ nM Stock/Previous Dilution 1X RRB
Total Vol 2400 uL 1 1000000/1000 4 396
10X RB 1100 uL 2.5 10000/10 4 396
H2O 1089 uL 4 100/0.1 4 396
1M DTT 11 uL 3 90/0.09 90 10
6 60/0.06 60 40
9 40/0.04 40 60
Total Vol 2800 uL Total Vol 4000 uL 30/0.03 30 70
5X RRB 630 uL 5X RRB 800 uL 2.5/0.025 25 75
H2O 2170 uL H2O 3200 uL 10/0.01 10 90
(1.125X RRB)
SUBSTRATE Master Mix [S] + MM Making
Stock Conc (nM) --> 500 nM @0.5µM MM 160
Subsr Concs for Experiments (nM) Actual Conc (10X) 500 nM [S] Stock 1x FB Total Vol [S] 20
2.5 25 5 95 100 uL Total Vol 180
5 50 10 90 100 uL
7.5 75 15 85 100 uL X[S] Stock In tube Before adding [E] After adding [E]
10 100 20 80 100 uL 1.111111111 1
1.111111111 1
1.111111111 1
Take out control: 1.111111111 1
18µL
Final Substrate (nM) Substrate MM (uL) MM (uL) Volume [E] Injection (uL) Final [E] (pM) EDTA Quench in each well  (uL) Volume to inject onto the WAVE
2.5 20 160 18 1, 2.5, 4 50 60
5 20 160 18 1, 2.5, 4 50 60
7.5 20 160 18 3, 6, 9 50 60
10 20 160 18 3, 6, 9 50 60
Dilution 500nM to 250nM EDTA:
5mL EDTA + 5mL H2O
Dilution 50µM - 5µM - 0.5µM » 50µM [S] Stock 1xFB
5µM @ 5000nM 5µL 45µL
(heat & anneal)
5µM [S] Stock 1xFB
0.5µM @ 500nM 10µL 90µL
1x RRBMaster Mix
Make 5X RRB Enzyme Dilutions Stock of 100 Um
Reaction Loop 10X/1X Mode Flow rateSwitch Position Push 1 Steps Push 2 Steps Delay Time (s) Time (ms) 5xRRB (6mL) Vol. (µl)
1 1 1X C 5 160 95 100 4.5 10xRB 3000
2 1 1X C 2 160 95 100 12.1 DTT 30
3 2 1X C 6 180 95 100 9.1 H2O 2970
4 2 1X C 3 180 95 100 19.4
5 2 1X C 2 180 95 100 27.6 Final Conc. For Experiment [E]2µM (10mL) µl [S]5 nM (10mL) µl
6 2 1X C 1 180 95 100 41.8 100 µM [E] 200 500 Nm [UP259EQ] 100
7 4 1X C 5 255 95 100 30.6 5xRRB 2000 5xRRB 2000
8 4 1X C 4 255 95 100 40.8 1xFB 1000 1xFB 900
9 4 1X C 3 255 95 100 57.5 H2O 6800 H2O 7000
10 4 1X C 2 255 95 100 82.1
11 4 1X C 1 255 95 100 124.2
12 4 1X I 4 160 95 100 140.8
13 4 1X I 4 160 95 200 240.8 Dilution 50µM - 5µM - 0.5µM » 50µM [S] Stock 1xFB
14 4 1X I 4 160 95 400 440.8 5µM @ 5000nM 5µL 45µL
15 4 1X I 4 160 95 800 840.8 heat & anneal
16 4 1X I 4 160 95 1600 1640.8 5µM [S] Stock 1xFB
17 4 1X I 4 160 95 3200 3240.8 0.5µM @ 500nM 10µL 90µL
18 4 1X I 4 160 95 6400 6440.8
19 4 10X I 4 160 95 1280 1281 Freshly prepare 1XRB
20 4 10X I 4 160 95 2560 25641 250nM EDTA
21 4 10X I 4 160 95 5120 51241
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Enzyme Concs for Experiments (pM) Concentration pM @ nM Stock/Previous Dilution 1X RRB
Total Vol 4800 uL 150 1000000/1000 4 396
10X RB 2400 uL 10000/10 3 set x 4 3 set x 396
H2O 2376 uL 1500/1.5 3 set x 30 3 set x170
1M DTT 24 uL
[S] + MM Making
Total Vol 8000 uL Total Vol 560 uL MM 160
5X RRB 1600 uL 5X RRB 126 uL [S] 20
H2O 6400 uL H2O 434 uL Total Vol 180
50nM PCNA
X[S] Stock In tube Before adding [E] After adding [E]
1.111111111 1
Stock Conc (nM) --> 500 nM @0.5µM
Subsr Concs for Experiments (nM) Actual Conc (10X) 500 nM [S] Stock 1x FB Total Vol Take out control:
5 50 50 450 500 uL 18µL
Final Substrate (nM) Substrate MM (uL) MM (uL) Volume [E] Injection (uL) Final [E] (pM) UREA Quench in each well  (uL) Volume to inject onto the WAVE
5 20 160 18 150 50 60
Dilution [S]: 50µM - 5µM - 0.5µM » 50µM [S] Stock 1xFB Dilution of 100μM of PCNA
5µM @ 5000nM 5µL 45µL
(heat & anneal)
5µM [S] Stock 1xFB
0.5µM @ 500nM 10µL 90µL
SUBSTRATE Master Mix
[PCNA]; nM (1.125X RRB) 2.5 5 15 30 60 180
5X RRB; μL 220 215 195 165 105 90
H2O; μL 755 735 655 535 295 110
50nM PCNA; μL 25 50 150 300 600 1800
TOTAL; μL 1000 1000 1000 1000 1000 2000
  Use for master mix to get the 2.5, 5, 15, 30, 60, 180nM of PCNA in experiment
1x RRB
Make 5X RRB Enzyme Dilutions Stock of 100 Um
*50nM of PCNA - 




An example threading experiment template for WThFEN1, R103A, R104A, K125A, 





An example threading experiment template for WThFEN1, R103A, R104A, K125A, 





A Control 2 Control 4 A Control 6 Control 8 A Control 10 Control 12
B 0:00:30 1:00:00 0:00:30 1:00:00 B 0:00:10 0:08:00 0:00:10 0:08:00 B 0:00:10 0:08:00 0:00:10 0:08:00
C 0:01:00 2:00:00 0:01:00 2:00:00 C 0:00:20 0:16:00 0:00:20 0:16:00 C 0:00:20 0:16:00 0:00:20 0:16:00
D 0:02:00 3:00:00 0:02:00 3:00:00 D 0:00:30 0:30:00 0:00:30 0:30:00 D 0:00:30 0:30:00 0:00:30 0:30:00
E 0:04:00 4:00:00 0:04:00 4:00:00 E 0:00:40 1:00:00 0:00:40 1:00:00 E 0:00:40 1:00:00 0:00:40 1:00:00
F 0:08:00 6:00:00 0:08:00 6:00:00 F 0:01:00 2:00:00 0:01:00 2:00:00 F 0:01:00 2:00:00 0:01:00 2:00:00
G 0:16:00 0:16:00 G 0:02:00 4:00:00 0:02:00 4:00:00 G 0:02:00 0:02:00
H 0:30:00 0:30:00 H 0:04:00 6:00:00 0:04:00 6:00:00 H 0:04:00 0:04:00
Total Vol 2000 uL Total Vol 2000 uL Total Vol 2000 uL
10X CaRB 1000 uL 5X CaRRB 400 uL 10X MgRB 200 uL [E]500nM (R104A)
H2O 995 uL H2O 1600 uL H2O 1800 uL [S]5nM  (SB5-1)
1M DTT 5 uL
Quench 
50uL of 8M Urea + 80mM EDTA
Total Vol 834 uL Total Vol 200 uL Total Vol 2002 uL
1x CaRRB 831 uL 1x CaRRB 180 uL 5X CaRRB 572 uL Vol. inject (wave)
Strp stock 3 uL E 20 uL H2O 1430 uL 60uL
5µM @ 5000nM 0.5µM @ 500nM 0.1µM @ 100nM Method (wave)
Total Vol 50 uL Total Vol 100 uL Total Vol 200 uL 22mer medium 12.5min test2
50µM 5 uL 5µM 10 uL 0.5µM 40 uL
1xFB 45 uL 1xFB 90 uL 1xFB 160 uL
Block 126uL MM 18uL [S] 18uL Strp 5 min 18uL [E] 2 min 1 min 370C 20uL cntrl
0.5 - 360 min (bench)
Trap 126uL MM 18uL [S] 18uL [E] 2 min 18uL Strp 5 min 1 min 370C 20uL cntrl
Premix 126uL MM 18uL [S] 18uL [E] 2 min 18uL 1XCaRB 5 min 1 min 370C 20uL cntrl
No Streptavidin
Final Concentration
Block Block Trap Trap No Streptavidin
Make 5X CaRRB 1X CaRRB 1X MgRRB
10X Streptavidin Master Mix10X E @10uM
0.00051 - 360 min (bench) & 0.004017 - 0.23402 min (QF)
0.166667 - 360 min (bench) & 0.004017 - 0.23402 min (QF)
160uL MgRRB (start) 
160uL MgRRB (start) 
160uL MgRRB (start)
Reaction Loop 10X/1X Mode Flow rateSwitch Position Push 1 Steps Push 2 Steps Delay Time (s) Time (ms)
Trap μl μl
10XCaRB 750 10XMgRB 750
3 2 1X C 6 180 95 100 9.1 H20 6635 H20 6730
4 2 1X C 3 180 95 100 19.4 1M DTT 19 1M DTT 19
5 2 1X C 2 180 95 100 27.6 [SB51] 5uM 15
6 2 1X C 1 180 95 100 41.8 [R104K132A] 100uM 75
7 4 1X C 5 255 95 100 30.6 Leave 2 minutes
8 4 1X C 4 255 95 100 40.8 17U/mg, 2mg/mL Strep 2.7
9 4 1X C 3 255 95 100 57.5 Leave 5 minutes
10 4 1X C 2 255 95 100 82.1
11 4 1X C 1 255 95 100 124.2 Premix μl
12 4 1X I 4 160 95 100 140.8 10XCaRB 750
13 4 1X I 4 160 95 200 240.8 H20 6635
14 4 1X I 4 160 95 400 440.8 1M DTT 19
15 4 1X I 4 160 95 800 840.8 [S] 5uM 15
16 4 1X I 4 160 95 1600 1640.8 [E] 100uM 75
17 4 1X I 4 160 95 3200 3240.8 Leave 2 minutes
18 4 1X I 4 160 95 6400 6440.8 H20 2.7
19 4 10X I 4 160 95 1280 1281 Leave 5 minutes
20 4 10X I 4 160 95 2560 25641
21 4 10X I 4 160 95 5120 51241
Left (enzyme/ line A) Right (line B)
Quench
8M Urea + 300mM EDTA
Buffer A













An example ECCD experiments template for WThFEN1, R103A, A107G, K125A, R129A 





An example ECCD experiments template for WThFEN1, R103A, A107G, K125A, R129A 






1 CD Sample Volume (µL) Sample Number +2 Common Volume (µL) MM
10X RB 50 18 50 1400 10X RB is: 1.0 M KCl, 100 mM CaCl2, 0.5 M HEPES pH 7.5
1 M CaCl2 0 18 0 0
1M DTT 0.5 18 0.5 14
H2O 337 18 337 9436
S or FB 50 Total 387.5 10850
E or SB 62.5 SB is: 100 mM KCl, 1 mM CaCl2, 5 mM DTT, 50 mM HEPES pH 7.5, 0.02% NaN3 (50% glycerol)
Total 500 for each sample:
run then add 25 µL 250 mM EDTA
FEC1 (+1-1 substrate) mix gently and run again
Sample MM (µL) 1×FB (µL) 100 µM ssS (µL) 100 µM S (µL) SB (µL) 100 µM E (µL) Total (µL) Sample Description
1 387.5 50 62.5 500 Blank1 (20°C)
2 387.5 50 62.5 500 ssFEC1 substrate only 10 µM [S] (20°C)
3 387.5 50 62.5 500 dfFEC1 substrate only 10 µM [S] (20°C)
4 387.5 50 62.5 500 12.5 µM hFEN1 with 10  µM [S] (20°C)
5 387.5 50 62.5 500 12.5 µM A107G with 10  µM [S] (20°C)
6 387.5 50 62.5 500 12.5 µM A98GA107G with 10  µM [S] (20°C)
Total S 100 µM 50 200
make at least 75 225
ECCD plan
1 CD Sample Volume (µL) Sample Number +2 Common Volume (µL) MM
10X RB 50 18 50 1400 10X RB is: 1.0 M KCl, 100 mM CaCl2, 0.5 M HEPES pH 7.5
1 M CaCl2 0 18 0 0
1M DTT 0.5 18 0.5 14
H2O 337 18 337 9436
S or FB 50 Total 387.5 10850
E or SB 62.5 SB is: 100 mM KCl, 1 mM CaCl2, 5 mM DTT, 50 mM HEPES pH 7.5, 0.02% NaN3 (50% glycerol)
Total 500 for each sample:
run then add 25 µL 500 mM EDTA
FEC2 (-1-2 substrate) mix gently and run again
Sample MM (µL) 1×FB (µL) 100 µM ssS (µL) 100 µM S (µL) SB (µL) 100 µM E (µL) Total (µL) Sample Description
1 387.5 50 62.5 500 Blank1 (20°C)
2 387.5 50 62.5 500 ssFEC2 substrate only 10 µM [S] (20°C)
3 387.5 50 62.5 500 dfFEC2 substrate only 10 µM [S] (20°C)
4 387.5 50 62.5 500 12.5 µM hFEN1 with 10  µM [S] (20°C)
5 387.5 50 62.5 500 12.5 µM A107G with 10  µM [S] (20°C)
6 387.5 50 62.5 500 12.5 µM A98GA107G with 10  µM [S] (20°C)
Total S 100 µM 50 200
make at least 75 225
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